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                                      Abstract 
Conventional cancer therapies can have severe side effects, so new strategies to limit these 
needs to be investigated. Several anticancer agents induce the expression of tumour suppres-
sor gene p21 in colorectal cancer cell line HT-29. Interestingly, the stress protein HSPA1A is 
also often elevated in tumour cells and has an anti - apoptotic activity. The main aim of this 
study was to examine whether a two - pronged approach, overexpressing p21 (using genetic 
approach and inhibition of HSPA1A using pifithrin - µ would be effective in inducing apoptosis 
in tumour cells. Chitosan or BSA based delivery systems were evaluated for cytotoxicity, with 
the intension of using it for plasmid DNA based cell transfections in this study. The interaction 
of HSPA1A protein in combination treatments involving UV radiation and hyperthermia at 
42℃ were also evaluated to perceive the various roles of HSPA1A in arresting colorectal can-
cer cells. Colorectal cancer cell lines HT-29 and leukaemia cancer cell lines U937 were used in 
the study. All experiments were performed with cancer cell lines maintained in culture me-
dium devoid of antibiotics. Cell cytotoxicity were evaluated using MTS and PI assays. The rate 
of apoptosis was determined using annexin V and PI staining by flow cytometry. Chitosan or 
BSA based microparticles or microgels were observed for size determination or morphology 
using scanning electron microscopy. Full length human p21 inserted plasmid DNA was a gift 
from Mien - Chie Hung, Addgene, USA. HT- 29 cells were subjected to p21 plasmid DNA trans-
fection effects. Cells were treated with pifithrin - µ (15µM) prior to gene transfection to ad-
dress its combined effect with p21 plasmid DNA transfection. HSPA1A and p21 protein ex-
pression studies were analysed using FITC labelled antibodies by flow cytometer. Combina-
tion studies with HSPA1A inhibitor pifithrin - µ and UV reflected enhanced cytotoxicity com-
pared with either of the treatments independently. Hyperthermia at 42℃  induced apoptosis 
by MTS assay, which was confirmed by flow cytometric analysis in both the cell lines tested. 
Considering the cytotoxicity reflected by the chitosan or BSA delivery systems in drug free 
states, the p21 plasmid DNA transfection was carried out using lipofectamine 2000. Both 
overexpression of p21 and inhibition of HSPA1A protein with pifithrin - µ enhanced the rate 
of apoptosis with statistical significance of (p-<0.0001****) compared to the respected con-
trols. The data in this thesis suggests the inhibition of HSPA1A in combination with increased 
p21 would be a promising therapeutic strategy for the treatment of colorectal cancers. 
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Chapter 1 
Introduction 
The eukaryotic systems are regulated by various genes which directly or indirectly participate 
in maintaining normal cell replication. Malfunctional status of these cell cycle regulatory 
genes results in uncontrolled cell proliferation, the state known as cancer. Cancer cells are 
stimulated to release certain unique factors called metalloproteinases which facilitate their 
active propagation by assimilation of surrounding tissue walls, paving into the circulatory 
stream, to fasten their “roots” throughout the host system (Rundhaug. 2003). Cancerous cells 
upon entering the host circulatory stream proliferate to the surrounding tissues and reaches 
a stage clinically termed as metastasis (Fig 1.1).  
                                  
Fig 1.1 The different stages of cancer initiation and metastasis adapted from (drugresource.com; 
thetruthaboutcancer.com) 
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Metastatic phase of cancer leads to poor prognosis rate with conventional treatments. In case 
of pancreatic malignancies metalloproteinases are found to induce its activity at the primary 
cancer stage (Bloomston et al. 2002; Hanahan. 1996). Despite many researchers over half a 
century focusing on cancer vaccine innovations and dissecting the underlying molecular 
connections related to abnormal gene expressions, tumour angiogenesis, apoptosis and 
metastasis, cancer remain a leading cause of mortality compared to other disorders.  
1.1 Cancer statistics 
Data from worldwide cancer statistical analysis reveals the incidence of different types of 
cancers rising at an alarming rate. Publication record from a recent analysis had shown that 
in United states, in women, breast cancer is the most prevalent cancer and studies further 
show, surprisingly that breast cancer is dependent on population ethnicity (DeSantis et al. 
2016). Women inhabited in Asian pacific regions possess less chance of breast adenomas 
compared to other regions of the globe. Life styles are shown to have a major part associated 
with breast cancer incidence, showing an increase of 3.2% in 2013 compared to breast cancer 
rates in 1970’s (DeSantis et al. 2016).   
(American cancer society report (2002) outline that women conceiving at their early age, 
lactate for prolonged periods are found resistible towards breast cancers. Awareness of self - 
examination of breast, mammographic detection at the early age of around 40 are highly 
recommended for increasing the life span and providing effective treatment in women 
diagnosed with breast tumour (Desantis et al. 2011). According to the recent statistical 
analysis by the American cancer society, the female population express a 20%  less prevalence  
towards almost all of the cancer types, except that for thyroid tumour, which accounts for 
higher rate of female 3 : 1 with the male population (Siegel et al. 2017). 
Population - based studies shows that breast cancers are highly associated with the age of the 
individual and ancestors – i.e. a strong genetic component (Ziv et al. 2006; Kamińska et al. 
2015). According to the histopathological examination findings of their research, women 
diagnosed with benign conditions were more likely to perceive proliferative breast cancers. 
Their findings also infers that the chance of acquiring the condition increased with age 
(Hartmann et al. 2005).  
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The incidence of colorectal cancers was revealed to be substantially more or less the same in 
terms of gender, the study also relates age as an important factor which determines the 
tumour developing destination within the colorectal regions (Siegel et al. 2014).  According to 
the study of prevalence of cancer in the United Kingdom alone, the incidence of cancer shows 
a dramatic inflation of around 2 million in the year 2010 which inclined with 400,000 more 
cases within a 5 year span and these figures are anticipated to rise at an alarming within the 
coming years (Maddams et al. 2012). As per the cancer incidence reports disclosed by the 
american cancer society in 2018, the incidence of the colon cancer  rates were only 3% less, 
while leukaemia  were found to be 16% lesser in females  compared to the male population 
in the united states (L. et al. 2018).  
1.2 Factors associated with cancer initiation and progression 
Ancestral gene mutations passed on to successive generations are the root cause of 
hereditary cancer according to population - based mapping analysis. Hence these expression 
studies provide an explicit outline of genetic alterations which can help, not only improve the 
quality of current treatment strategies, but also enhances early diagnosis (Bock Schwartz et 
al. 2009; Chen et al. 2001).  
Apart from mutations, exposure to chemical carcinogens, ionizing radiation and oxidative 
stress are some important factors which hampers the normal functioning of genes associated 
with cell regulation, eventually leading to uncontrolled cell replication. Besides mutation and 
hereditary factors, cancer stem cells as one of the main causes of reappearance of several 
solid malignancies. The cancer stem cells are also the root cause of emergence of bone 
marrow mutation resulting in leukaemia cancers (Huang et al. 2010). The colorectal 
carcinoma is reported to have close association with the gut microflora that is involved in the 
stabilization of the intestinal pH. Less levels of intestinal microflora attributed towards 
enhancing the pH, which is one of the factors favoring colorectal cancer initiation (Ohigashi 
et al.  2013).  
1.2.1 Cancer and apoptosis 
The term apoptosis refers to programed cell death. In healthy tissues, normally, the cells 
receive signals to undergo apoptosis upon reaching cellular maturation or due to unhealthy 
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states, to sustain a stable cell population (Wong et al. 2011). Cells are also triggered to 
undergo apoptosis by intracellular and extracellular responses including pathogenic intrusion, 
hypoxia and cellular stress responses (Susan et al. 2007). The normal cells losing its property 
to undergo apoptosis becomes cancerous. Avoidance of apoptosis is a major tumour 
property. Malfunctional status of apoptotic genes mainly tumour suppressor genes and the 
active involvement of anti - apoptotic signaling pathways helps in sustaining cancer cell 
survival. Besides this, the cancer cells express elevated levels of stress protein HSPA1A, which 
not only defend the cancer cells from apoptosis but also plays an eminent role in perverting 
cancer treatment resulted nucleic acid repairs (Kaul et al. 2011). Hence therapeutic 
efficiencies could be improved through inhibition of HSPA1A protein. This thesis involves 
studies on how cancer treatments could be made more effective by modulating apoptosis, 
principally by inhibition of HSPA1A and overexpressing tumour suppressor protein p21. 
1.2.2 Genes associated in proceeding apoptosis 
Genes in the BCL - 2 apoptotic route are strongly dependent on each other’s functional status 
in initiating apoptosis. Among these genes include mainly PUMA, which is eminent protein in 
hampering the activity of anti - apoptotic molecules, thereby assisting apoptosis (Fricker et 
al. 2010). Studies relate the instability of this polypeptide resulted from phosphorylation at 
its serine 10 amino acid sequence, thus hampering the apoptotic process in cancer cells 
(Fricker et al. 2010). NOXA is another protein whose impaired functional status adversely 
affects the p53 and p21 gene directed cell death routes (Shibue et al. 2003).  
In vivo study shows the active participation of NOXA not only in activating the host defense 
system, but also in enhancing cancer cell sensitivity towards conventional anti - cancer agents 
(Ploner et al. 2008). Other proteins in this apoptotic signaling network includes BID (BH3 
interacting domain) which are studied to works as vehicle in driving the pro apoptotic protein 
Bax to the mitochondrial destination, upon reaching the mitochondrial outer core, the Bax 
protein accompanies the Bak polypeptide to facilitate the liberation of cytochrome c, which 
is an intermediate process in initiating programmed cell death through the p53 directed 
apoptotic pathway (Westphal et al. 2011). The up regulatory status of the Bax protein is 
evidence to promote apoptosis in response to phytic acid in colorectal cancer cell lines HT-29 
(Shafie et al. 2013). The Bax protein is studied to be transported to the mitochondria, which 
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in turn disrupts the mitochondrial membrane resulting in apoptotic response towards 
resveratrol treatment in leukaemia cell lines U937 (Guha et al. 2011). 
The role of BAD protein of pro apoptotic gene family serves the apoptotic pathway through 
TNF - α mediated cell death route. Studies evidence the role of these proteins being 
attenuated by Ikb kinase complexes in cancer cases, thus defending them from undergoing 
apoptosis (Yan et al. 2013; Westphal et al. 2011). 
 
 
 
 
Fig 1.2 The diagram illustrates the p53 directed impaired apoptotic pathway in cancer cells. It involves the 
downregulation of apoptotic signaling machineries together with over expressive status of anti - apoptotic genes and above 
all mutation of p53 genome, thus promoting cancer cell progression, adapted from (Haupt et al. 2003) nature.com.    
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1.2.3 Genes associated in hampering apoptosis   
The cellular programmed death signaling routes are halted by the interaction of several 
oncogenes thus allowing cells to become immortal leading to cancers (Figure 1.2).  BCL - 2 
and BCL - XL polypeptides in the apoptotic signaling network are studied to block the function 
of apoptotic promoting genes BAX and BAD, thus refraining the liberation of cytochrome c 
from the cells ATP factory, finally preventing apoptosis (Huang et al. 1998). Other genes 
accompanying the anti - apoptotic process in the BCL - 2 signaling cascade include MCL - 1, 
BCL 0 - B and A1/BF1 (Huang et al. 1998). The BCL-2 protein plays a central role in preventing 
apoptosis. BCL-2 knock down studies in leukaemia cell lines U937 transfected with 
phytochemical anthocyanins, exhibited apoptosis through the activation of  the caspase 
cascade 3, 8 and 9, which eventually resulted in apoptosis, compared to BCL-2 overexpressing 
cell lines (Lee et al. 2009). In vitro studies reveal the  suppressive role of anti-apoptotic protein 
BCL-XL in inducing apoptosis in response to treatment with phytic acid  in colorectal cancer 
cell lines HT-29 (Shafie et al. 2013).         
1.2.4 Heat shock genes and apoptosis 
Cancer cells express escalated levels of HSPA1A proteins which plays a protective role in 
cancerous cells, preventing cell death. Heat shock proteins are produced in both eukaryotes 
and prokaryotic organisms as an evolutionary path shielding intracellular proteins from 
thermal denaturing (Chatterjee et al. 2017). Elevated heat exposure, ultra violet radiation 
exposure, and oxidative stress are some of the major factors studied to be linked with over 
expression of heat shock genes, mostly HSPA1A and HSP90A (Chatterjee et al. 2017).  
Heat shock effects were reported to be first observed in tissues of fruit fly Drosophila 
melanogaster during its different pre - pupal developmental stages, their experimental 
inference evaluated significant variation in chromosomal puffs in tissues subjected to heat 
shock treatment (Ritossa et al. 1996). In mammals, Heat shock genes are categorized as 4 
annexes based on their high molecular mass into, HSPD1, HSPA1A, HSP90A and HSP as low as 
10 - 15Kda which comprises of HSPB1. These molecular chaperons are found to be engaged 
in maintain the conformational status of proteins, signaling, functioning and regulation of 
other proteins within mammalian cells (Jolly et al. 2000). The function of these unique 
peptides alters with their molecular weight and their cellular localization which are studied to 
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differ with cancer types (Ciocca et al. 2005). Considering their functional role within various 
intracellular compartments, they are classified into eight annexes, two of which include - the 
HSPA5 working in relation with proteins of the endoplasmic reticulum and HSP90A which is 
studied to be associated within the mitochondria of eukaryotic cells (Ciocca et al. 2005).   
On the other hand, low expression levels of HSP60 and HSP90 were studied in high tumour 
status, which resulted in reappearance of superficial bladder malignancies in patients after 
primary surgery, thus proving the active participation of these molecules in enhancing the 
host immune response (Lebret. et al. 2003). And hence are studied to be good prognostic tool 
for patients resistant to normal cancer treatments and the risk of reoccurrences could be 
tackled at the early stages of the condition. These proteins are studied to be remarkable 
prognostic markers for not only cancers but for conditions like immune thrombocytopenic 
purpura in pediatric cases where antibodies against HSPA8 are detected predominantly. 
Hence screening of HSPPA8 antibodies makes treatment procedures far promising (Xiao et al. 
2004).  
Intriguingly, heat shock proteins function as alarm system, eliciting the natural defense 
mechanism, or in some instances, their expression works to demote natural immunity, 
allowing the progression of malignant cells. Cellular contents released as result of necrosis, 
allows the intracellular heat shock proteins reach exterior, helping trigger the immune system 
identify the threat and act accordingly (Klink et al. 2012), hence heat shock proteins are 
studied to be important proteins in activation of immune response and render tumour 
invasion. Several pharmaceutical trials output the positive potential of using high molecular 
weight heat shock proteins such as HSP110 as powerful tools in generation of cancer targeting 
vaccines. Hence an explicit overview of function of these proteins at intracellular and 
extracellular levels may help improve conventional therapeutic index in cancer patients 
(Multhoff. 2006; Daming Zou. 2016).  
The overexpression of HSPA1A are studied to be key factors associated to cellular 
proliferation in most of the malignancies, although scientists have introduced several drugs 
which hamper the function of these genes, recent findings reveals that, the transcription of 
HSPA1A can be managed indirectly by attenuating the intracellular link mediated through 
several other factors such as NEF - Nucleotide exchange factors and TPR - Tetratricopeptide 
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chains, which works in close connection with HSPA1A protein resulting in  insensitiveness to 
natural host defense, promoting cancer survival (Assimon et al. 2013). The HSPA1A within an 
extensive network indirectly hinders the transcription of apoptotic factors such as BAX, and 
cellular death accelerating systems DR4 and DR5 (Figure 1.3), promoting cancer proliferation 
(Guo et al. 2005; Murakami et al. 2015). 
Intriguingly, cancer cells are guarded by HSPA1A proteins from the host cell natural defense 
mechanism exerted by TNF - α (Tumour necrosis factor), thereby preventing cellular necrosis 
(Daugaard et al. 2007). HSPA1A deregulates the cells apoptotic process by engaging 
themselves in reverting the segregated proteins conformational status and switching back to 
their function mode (Murphy. 2013).  
 
            
   
 
Fig 1.3 The diagram illustrates the involvement of stress induced HSPA1A protein in preventing apoptosis. The 
overexpressed proteins bind to death cell receptors and apoptotic protein BAX, hampering their role in initiating the 
apoptotic process, adapted from (Wang et al, 2012) and from the data demonstrated in this thesis. 
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1.2.5 Interactive role of tumour suppressor gene p53 and p21 in cancer 
Researchers point out that half of the global cancers are resulted due to the impact of 
alterations of p53 genome in cancers. One of the important factors known as histone 
acetyltransferase (HAT) enzymes are studied to be involved in the acetylation of lysine amino 
acid residues to form N - acetyl lysine, which is a necessary for the  transcriptional activation 
of p53 gene (Wright et al. 2016). Despite being a tumour suppressor in function, p53 under 
altered status, replace a negative role as a tumour accelerator, which is notified to be main 
cause of cancer insensitivity towards several therapeutics (Goldstein et al. 2011; Parrales. 
2015).  
Report suggests that p53 expression levels are counterbalanced in cells by certain proteins 
referred to as ESTIC, which encounter a major role in assisting p53 gene mediated repair of 
nucleic acids (Luo et al. 2016). In vitro ESTIC silencing study reflected the malfunctional status 
of p53 gene is due the absence of these unique factors which play a key role in degradation 
of mutated p53 mRNA, thereby preventing cancer cells resulted from DNA damage from 
undergoing apoptosis (Luo et al. 2016). Hence, most of the cancer cases can be addressed by 
implementing therapeutic strategies focussed at ablation of non - functional p53. Although, 
tumour suppressor gene p53 is designated by the scientific community as the guardian of the 
DNA double helix, the cyclin dependent kinase inhibitor p21 functions in connection with p53 
tumour suppressing network arresting the cancer cell growth and metastasis. More explicitly 
stating, in the p21 mediated apoptotic pathway, p53 fulfils its tumour inactivation by binding 
to p21 gene which in turn binds to CDK1, CDK2, CDK4 and CDK6 complexes, arresting the cell 
cycle at the G1 phase (Fischer et al. 2015). Natural cell deterioration widely known as 
senescence resulting from external or internal cellular stress is an important factor involved 
in replication arrest. This mode of cellular growth arrest is assisted through tumour 
suppressor p53 (Schmitt et al. 2002). 
Phosphorylation of p53 at its serine residue evidenced to elevate p53 expression in response 
to anti-cancer agent curcumin, which in studies highlight the active role of JNK signalling 
pathway in promoting p53 independent cell death in response to chemotherapeutic cisplatin 
in U937 leukaemia cancers (Bae et al. 2006). Hence the anti-cancer mechanism exhibited by 
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JNK may be useful therapeutic target for cancers devoid of p53 functional status. Moreover, 
the phosphorylation status of p53 is also crucial in p53 mediated apoptosis. Phosphorylation 
in turn transactivated anti-apoptotic factors Bax, resulting in programmed cell death in 
colorectal cancer cell lines HT-29 (Song et al. 2005). 
Interestingly elevated expression of p21 genes are studied to accelerate programmed cell 
death in response to chemotherapeutic treatment, thus displaying the eminent role of p21 
gene in a wide range of malignancies. Adenoviral mediated gene transfection scientific 
reports support the potency of p21 gene in arresting colorectal progression and metastasis 
(Wang et al. 2015).  
 
Fig 1.4 The diagram depicts the tumour suppressor gene mediated DNA repair. The figure displays how DNA 
damage due to radiation, mutation, infection or carcinogens are repaired by the active involvement of the tumour suppressor 
genes p21 and p53 signaling cascade in initiating apoptosis, adapted from (Fischer et al. 2015; Shibue et al. 2003).  
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1.2.6 Genes associated with p21 upregulation 
The status of p21 activity relies on its position in cellular compartments, which is the main 
factor which determines its function as tumour promoter or tumour suppressor. Besides 
genes that promote cancer cell progression and metastasis, there are several signalling 
proteins which act as switch boards in cancer cell control and regulation (Figure 1.4). p21 gene 
is studied to be accelerated in colorectal cancers by various pathways, one such route is 
MEK/ERK - signalling network. Although MEK/ERK pathway directs extracellular signals to the 
DNA for transcription and replication, allowing cancer progression, this pathway is studied to 
induce nuclear p21 expression in vitro in colorectal cancer cell lines HT-29 subjected to 
treatment with zinc (Park et al. 2002). Moreover, the downregulatory status of anti-apoptotic 
proteins BCL-2 and survivin are closely linked with enhancing the expression of tumour 
suppressor protein p21, which evidenced to induce apoptosis in leukaemia cell lines U937 
transfected with 12 - O - tetradecanoyl phorbol -13 acetate (TPA (Luo et al. 2005). The 
transforming growth factor TGF - β also plays a key role in increasing the expression of p21, 
which in turn bind the CDK complexes, arresting the cell cycle at G1 phase. TGF - β works 
through SMAD signalling cascade boosting the level of p21 initiating cell cycle arrest (Bauer 
et al. 2015; Padua. 2009).  
Reports point out that p21 genes are counter controlled by microRNAs in achieving their 
apoptotic role in colorectal cancers. In vitro transfection of MIR 106 and MIR 13a evaluated 
their active requirement in the p21 apoptotic cycle in the presence of butyrate (Schlörmann 
et al. 2015). Moreover, in vivo MicroRNA transfection experiments evaluated the inhibition 
of MIR 708 - 5p which resulted in elevated p21 expression levels, suggesting the association 
of MIR 708 - 5P with the cyclin dependent kinase inhibitors signalling cascade initiating 
tumour suppressive properties in adenomas of lungs (Wu et al. 2016). 
Hence, cancer treatments can be modified by implementing drugs that target microRNA - 208 
and MIR708 - 5P, enhancing survival rates. The receptor tyrosine kinase network 
communication in cancer cells are studied to be coordinated by genes collectively designated 
as SPRY, referred to as sprouty (Zhang et al. 2016). The cyclin dependent kinase inhibitor gene 
switchboard is interlinked to the expression of SPRY genes. In vivo and in vitro studies support 
the demotion of colorectal carcinoma upon declined expressive status of sprouty genes 
(Zhang et al. 2016). 
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1.2.7 Up regulatory status of p21 in chemotherapeutic induced cancer arrest  
Reports have shown increased expression status of p21 protein in several cancers in response 
to apoptosis induced by conventional chemotherapeutics including genistein, 
lysophosphatidic acid etc (Majid et al. 2008; Wu et al. 2011). Apart from FDA approved 
chemotherapeutics, commercially available antibiotics including ascocholrin and 
ascofuranone have also proved to possess not only antibacterial properties, but also are 
promising anticancer agents according to latest in vitro report (Jeong. 2010). In vitro study 
emphasize the promising therapeutic index of several iron chelating agent such as Dp44mt 
(Rao et al. 2009). Chelating effect varied with cancer type.  p21 expression was observed to 
be elevated in pancreatic and melanoma malignant tissues exposed to Dp44mt. On the other 
hand, Dp44mt evidenced a declined p21 expression in breast cancers (Rao et al. 2009).  
Hence these anti-cancer agents are found to be promising treatment strategies towards p53 
mutant cancer treatments and safe to use as they are proved non - toxic through in vivo 
investigations (Rao et al. 2011; Rao et al. 2009). Besides, chemotherapeutics, dietary fibre 
content helps as a defensive factor in colon tumour, as they release an important compound 
called butyrate which abstain anti - tumour progressive properties. Translation of p21 protein 
is studied to be an inevitable factor in assisting butyrate provoked cell death in colorectal cell 
lines HT-29 (Schlörmann et al. 2015; Archer et al. 1998). p21 is also reported to be an 
upstream regulator of apoptosis mediated through caspase - 3, 8 and 9 in leukaemia cell lines 
U937 transfected with grape seed extracts (Gao et al. 2009).  
1.3 Role of p21 in cell cycle regulation and HSPA1A  
The tumour suppressor gene p21 plays a major role in controlling the eukaryotic cell cycle in 
response of several factors including DNA repair, cellular inflammation and oxidative stress. 
p21 mediates this regulatory function by directly inhibiting the function of cyclin dependent 
kinase complexes Cdk 2,4 and 6 at the G1 phase, Cdk2 at the G2 phase and PCNA - cell prolif-
erating antigen at the S phase, thus preventing their role in DNA replication, finally arresting 
cell cycle progression (Gartel et al. 2002). The function of p21 exclusively dependent on the 
phosphorylation of p21 protein at different sites, which in turn determines its function in halt-
ing the cell cycle check points. Reports also show that phosphorylation of p21 at threonine 
145 prevents p21 assisted PCNA inhibition, preventing DNA synthesis (Li et al. 2002). 
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Besides the phosphorylation status of p21, its localization within the cell compartments de-
termine its function as positive or negative regulator of cell cycle. The presence of this protein 
in the nucleus presents its function in negative regulation of cell cycle, while its location in the 
cytoplasmic region reflected its role in tumour promotion (Xia et al. 2004). Moreover, studies 
reflected the degradation of p21 by E3 ubiquitin ligases, which in turn compromises the sta-
bility of p21 with in cells. 
Intriguingly, the anti-proliferative stress response mediated cellular arrest are studied to be 
overridden by the counter protective role of heat shock protein HSPA1A in eukaryotic cells 
(Daugaard et al. 2005). The heat shock protein HSPA1A function in binding to and re-estab-
lishing the functional status of impaired proteins, thus prevented cell cycle arrest. Reports 
have stated the inhibitory status of HSPA1A not only in enhancing cellular arrest but also sug-
gesting its inhibitory status in sustaining cellular stability (Daugaard et al. 2005). Studies have 
evidenced the active binding of HSPA1A with the tumour suppressor protein p53, which pre-
vented the interaction of HSPA1A from repairing damaged proteins, resulting in enhanced 
cell death in cancer cells (Elengoe et al. 2015). However, no studies have elucidated the inter-
action of HSPA1A and p21 proteins. 
1.4 Apoptosis and necrosis in eukaryotic cells 
In eukaryotic cells, the process of apoptosis, which is considered as programmed cell death, 
through which the cells undergo dramatic changes morphologically, form apoptotic vesicles 
comprising aggregates of the mitochondria, ribosomes and condensed nucleus bound within 
the rigid cell membrane as illustrated in (Fig 1.5 A). Whereas in case of necrotic cell death, the 
cell membrane ruptures releasing the disintegrated cell organelles as illustrated in (Fig 1.5 B). 
Finally, the cells that undergo death by either of the pathways are eliminated from the system 
by the process of phagocytosis ( Fink et al. 2005).  
The stress protein HSPA1A has been reported to have strong interaction with the apoptotic 
pathway, hampering cell death. The apoptotic pathway in brief involves the participation of 
several signaling molecules that include mitochondrial product - cytochrome c which upon 
binding with Apaf - 1, finally generates apoptosome, which is the fundamental element to 
initiate the apoptotic process. HSPA1A play an anti - apoptotic role in hampering the 
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generation of apoptosome, thus protecting cancer cells from undergoing apoptosis (Beere et 
al. 2000).  
                                              
 
Fig 1.5 The diagram illustrates eukaryotic cell death routes (A) Apoptotic cell death which involves the formation of 
apoptotic vesicles comprising of cell organelles enclosed within rigid cell membrane; (B) The necrotic death route in which 
the disintegrated cell organelles are released to the cell exterior; adapted from elsaivadoria.com; (Fink et al. 2005). 
1.5 Cancer treatments and issues addressed  
1.5.1 Surgery 
Cancer at it’s initial stage is highly localized small tissue outgrowth. This tissue mass increase 
in size reaching its secondary cancer stage. The cancer cells eventually migrate to surrounding 
tissues and reaches the stage of angiogenesis – the third stage of cancer. Once the cancer 
enters the circulatory stream, it spreads uncontrollably. Tissue resectioning is a successful 
cancer treatment for benign tumour and solid malignancies until it breaches the stage of 
angiogenesis. Once the cancer is metastasized to the surrounding tissue regions, surgery 
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along with adjuvant chemotherapy or radiation therapy is administered, refraining the cancer 
from further proliferation. Surgery is recommended as first phase treatment of colorectal 
cancers, followed by adjuvant therapies administered to prevent future reoccurrence (Dorudi 
et al. 2002). Surgery on the otherhand is not suitable treatment strategy for leukaemia 
cancers as the cancer cells are localized in the circulatory blood stream. 
1.5.2 Radiation therapy 
Treatment of cancerous tissues with ionising rays such as X - rays, ultra violet rays 
independently and in combination with chemotherapeutics accounts for more than half of 
the cancer survivals. Undesirable side effects generated due to radiation exposure is of high 
consideration, hence this issue needs to be tackled by modulating this treatment approach 
more tumour precise, expressing less side effects. The radiation waves results in direct 
accumulation of energy in the exposed tissues, creating multiple breaks in the nucleic acid 
resulting in cellular death irrespective of cancerous or healthy tissues (Maier et al. 2016). 
Despite inducing DNA destruction, the effects of radiation rays are studied to activate the 
transcription of several anti - apoptotic genes. These genes include mainly the AKT/P13 
signalling pathway, which are closely associated with the transactivation of enzyme DNA 
dependendent protein kinase, which assist non - homologous repair of broken stands resulted 
from radiation therapy (Schuurbiers et al. 2009). Hence, this anti - cancer signalling pathway 
play a crucial role not only in defending cancer cells from undergoing programmed cell death, 
but also studied to be the main cause for emerging insensitiveness to radiation therapy (Hein 
et al. 2014). Other genes including the members of mitogen activated kinases (MAPK) are also 
evidenced to protect cancer cells from death responses from radiotherapy (Dent et al. 2003). 
The underlying molecular mechanisms behind the enhanced transcriptional status of MAPK 
genes upon radiation exposure varied with the cancer type, with various factors in close 
connection including the cellular growth signalling members of the P13 kinases and autocrine 
mechanisms (Dent et al. 2003). Hence, there arises the necessity to develop treatment 
modalities capable of attenuating these anti - apoptotic signalling networks, which may 
enhance the therapeutic index of radiation - based cancer treatments. 
1.5.3 Chemotherapy 
Chemotherapeutics are potent in triggering apoptosis in cancercerous tissues due to their 
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active participation in enhancing expression of tumour suppressor genes, inhibition of heat 
shock proteins, BCL2, ATG5, coupled with low expression status of VEGF genes (Lai et al. 
2012). Cancer therapeutics such as ginsenoside are reported to actively release the immune 
T - cell effector molecule IFN – γ, which resulted in immune response induced apoptosis in 
melanoma and colon cancers (Keum. 2016). Moreover, Ginsenoside treatment also showed 
elevated expression of heat shock proteins HSP60, HSP70 and HSP90 which reflects the active 
participation of these proteins in apoptosis induced by ginsenoside (Son et al. 2016). 
However, one of the major concerns in using chemotherapeutics is that it destructs healthy 
tissues as well.  
1.5.4 Combination therapies 
Due to gradual resistance addressed by 5 - fluorouracil administration, combined treatment 
of 5 - fluorouracil with other chemo agents like leucovorin, methotrexate, oxaliplatin and 
irinotecan has paved the way for improved treatment outcomes in advanced cancer stages. 
However, in relapsed colorectal cancer conditions, 5 - fluorouracil fails to produce the 
expected treatment outcome, presenting 80-85% of drug resistance (Boige et al. 2010). This 
insensitiveness of cancers towards conventionally available chemotherapeutics confines to 
poor survival rates, which is the major problem encountering cancer treatment.  
Research studies show that combining 5 - fluorouracil with curcumin, which is generated from 
the root portion of turmeric plant accelerates anti - metastatic properties, initiating 
cytotoxicity in HCT - 116 colorectal cancer cells which were found insensitive to 5 - fluorouracil 
treatments in its intact form (Shakibaei et al. 2015). Cancers irresponsive to intact 5 - 
fluorouracil depicted significant cytotoxicity upon treatment with curcumin at limited dose as 
low as 5µM of 5 - fluorouracil in original HCT - 116 cell lines (Shakibaei et al. 2015). Curcumin 
in combination with anti-cancer agents have shown accelerated effects compared to 
chemotherapeutics in its intact form (Shakibaei et al. 2015; Giaccone. 2004). Curcumin in 
combination with 5 - fluorouracil works through strict management of thymidylate synthase, 
which plays a major role in DNA repair and replication process, in turn blocking the function 
of nuclear factor kappa in breast cancers (Tian et al. 2012; Vinod et al. 2013). Drug 
combination trial including irinotecan and 5 - fluorouracil have increased the treatment 
efficacy in highly relapsed cancer cases, most effectively in colorectal cancers (Rothenberg. 
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2001). Clinical trials focused on implementing irinotecan together with cisplatin 
administration reflected improved therapeutic index in various malignancies involving small 
cell lung cancers (SCLC) and non - small cell lung cancers (NSCLC). Although several studies 
reveal the activity of topoisomerase 1, the mechanism of irinotecan remains unclear. An 
insight into exact cellular activity by irinotecan administration, and the causes of drug 
insensitivity may throw light in designing cancer therapeutic like irinotecan in a more target 
specific manner, making it a complete chemotherapeutic (Rothenberg. 2001). 
Although conventional treatment strategies arrest cancer growth, these treatment 
approaches are found to express side effects and so are deleterious to the healthy cells. 
Moreover, in relapsed cancer conditions, these treatments tend to become less responsive, 
leading to increased mortality rates. Hence in this present scenario, there arises the necessity 
to establish highly responsive treatments with confined side issues.  
1.5.5 Hyperthermia treatment 
Besides, chemotherapy and radiation therapy, heat therapy is also an effective treatment 
modality for cancer. Hyperthermia at temperature range within 45℃ evidence cancer cell 
destruction, even in deep tissue destinations (Hildebrandt et al. 2002). Cancer cells disrupted 
due to heat induction, release damaged proteins to the cell surface, which act as alarm 
signals, by which the host immune cells detect the threat and act accordingly (Skitzki et al. 
2009). 
Interestingly, administration of hyperthermia has reported to enhance the therapeutic po-
tential of cancers. Hyperthermia evidence to work through ubiquitination of the FLIP protein 
which is involved in modulating death receptor signalling, directing the transactivation of the 
mitochondrial apoptotic pathway resulting in apoptosis in colorectal cancers (Song et al. 
2013). Studies also reflected the key role of hyperthermia in combination with as β - elemene 
which mechanistically arrested the cell cycle at the S phase, enhancing the transcription of 
apoptotic factors p21 and BAX genes in accelerating apoptosis (Wu et al. 2017). Their findings 
also reflect the active participation of hyperthermia in suppressing further proliferation of 
cancer cells, enhancing the therapeutic index of lung malignancies (Wu et al. 2017).  
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Moreover, adjuvant administration of hyperthermia with currently practised treatments play 
a major role in rendering the natural self - rectifying mechanism, preventing pro - survival of 
cancer cells (Oei et al. 2015). Thus, allowing treatment modalities to overcome resistance 
towards conventional cancer therapeutics (Oei et al. 2015). Report show the active 
participation of hyperthermia in inducing apoptosis through caspase - 3 activation and 
increasing the expression of p38 in adjuvant therapy using baicalin in leukaemia cell lines 
U937 (Zakki et al. 2018). Moreover, hyperthermia effect could also be boosted by the effect 
of antioxidant such as melatonin, which can activate the mitochondrial apoptotic signalling 
factors in Leukaemia cell lines U937 (Quintana et al. 2016).  
The side effects generated due to conventional cancer treatment strategies often weakens 
the host system. Studies also point that hyperthermia in combination with conventional 
treatments help in eliciting host immune responses, which is eminent in defending cancer 
cells from further proliferation post conventional treatment strategies. Hence the destructive 
impact induced by hyperthermia helps overcomes the resistance experienced with 
conventional treatment and the confined side effects of hyperthermia to non - cancerous 
tissues makes it an excellent treatment strategy for cancer treatment (Ahmed et al. 2013).   
1.5.6 Natural anti-cancer agents 
Apart from conventional cancer treatment strategies, naturally occurring phytochemicals are 
also experimentally proved to have effective anti-cancer properties. Over the years, studies 
have showcased the cancer therapeutic efficiency of individual application of herbal plant 
parts individually. However recent reports highlight the therapeutic potency of using the 
whole plant essence of Asteraceae and Urtcaceae (Solowey et al. 2014). This report highlights 
the effectiveness of Urtcaceae herbal contents in not only inducing apoptosis, but also in ren-
dering further proliferation of breast malignancies. Moreover, these herbal essences are 
proved to be highly cancer targeted, hindering the healthy tissues from its cytotoxic effects 
(Solowey et al. 2014).  
Besides herbal anti-cancer agents, chemical compounds enriched in foods including broccoli 
and watercress are evidenced to have profound anti-cancer properties capable of arresting 
the roots of colorectal carcinomas (Pereira et al. 2017). In vitro studies reveal the therapeutic 
potential of phytochemicals enriched in curcumin, which play a major role in blocking the 
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construction of new circulatory routes within cancer cells, finally suppressing metastasis 
(Shao et al. 2002). Apart from curcumin, vitamin D also shown to disrupt the function of re-
ceptor tyrosinase activity, which in turn repress cancer growth, angiogenesis and induce pro-
grammed cell death in breast, prostate and colorectal malignancies (Campbell et al. 1997; 
Chakraborti et al. 2011).       
1.6 Strategies in improving the therapeutic potential of cancer therapies 
1.6.1 Intracellular delivery entities - nanoparticles and drug delivery 
Although conventional therapies including chemotherapy are effective treatment strategies 
against cancers, the side effects generated due to high dose administration, poor drug 
bioavailability and chemo - resistance are some of the issues encountered by these 
treatments. Hence, these issues could be resolved with the use of nano-based drug delivery 
systems, which are becoming powerful and promising platform for cancer therapies. Nano 
elements modulated with specific surface ligands such as polyethylene glycol  with nano scale 
ranging from (1nm to 100nm) provides direct access towards precise tumour destinations 
within biological systems enhancing effective drug delivery (Davis et al. 2008). Moreover, 
studies show that nanoparticles known as nanoflares introduced into the circulatory stream 
helps bind the cancerous cells due to their selective cancer target binding property resulting 
in light emission upon reaching the cancer destination. Hence, these agents are excellent 
diagnostic tools, thus promoting opportunities for developing new perspective cancer 
therapies (Davis et al. 2008). 
Nanoparticles  engineered from different sources such as metals, liposomes, dendrimers, 
nucleic acid, protein and polymer conjugate nano particles are explored to have therapeutic 
application as drug carrier platforms in medical oncology (Zhang et al. 2008). As far as drug 
delivery is concerned, the most important aspect is the selection of nanoparticle, taking into 
concern, its toxic free nature, high rate of biodegradability, prolonged circulation time and 
targeted drug delivery application within biological systems. These properties of 
nanoparticles help overcome certain limitations of conventional therapy such as reduced drug 
bioavailability, high dosage induced toxicity and developing drug resistance together with lack 
of specificity affecting both cancerous and healthy tissues irrespectively are few of the issues 
encountering traditional cancer therapies. Studies interprets that iron nanoparticles from 
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degraded spions, which comprise  superparamagnetic properties are absorbed naturally by 
hemoglobin, the iron reservoir of the human system (Nakamura et al. 2013). Moreover, the 
super magnetism provides magnetic resonance imaging, which helps to quantify the iron 
accumulated in the brain due to disease conditions such as multiple sclerosis, helping 
clinicians diagnose cancer status and to modify treatment procedures accordingly (Nakamura 
et al. 2013). The therapeutic and diagnostic application addresses spions as promising 
candidates for effective delivery and tracking of biological anti-cancer agents to intended 
tumour regions and brings hopes of developing highly potential and safe personalized cancer 
therapies, reducing cancer mortality. 
Magnetic nanoparticles are competent systems possessing diagnostic as well as therapeutic 
value. The magnetic nano spheres function to elevate the normal body temperature within 
cancer tissues, a mechanism known as hyperthermia, resulting in DNA damage, making 
tumour tissues more susceptible towards conventional chemotherapy and radiotherapy 
(Giustini et al. 2010). These magnetic particles possess electro - magnetic energy, once 
entering a magnetic undergo oscillatory movement releasing heat high enough to degrade 
proteins associated with tumour progression (Giustini et al. 2010).  
The sizes of magnetic nanoparticles are of great consideration in creating the desired 
hyperthermia effect. The smaller the particle size the more effective will be the hypothermic 
effect and lesser will be the interaction between particles, which in turn prevent particle 
aggregation. On the other hand, as the particle size increases, the particles fail to cross 
biological barriers within cancer tissues, ending up in particle aggregation, which are studied 
to cause deleterious effects such as hemostasis (Bañobre. et al. 2013). 
Taking together the issues generated due to size distribution of these magnetic nanoparticles, 
researches are now focusing at modifying the outer surface of these nano spheres with 
biological polymers or site-specific antigenic receptors, which enables specific targeting of 
cancer cells and initiate hypothermic effect (Manual Baobre. 2013). 
Metals nanoparticles of gold, silver, iron and copper are excellent nano carriers in the field of 
biotechnology. Scientists are evaluating the intracellular dispensation of gold nanoparticles 
within human systems using computer system - based research. These computational 
analyses may provide access to information regarding not only bio - distribution of nano 
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elements, but also helps in assessing the toxic nature of nano elements, which is to be taken 
into high consideration in developing safe drugs (Cheng et al. 2018). Apart from various 
chemo - agents, doxorubicin produces expected results in primary lung cancers, doxorubicin 
together with other chemo - agents are also applicable for relapsed cancers. Doxorubicin 
packed within nano - delivery systems of poly (butyl cyanoacrylate) was developed by 
researchers to overcome the poor drug bioavailability within circulatory system to produce 
desired cytotoxic activity within lungs (Consolacion et al. 2015).  
Statistical analysis reveals pancreatic cancers as a major disease presenting increased 
mortality rates (Del Chiaro et al. 2014). Gemcitabine is widely accepted drug administered for 
pancreatic cases. Although the drug shows desired cytotoxicity against pancreatic cancers, 
the problem encountering gemcitabine drug involves poor bioavailability due to very confined 
drug retention rate of up to 8 minutes within circulation (Kevin Affram et al. 2015). 
Researchers are focusing at improving the therapeutic potential of this drug by designing the 
drug, encapsulating the drug in liposomal delivery vehicles, to enhance prolonged drug 
circulation time to produce expected cytotoxicity towards pancreatic carcinomas (Kevin 
Affram et al. 2015). 
Ibuprofen an anti - inflammatory drug which is administered normally through oral routes 
were framed with chitosan polymer together with glutaraldehyde reagent, emulsified with 
equal volumes of toluene, this clinical study aimed at bringing low gastric aftereffects 
normally developed due to prolonged Ibuprofen intake (Kcofokansi. 2013). The study 
presented expected results showing substantial drug output from the micro - system 
preventing undesirable effects caused as result of ibuprofen in its intact form (Kcofokansi. 
2013). 
Using felodipine as a model drug, Jung. A. Ko and group demonstrated the difference in drug 
output from microparticles generated by ionic cross - linking process, their data evidenced to 
have high impact in iso - electric nature of the system (Jung.A. KO. 2014). The pH of the cross-
linking mixture increased together with drug liberation rate. Moreover, their finding also 
suggest that drug encapsulation and liberation is not only solely dependent on high pH and 
concentration of the cross - linking agent, but also based on the low molecular weight of 
chitosan molecule as low as 1% in concentration.  
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In human systems, liver is the main organ which plays the eminent role in removal of 
unwanted by - products, and so will be the final settling destination of retaining nano -
elements in nano - drug administrations. A systemic clearance is required to avoid un-
necessary accumulation of these nanoparticles in liver and other body parts, to prevent other 
nanoparticle - based inflammations and disorders. A nano drug administration experimental 
investigation evidenced a systemic release of cyano - acrylic nanosphere released by living 
systems naturally. The size distribution of the nanoparticles displays the major part in exerting 
toxicity. The smaller the dimension the higher is the toxic effect. Researchers exhibit that 
human lymphatic tissues are capable of gripping nanoparticles at surface area less than 100 
nano - meter rapidly than intestinal tissues, revealing that toxicities are borne to be likely 
affected towards lymphatic cells by low nano - scales delivery systems (Jafar Ai et al. 2011).  
One of the major problems hampering chemotherapeutic administration are confined with 
the side - effects. Second issue is about poor drug retention of these agents under circulation, 
considering precise drug release and bioavailability. In case of 5 - fluorouracil treatment, 
researchers framed this drug within liposomes for a site-specific continual release 
performance. Their results evidenced a gradual release from the delivery system, providing 
enhanced bio - availability together with enhanced cytotoxicity. This in vitro assessment 
related drug release to the pH of the environment and the drug release was higher at acidic 
pH and reduced release was observed at alkaline pH (Ofonime Udofot. 2015). 
Together with improved drug retention, a systemic clearance of drugs from human system is 
equally important. Taking this aspect into concern, bio - degradable entities are interesting 
for drug designing. In various processes, various types of cross-linking polymers are used, that 
define the swelling capacity and size of the particles, encapsulation efficiency and bio-
availability together with temperature and pH control of systems. 
Moreover, considering the aggregation of nanoparticles after drug delivery, a clear 
understanding of their biological clearance is a necessity to introduce them as safe 
therapeutics within living systems. Hence in this present scenario, due to the increasing 
resistance to conventional treatment approaches, there arises the necessity to establish 
highly responsive tumour targeted drugs with confined side issues.  
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1.6.2 Carbon nanoparticles in clinical research 
Cylindrically modified allotropes of carbon are interesting candidates for accommodating 
large volume of therapeutic molecules. Therefore, several clinical trials subject to application 
of these nano tubes in cancer therapy are at the merge of clinical phase trials. In cases of 
Paclitaxel administration in cancer treatments, since the drug has poor bioavailability and 
solubility, they are rendered from producing the desired effect (Mahmood et al. 2009). 
Carbon nanotube mediated chemotherapeutic delivery, presents caspase - 3 activation, 
inducing apoptosis in pancreatic and brain tumour cell lines, the results suggest structural 
deformation and nuclear separation upon treatment with CNT agents, which eventually lead 
to programmed cell death (Mahmood et al. 2009; Liu et al. 2008). Researchers have evaluated 
the positive potential output of gold nano elements embedded in carbon nano tubes using 
different linkage systems. According to their experimental analysis multivalent carbon nano-
systems processing hydrazone linkage can release the delivery entity in environments entitled 
to have acidic pH levels (Jian Li et al. 2015).  
Our scientific community has proven in vitro and in vivo studies, highlighting the positive 
output of CNTS mediated drug transport entities for effective drug response at very limited 
doses. But considering, the safety of implementing these nano - elements within biological 
systems, the negative impacts which are likely to be produced by these drug delivery systems 
towards human body and the environment has yet to be thoroughly examined and are still of 
high concern. Several nano - toxicological studies suggest the toxic aftereffects exerted by 
these nano molecules towards introducing respiratory disorders (Buzea C et al. 2007).  
1.6.3 Chitosan nanoparticles - properties and applications 
The exoskeleton of crustaceans possesses a component known as chitin, which is decalcified 
and deacetylated to extract chitosan, an efficient polymeric carrier system for the delivery of 
chemotherapeutic drugs (Ahsan et al. 2017). Chitosan molecules are highly degradable. Their 
biocompatible nature, together with scarce toxicity and high target accessing potential 
designate chitosan nano - combinations outstanding in drug delivering applications (Kalpana. 
2010). Chitosan is predominantly soluble in organic acids and it confers a positive charge 
enhancing electrostatic interactions, which is necessary for nanoparticle formation within 
colloidal systems. The mucus adhesive characteristic feature of chitosan confines it not only 
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to cancer drug deliveries but also for ophthalmic conditions, in which drugs are required to 
be transported across the mucosal barriers (Artursson. 1994).  
The molecular weight of chitosan molecule plays a prominent role during the degradation 
process within biological systems. The lower the molecular weight the easier will be the 
degradation. In cases of ophthalmic disorders, chitosan nanoelements after drug delivery 
undergo degradation by the enzyme lysozyme present abundantly within ocular areas (Maria 
Jose et al. 2003). Hence low molecular weight chitosan are selective natural polymers for drug 
transport applications.   
Chitosan molecules are excellent carriers of proteins as the stability and bioavailability of 
proteins are well maintained upon chitosan encapsulation. Studies shows that proteins such 
as insulin embedded in chitosan polymer matrix were well insulated from gastric fluid 
degradation, promoting greater drug retention and controlled release for prolonged time 
duration (Zhang. N. 2010). MicroRNAs are studied to play an eminent part in knocking down 
proteins associated with prostate cancer progression. A recent study highlights that 
introducing chitosan encapsulated MiR-34a, depicted a massive decline in proliferative 
activity in bone metastatic prostate cancers in a xenograft model compared to that of existing 
FDA approved drugs for such cases (Sanchaika et al. 2015). 
Apart from the aspect of drug delivery application, chitosan is investigated to have good 
potential as an antimicrobial agent. Report refer to the amino - groups in chitosan responsible 
for hindrance of microorganisms (Anders y et al. 2008), however, the anti -microbial activity 
of the compound is still inexplicit. Although 5 - fluorouracil is a broadly accepted 
chemotherapeutic for head, neck, pancreatic, breast cancers and highly recommended 
therapeutic for metastatic colorectal carcinomas, however it is bound to express less 
therapeutic index combined with higher  issues including cardiovascular toxicities (Llorca 
Ferrandiz et al. 2005; Focaccetti et al. 2015).  
Hence Research studies are now focused at improving the bioavailability of these 
fluropyramidines through induction of nano - technology. Chitosan and alginate  are naturally 
occurring toxic free molecules which are studied to be successful drug carrier entities (Ciofani 
et al. 2008). The acid pH nature of the drug encapsulated chitosan matrix directs the nano 
sphere to release drugs at precise tumour destinations, setting free the healthy tissues from 
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the deleterious side effects exerted by the drug upon independent administration (Bhattarai 
et al. 2010).  
Gefitinib is another extensively used chemotherapeutic which encounter its key participation 
in repressing the task of epithelial growth factor receptors, which in turn leads to 
programmed cell death in epithelial cancer cells. But the systemic absorption of gefitinib is 
considerably poor upon direct administration, therefore, studies are aiming at improving the 
bioavailability of gefitinib by entrapping in nano - sized carrier systems for pronounced drug 
effect at desired tumour destinations (Cappuzzo et al. 2005).  
1.6.4 Bovine serum albumin (BSA) nanoparticles 
Engineering toxic free protein nano - systems evidence to increase the therapeutic value of 
chemotherapeutics. BSA is one such entity, which is studied to be highly stable, with greater 
entrapment capacity and excellent biocompatibility and toxic free nature making them 
human friendly drug transporter compared to other natural polymers employed for drug 
deliveries (Yu et al. 2014). Moreover, BSA proteins are cleared out explicitly naturally from 
our human system by means of proteolysis. Hence, the application of this protein as a carrier 
molecule is widely accepted.  
Apart from bovine serum, egg white and human serum are reservoirs of albumin. Albumin is 
unique in its high solubility in water, blood and organic solvents like sodium chloride. The 
main role of the protein is associated with balancing osmotic pressure and transport of 
endogenous entities within cells. Studies evidence that albumin proteins unlike other proteins 
withstand structural stability even if exposed to temperatures as high as 60℃. This 
temperature resistive nature of this molecule makes them attractive drug carrier systems 
(Takeda et al. 1989). 
In patients suffering from inner ear illness, drugs administrated, upon travelling through the 
eustachian channels undergo disorientation, failing to reach the inner ear to perform desired 
treatment. Zhan Yu et al developed a novel nanoparticle system via heat denaturation, for 
treating infections associated within inner ear, using BSA for transporting Rhoda mine - B, a 
drug conventionally used for inner ear disorders. In vivo findings in guinea pigs evaluated by 
scanning electron microscopy and fluorescent imaging techniques exhibited prolonged 
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retention and penetration of the Rhoda mine - B - BSA loaded nanoparticles within the inner 
ear, producing expected drug effect (Zhan Yet al. 2014).   
In an in vitro research with gefitinib loaded folate encapsulated BSA nanoparticle in brain 
tumour, these nanosphere unlike free drug administration, exhibited their efficient 
participation in knocking down LC3 - microtubule - associated protein light chain -3, together 
with caspase activation in cancer cells initiating apoptosis (Yijie Shi et al. 2014). 
1.6.5 Lipid nanoparticles and transfection 
Lipid nanoparticles are explored to be efficient intracellular transport systems, which provides 
retention of transfection molecules accessible to biological systems for in vitro and in vivo 
gene transcriptional studies addressing high efficacy in their roles in therapeutic perspective 
(Müller et al. 2000; Yu et al. 2016). Research evidence lipofectamine CRISPRMAX to be highly 
recommendable transfection agent considering cell toxicities exerted by the system, 
compared to lipofectamine 3000 and lipofectamine RNA Imax (Yu et al. 2016). The in vitro 
transfection efficacy of these unique elements varies depending on the temperature 
fluctuations, studies interpret reduced particle segregation during frozen state, enhancing a 
more pronounced transfection activity of these lipid nano - systems (Sork et al. 2016). 
Considering toxicities exerted by other delivery entities, studies showcase lipofectamine 2000 
less toxic towards hepatic organs, moreover, their efficacy in delivering fluorescent tagged 
biological systems across intracellular destinations designate them attractive transfection 
system not only for in vitro experimental setting, but also for in vivo gene transfers as well 
(Gao et al. 2012; Enlund et al. 2014).  
1.6.6 Gene therapy  
Considering the after effects produced by conventional chemotherapy and radiation 
therapies and toxicities addressed by nano delivery systems, gene therapy is a promising 
platform for restoring the function of impaired target genes or enhancing the host defence 
mechanism, targeting only cancerous cells (Amer. 2014). 
Gene therapy is a therapeutic strategy in treating conditions evolved due to gene 
abnormalities or mutations. The first successful effort of administrating target genes in cancer 
treatment was established by inserting tumour suppressor gene p53, in 2003 by Chinese 
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researchers (Pearson et al. 2004). Studies are exploring the efficiency of several biological 
delivery agents including viruses, nanoparticles, plasmid DNA and lipoproteins and non - 
biological methods including electroporation for safe and targeted gene delivery applications 
(Niidome. 2002). A novel biological transfection moiety referred to as TEMTAC (Tunable 
endogenous mammalian target complementation system) has been recently explored to 
procure multifunctional properties, involving switching on and off several transcriptional 
factors respective to normal cellular requirements in mammalian tissues ( Benisty et al. 2015).  
Hence introducing these multifunctional implants may pave way for highly targeted and more 
promising treatment strategy, not only for cancers but also several other disorders associated 
with gene overexpression or in non - functional modes.  
Latest investigation in gene therapy referred to as CAR T, which entitles the genetic 
modification of patient’s immune cells ex vivo and reinstallation, act as powerful tool for the 
treatment of acute lymphoblastic leukaemia cases however, this therapeutic strategy is 
studied to be ineffective for solid malignancies (Richard et al. 2017). 
In in vitro experimental settings, nucleic acids need to be safely transported across cellular 
membranes for successful gene transfection and expression studies, making experimental 
studies quite challenging. However, in clinical setting, although nucleic acids are studied to be 
easily administered through intravesical or intra - cutaneous routes for in vivo therapeutic 
applications, the treatment reflects reduced efficacy due to less genes reaching the desired 
destinations (Jinturkar et al. 2011). Hence to reflect a complete gene therapeutic index, the 
therapeutic genes needed to be successfully delivered to target destinations.  
The second phase of this thesis have explored the cytotoxicity of chitosan and BSA based 
microgels and microparticles in colorectal cancer cell lines HT - 29 with the objective of using 
it for delivery of plasmid DNA for evaluation of transfection studies under non - cytotoxic 
circumstance. 
1.7 Rationale of the study 
Colorectal cancer is the world’s third leading cancer according to recent statistics (Siegel. et 
al. 2014). One of the eminent challenges, cancer patients facing is the developing resistance 
to conventional therapeutics (Axelrod. et al. 2017). Hence the necessity of developing highly 
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personalised treatment strategies are at top priority. In vitro studies have evidenced the over-
expression of p21 in inducing apoptosis, demonstrating that p21 protein in its inactive stage 
has turned into its active form in response to the anti - cancer agents and is found to play a 
crucial role in arresting the cells at the G1 and G2 phase of the cell cycle, thereby preventing 
cellular proliferation (Gartel. 2002; Pavelic et al. 2008).  p21 gene functions a negative atten-
uator of DNA replication, in response to translation of several genes including PCNA and p53 
in attenuating cancer proliferation (Pavelic et al. 2008). 
Besides the tumour suppressor protein p21, another protein - HSPA1A is often elevated in 
tumour cells and has an anti-apoptotic activity. Eukaryotic cancer cells under physiological 
stress response are encountered with elevated levels of stress protein HSPA1A, which are 
studied to participate closely with signalling pathways assisting a protective role under cellu-
lar stress, enhancing tumorigenicity. Recent studies, reveals the resistance acquired by 
chemotherapeutic in colorectal cancer cells abstaining elevated levels of HSPA1A, expressing 
its defensive role against apoptosis (Grivicich. et al. 2007).  
Hence, repression of HSPA1A proteins evidenced to improve the chemotherapeutic sensitiv-
ity in colorectal cancers (Sherman. 2015; Jagadish. et al. 2016). This thesis at the initial stage, 
investigated the inhibitory effects of HSPA1A using pifithrin - µ independently and in combi-
nation with UV and their roles in hyperthermia treatments in both leukaemia cancer cell lines 
U937 and colorectal cancer cell lines HT-29 to perceive the roles of HSPA1A in different cancer 
cells.  
1.8 Objectives and hypotheses of the thesis 
This thesis aimed at investigating whether a two - pronged approach, overexpressing p21 and 
inhibiting HSPA1A protein activity with pifithrin - µ, would be effective in inducing apoptosis 
in colorectal cancer cell line HT-29. 
Considering, the main aim of research, the thesis had the following objectives and 
hypotheses: 
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1.To evaluate the effect of antimycotic/ antibiotic on colorectal cancer cell lines  
                 HT-29. 
Hypotheses- 
H0 Antimycotic/ antibiotic will not induce stress or inhibit the growth of HT29 cells. 
H1 Antimycotic/antibiotic may induce stress response and inhibit the growth of HT-29 cells. 
 
           2.To investigate the role of HSPA1A protein in combination treatments including  
               UV radiation or hyperthermia. 
Hypotheses- 
H0 UV radiation, pifithrin chloride, pifithrin - µ or hyperthermia at 42℃ treatment will not 
induce cell death in leukaemia cell lines U937 and colorectal cancer cell lines HT-29. 
H1 UV radiation, pifithrin chloride, pifithrin - µ or hyperthermia at 42℃ will induce cell death 
in U937 and HT-29 and the inhibitory activity of HSPA1A protein by pifithrin - µ in combination 
with UV may enhance the treatment effect of UV in HT-29 and U937 cancer cell lines. 
 
            3.The effectiveness of chitosan or BSA modulated intracellular delivery systems for 
                       the successful and safe delivery of human p21 - plasmid DNA for transfection  
                studies on colorectal cancer cell lines HT-29. 
 
 Hypotheses - 
H0 chitosan or BSA modulated intracellular delivery systems will be non - cytotoxic in drug 
free states on HT-29 cells. 
H1 chitosan or BSA modulated intracellular delivery systems will be cytotoxic in drug free 
states on HT-29 cells. 
 
          4. Whether the inhibitory activity of HSPA1A proteins would accelerate the    
                     apoptosis induced by p21 plasmid DNA transfection in HT-29 cell lines. 
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Hypotheses - 
H0 transfection with p21 plasmid DNA will not arrest the growth of HT-29 cells and inhibition 
of HSPA1A in combination with increased p21 will not enhance apoptosis in HT-29 cells.   
H1 transfection with p21 plasmid DNA may arrest the growth of HT-29 cells and the inhibition 
of HSPA1A in combination with increased p21 will enhance apoptosis in HT-29 cells.   
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Chapter 2 
2.1 Materials 
     Table 2.1.1 Laboratory materials  
Consumables 
 Micropipette (1-5 ml) 
 Micropipette (1000 µl) 
 Micropipette (100-500 µl) 
 Micropipette (10 -100 µl) 
 Micropipette (1 - 10 µl) 
 Micropipette (0.2 - 2 µl) 
 Microplate 96-well sterile flat bottom lidded 
 Microplate 96-well sterile v- bottom lidded 
 Microplate 6-well sterile flat bottom lidded 
 Tissue culture flasks (25cm³)                                 
 Centrifuge tubes (15 and 50 ml) 
 Micro centrifuge tubes (0.5, 1.5 and 3 ml) 
 Micro adhesive plate seals 
  
 
Manufacturer 
Thermofisher scientific 
Thermofisher scientific 
Thermofisher scientific 
Thermofisher scientific 
Thermofisher scientific 
Thermofisher scientific 
Costar 
Costar 
Thermo scientific 
Costar 
Thermo scientific 
Thermo scientific 
Thermo scientific 
 
Catalogue number 
LH 96952 
MH 60159 
MH 59984 
MH 37243 
MH 59944 
MH 59204 
01317002 
CUS 326801 
01617052 
136196 
156499 
S1615,5500 
00445503 
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 Table 2.1.2 Laboratory equipments 
Equipment 
 Incubator (water jacketed) 
 Biological safety cabinet 
 Microscope 
 Haemocytometer 
 Cooling centrifuge (Heraeus, multifugeX3R) 
 Centrifuge (Heraeus, Fresco 17) 
 Mini vortexer 
 Water bath 
 Hot plate vortexer 
 Microplate reader (Varioskan LUX) 
 pH meter (AB 150Ph/mv 
 Nano drop (Simplinano) 
 BD Accuri flow cytometer 
 Electrophoresis system 
 Power pack (1000 volt) 
 G-Box gel imaging (Chemi X RQ)  
 Scanning electron microscope 
 
Manufacturer 
Thermo scientific 
Thermo scientific 
EVOS, Life technologies 
EVOS, Life technologies 
Thermo scientific 
Thermo scientific 
Thermo scientific 
Fisher brand 
Clifton 
Biocote 
Thermo scientific 
 Fisher scientific 
 Biochrome LTD 
 BD Biosciences                     
 Thermo scientific 
 Syngene 
 Gemini 
 
 
Catalogue number 
20150709 
41852324 
SN 10415-1727-371 
B 1015-181C-024 
75004515 
75002420 
14-955-151 
115724 
01270524871 
3020166 
13-620-631 
29061712 
- 
- 
150728116 
D 24V2/3345 
- 
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    Table 2.1.3 Materials for cell culture and viability measurement assays 
Consumables 
 Leukaemia cell line -U937 
 Colorectal cancer cell line- HT-29 
 Eagle’s Minimal Essential Medium (EMEM) 
 Roswell Park Memorial Institute (RPMI)1640  
 Foetal bovine serum (FBS) 
 Trypsin-EDTA  
 Dimethyl sulfoxide (DMSO) 
 Trypan Blue 
 MTS reagent (4,5-dimethylthiazol-2yl)-5-(3- 
carboxy methoxyphenyl)-2-(4-sulfophenyl)-2H- 
tetrazolium                 
 Phenazine ethosulphate (PES) 
 Antimycotic/ antibiotic solution  
Manufacturer 
European culture collection 
European culture collection 
Lonza 
Lonza 
Life technologies 
Lonza 
Sigma aldrich 
Sigma aldrich  
 
Promega 
 
Santa Cruz                                         
 
Sigma aldrich   
 
  
 
 
 
 
Catalogue number 
85011440 
91072201 
BE 12-611F 
BE 12-702F 
10270-106 
BE 17-161E 
67-68-5 
T 8154 
G 3 582 
SC 215699 
P4170  
A 1593   
                                                      
 
 
 
 
 
 
       
   Table 2.1.4 Chemotherapeutic Drugs  
Consumables 
 Pifithrin - µ 
 Pifithrin chloride 
 5 - Fluorouracil 
Manufacturer 
 Sigma aldrich 
 Calbiochem 
 Sigma aldrich 
Catalogue number 
     P 0122 
      53106 
      F 6627 
    
51 
 
    Table 2.1.5 Reagents for microgel/microparticle preparation 
Consumables                                                                       Manufacturer          Catalogue number 
 Low molecular weight chitosan powder                         Sigma aldrich                       448869 
 β - glycerol phosphate                                                        Sigma aldrich                       G 9891-25G 
 Glutaraldehyde                                                                    Sigma aldrich                       G 5882 
 Sodium tripolyphosphate                                                  Sigma aldrich                        238503 
 Bovine serum albumin powder                                        Fisher Scientific                  E 0665 DF/17  
  
                                                                      
     Table 2.1.6 Reagents for flow cytometer 
Consumables                                                                           Manufacturer              Catalogue number 
BD Cytofix/cytoperm                                                             B D Biosciences                      51-2090KZ 
FITC Annexin V                                                                        BD Pharmingen                      556419 
Propidium iodide                                                                    Sigma aldrich                          25535-16-4 
 DPBS -Dulbecco’s phosphate buffered saline (500 ml)     Lonza                                       BE 17 513F                                                                            
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Table 2.1.7 Antibodies consumed 
Antibodies 
p21 Antibody (FITC conjugated) 
HSPA1A Primary antibody DEG 
HSPA1A Secondary antibody (extravidin FITC)   
Manufacturer 
Santa cruz biotechnology 
Purified in Laboratory 
 Sigma aldrich 
 
 
Catalogue number 
     SC 6246 
 
     E 2761 
 
   
Table 2.1.8 Reagents for bacteriological media preparation 
 
 
 
 
 
Consumables                                                                   Manufacturer                        Catalogue number 
Magnesium chloride                                                        Sigma aldrich                              M – 1028  
Magnesium sulphate solution                                       Sigma aldrich                               M - 3409                                                                                                                                     
Lactose                                                                               Sigma aldrich                               63 – 42 - 3 
Tryptone                                                                            Lab M Limited                             M C005 
Yeast extract                                                                     Lab M Limited                             M C 001 
Agar                                                                                     Oxoid                                           L P 0013 
Glucose                                                                              Sigma aldrich                               59 - 99 - 7 
Sodium chloride                                                               Fisher scientific                           7647 - 14 - 5 
Ampicillin                                                                           Fisher scientific                          11668030                                                   
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 Table 2.1.9 Commercial kits for p21 plasmid DNA based studies 
Commercial Kit 
Flag p21 plasmid 
Endofree maxi prep kit 
Restriction enzyme BamHI (10 U/ µl) 
Restriction enzyme Ndel (10U/µl) 
Hyper ladder (100 lanes) 
Gel red stain 
Agarose gel 
TAE buffer (50X) 
Isolate II PCR and gel kit 
DNA repair kit 
Pure link PCR purification kit 
Quick stick ligase kit 
DH5 α chemical competent cells 
Lipofectamine 2000 
Manufacturer 
Addgene 
Qiagen 
Thermo scientific 
Thermo scientific 
Bioline 
Biotium 
Promega                                                                                 
Fisher bioreagent 
Bioline 
Thermofisher scientific 
Invitrogen  
Bioline 
Bioline 
Invitrogen 
Catalogue number 
16240 
12162 
ER0051 
Er0581 
BIO-33053 
41003 
V3121
BP1332-1 
BIO 52058 
IVGN2504 
K3100-01 
BIO 27027 
BIO-85026 
11668 - 030 
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2.2 Preparation of tissue culture medium, reagents and buffers 
2.2.1 Tissue culture medium  
Eagle’s Minimal Essential Medium (EMEM) and Roswell Park Memorial Institute Medium 
(RPMI)1640 were supplemented with 10% of foetal bovine serum. The medium was stored at 
-20℃ and thawed in water bath preset at 37℃ before use. 
2.2.2 Reagents for cell - based assays 
2.2.2.1 MTS reagent 
MTS reagent 0.20% w/v was prepared using DPBS solution using magnetic stirrer. 1M HCl was 
used to adjust the pH of the solution to 6.5. Phenazine ethosulphate (PES) (0.09% w/v) was 
prepared in DPBS solution. The pre - prepared MTS solution 40 ml was incorporated with 2 
ml of PES thus prepared. The solution was aliquoted and covered for protection from light 
and stored for future use at -20℃. 
2.2.2.2 Phosphate buffered saline (PBS) 
1L of PBS was prepared by using sodium chloride (0.8% w/v), potassium chloride (0.02% w/v), 
potassium dihydrogen phosphate (0.024% w/v) and sodium phosphate (0.144% w/v). The 
solutes were dissolved in 850 ml of distilled water using magnetic stirrer. Upon complete 
dissolution of the solutes, the solution was made up to 1L with distilled water. 
2.2.2.3 PI reagent  
PI reagent (0.01% w/v) was prepared using PBS solution. The reagent was aliquoted and 
protected from light and stored at -20℃. 
2.2.2.4 Blocking buffer 10 ml  
Blocking buffer was prepared with FBS (5% v/v) in DPBS solution. Freshly prepared blocking 
buffer was used for experiments. 
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2.2.3 Preparation of chemotherapeutics 
2.2.3.1 Pifithrin chloride (1mM) 
1mM working solution of Pifithrin chloride was prepared by solubilizing 10 µl of (100 mM) 
stock in 990 µl of culture medium.   
2.2.3.2 Pifithrin - µ (100 mM) 
551.84 µl of filter sterilized DMSO was added to 10mg of pifithrin - µ to make 100 mM stock 
solution. 
2.2.3.3 5 - Fluorouracil (100 mM) 
10mg of 5 - Fluorouracil was dissolved in 768.75 µl of filter sterilized DMSO solution to make 
100 mM stock solution. 
2.2.4 Reagents for chitosan and BSA based microgels and microparticles 
2.2.4.1 Chitosan solution (1% w/v) 
Chitosan solution (1% w/v) was prepared using Low molecular weight chitosan in HCL (0.1 M) 
solution by magnetic stirring. The solution was filter sterilized prior to use. 
2.2.4.2 β - glycerol phosphate solution 
1ml β - glycerol phosphate solution of (0.5, 1, 5, 10% w/v) concentrations, were prepared by 
dissolving (0.005, 0.01, 0.05, 0.1g) beta glycerol phosphate powder accordingly using exactly 
1ml of distilled water. The mixture was sterile filtered before use. 
2.2.4.3 Hydrochloric acid (HCL) 10 ml (0.1M) 
10 ml of 0.1M HCL was prepared by diluting 1 ml of 1M HCL solution in a standard flask and 
make this up to 10 ml using distilled water and filter sterilized. 
2.2.4.4 Sodium tri - poly phosphate 10 ml  
Sodium tri - polyphosphate (0.1% w/v) was prepared using distilled and filter sterilized. 
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2.2.4.5 Aqueous acetic acid 10 ml (1% v/v) 
Acetic acid (1% v/v) was prepared by suspending 0.1ml of 99.9% acetic acid into 10 ml 
standard flask. The solution was made up to 10 ml using distilled water. 
2.2.4.6 BSA (10% w/v) 
0.1 g of BSA was suspended in 1 ml of pre - prepared 10mM NaCl solution to obtain 10% w/v 
concentration of BSA. 
2.2.4.7 Sodium chloride (10mM) 
 0.00584 g of sodium chloride was dissolved in 10 ml of distilled water to make a stock of    
10mM. 
2.2.5 Reagents for agarose gel electrophoresis 
2.2.5.1 Agarose gel 
Agarose gel (0.7% w/v) was prepared by dissolving 0.24g of agarose powder in 35 ml of pre-
prepared 1X TAE buffer, using hot plate magnetic stirrer pre - set above 100℃. The mixture 
was observed for complete dissolution. The mixture could cool as the hot solution may warp 
the casting apparatus. Upon reaching bearable temperature, 3.5 µl of nucleic stain gel red 
was added to the agarose. The gel solution was subsequently incorporated into the pre - 
casted gel apparatus and allowed to cool for 45 - 60 min until it is set for experimental 
proceedings. 
2.2.5.2 TAE buffer (1X) 
1 litre of (1X) TAE buffer was prepared by adding 20 ml of (50X) TAE stock solution into a 
standard flask and make up to exactly 1 L using distilled water. 
2.2.5.3 EDTA 1 ml (0.5 M) 
0.14612 g of EDTA was dissolved in 1 ml of distilled water to make 0.5 M EDTA solution. 
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2.2.6 Preparation of reagents and microbiological growth media 
2.2.6.1 Ampicillin antibiotic 10 ml (1% w/v) 
0.1g of ampicillin antibiotic was dissolved in 10 ml distilled water to obtain a final 
concentration of 1% w/v. This was filter sterilized before use. 
2.2.6.2 Preparation of Luria-Bertani broth 
Sodium chloride(4g), Tryptone (4g) and 2g of yeast extract were weighed into 360 ml of 
distilled water in a clean glass bottle. The mixture was dissolved using magnetic stirrer. The 
pH of the solution was then calibrated to 7.0 using 5M NaOH, and distilled water was used to 
make up the total solution volume to 400 ml. This was subjected to autoclaving. Following 
autoclaving, the broth was cooled, and filter sterilized ampicillin antibiotic (1% v/v) was added 
prior to use. 
2.2.6.3 Preparation of Luria-Bertani agar 
Sodium chloride (4g), Tryptone (4g), 2g of yeast extract and 8g of agar were weighed into 360 
ml of distilled water in a clean glass bottle. The added solutes were dissolved with the aid of 
magnetic stirrer. The pH of the solution was then calibrated to 7.0 using 5M NaOH, and 
distilled water was used to make up the total solution volume to 400 ml. Following 
autoclaving, the mixture was cooled and incorporated with filter sterilized ampicillin 
antibiotic (1% v/v). The mixture was uniformly poured in 20 ml volume into sterile disposable 
petri plates and allowed to solidify. The agar plates were stored in refrigerator at 4℃ with the 
lid upside down position or directly used. 
2.2.6.4 Preparation of SOC medium 
Sodium chloride (0.1g), Tryptone (4g) and Yeast extract (1g) were weighed into 150 ml of 
distilled water in a clean glass bottle. The added solutes were dissolved using magnetic stirrer. 
The mixture was made up to 200 ml using distilled water, autoclaved and allowed to cool. The 
medium was incorporated with filter sterilized 1M (1% v/v) of Magnesium chloride and 
magnesium sulphate. The medium was incorporated with 4 ml of 20% v/v sterile glucose prior 
to experimental use. 
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2.3 Methods 
2.3.1 Tissue culture  
2.3.1.1 U937 Leukaemia cancer cell line 
The leukaemia cancer cell line U937 in suspension were maintained in RPMI culture medium 
pre - supplemented with 10% foetal bovine serum. The cells were cultured in 25cm² tissue 
culture flask under sterile cell culture conditions and incubated at 37℃ in the incubator 
provided with 5% CO₂ and 95% air. The cells were observed every 24 h for normal growth. 
The cells upon reaching confluency of 70 - 75%, were sub cultured by seeding 1 ml of cells in 
9 ml of culture medium. 
2.3.1.2 Colorectal cancer cell line HT - 29 
Adherent cell lines of colorectal cancer HT-29 were maintained in EMEM cell culture medium 
under standard cell culture conditions in 25cm² or 75cm² cell culture flask in incubator 
provided with 5% CO₂ and 95% air at 37℃. The attached cells were subcultured upon reaching 
confluency of 70 - 75%, every 72 h. The cells were rinsed with 1 ml of trypsin/EDTA (0.25%) 
and the cells were resuspended with 2.5 ml of trypsin/EDTA (0.25%) and incubated for 5 - 7 
min in incubator at 37℃. The cells were then microscopically observed for surface 
detachment. Trypsin was deactivated by addition of 7.5 ml of EMEM medium incorporated 
with 10% FBS - containing α -1 antitrypsin, which inhibits the protease activity of trypsin. The 
cells were then pooled out from the culture flask using sterile pipettes onto sterile 15 ml 
centrifuge tubes. The cells were centrifuged at 500 x g for 5 min. The cells were then 
resuspended in EMEM culture medium and subcultured by seeding 2 ml of cell culture in 8 ml 
of culture medium. 
2.3.2 Frozen cell Storage and recovery 
The colorectal cancer cell line HT-29 and leukaemia cell line U937 were subjected to 
cryopreservation for future use. The U937 cells in suspension upon reaching growth 
confluency of 50 - 60% in cell culture medium were extracted by centrifugation at 500 × g for 
5 min. The cells were then resuspended in 1 ml of freezing medium comprising of 10% of 
DMSO in foetal bovine serum in pre - labelled 1 ml cryo vials. The HT-29 cell lines were 
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extracted as illustrated in (section 2.3.1.2), centrifugated at 500 × g for 5 min. The cells were 
then resuspended in 1 ml of freezing medium comprising of 10% of DMSO in foetal bovine 
serum in pre - labelled 1 ml cryo vials. The cryovials following 2 h incubation in liquid nitrogen 
were subsequently transferred into the cryostat. 
2.3.2.1 Recovery procedure 
The cancer cell lines stored in 1 ml cryovials in the cryostat were removed and recovered by 
thawing in a water bath pre - set at 37℃. The cells were then transferred into 25 cm² tissue 
culture flask containing 9 ml of cell culture medium. The cells were then incubated in 
incubator provided with standard tissue culture conditions. 
2.3.3 Determination of cell viability by microscope 
The cell viability of both the cancer cell lines were determined using trypan blue exclusion 
method prior to all experiments performed. The cells in suspension state (100 µl) were 
suspended in trypan blue reagent (100 µl) and 20 µl of cells in trypan blue was placed in 
haemocytometer and sealed using sterile cover glass. The cells were then observed and 
assessed for viability using light microscope. The viable cells were observed white in colour 
and dead cells due to disruption in cell membrane, absorbed the trypan blue dye and 
appeared blue in colour.  
2.3.4 MTS cell viability assay 
The MTS cell viability assay is based on enzymatic reaction. The compound tetrazolium 
present in MTS reagent is catalysed into a chemical known as formazan due to the presence 
of NAD (P) H-dependent dehydrogenase in viable cells. The cell viability is assessed at 490nm 
using plate reader. The MTS assay absorbance values defines the cell viability from the 
quantity of the reduced compound in the cell pool. 
The U937 cancer cell lines in suspension in 25 cm² tissue culture flask was counted using a 
haemocytometer. The colorectal adherent cancer cell lines grown in 25 cm² was trypsinated 
using trypsin EDTA as illustrated in (section 2.3.1.2). The cells count was determined using 
haemocytometer (section 2.3.3). The 96 well sterile assay plates were suspended with 100                       
µl/well of cancer cells at cell density of approximately 5 × 10⁵ cells/ml. Untreated cell lines 
were placed as controls. Dead cells plated at the same density were prepared by repeated 
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cycles of simultaneous freezing in liquid nitrogen and thawing in water bath pre - set at 37℃. 
Culture medium alone was also placed as reference. Treatment with U937 cancer cell lines 
were performed simultaneously upon seeding the cells in 96 well assay plates. However, the 
colorectal cancer cell lines HT-29 seeded onto the 96 well assay plates were allowed for 
attachment for 24 h at 37℃ in incubator. The cells upon attachment were replaced with fresh 
medium, except for the dead controls to prevent cell loss and subsequent treatments were 
performed. The cells were then allowed for incubation for 24 h or 48 h for the treatments. 
The cells following subsequent incubation are measured for cell viability by MTS assay. 
Approximately 20 µl of the pre - prepared MTS working reagent (section2.2.2.1) was added 
to each well of the 96 well assay plates containing cells and allowed for incubation for 1 - 2 
hours providing 37℃ in incubator. The cell viability was determined by measuring the 
quantity of the reduced product at an absorbance of 490nm using plate reader. 
2.3.5 Propidium iodide assay 
The propidium iodide assay is used to determine cellular necrosis. The intercalating bases of 
the DNA of the necrotic cells due to the absence of membrane stability are subsequently 
permeable to this fluorescent dye. The cells in cell culture medium, upon subsequent 
treatments were subjected to treatment with propidium iodide (0.5% v/v) working dilution in 
sterile phosphate buffered saline (section 2.2.2.2). 
Both the cancer cell lines used in the experiments were counted using haemocytometer 
(section 2.3.3). The cancer cells 100 ul/well at cell density of approximately of 5 × 10⁵ cells/ml, 
were seeded onto 96 well sterile assay plates. Untreated cell lines were placed as controls. 
The dead cell controls were prepared by repeated cycles of simultaneous freezing in liquid 
nitrogen and thawing in water bath pre - set at 37℃. Culture medium alone was also placed 
as reference. Treatment with U937 cancer cell lines were performed simultaneously upon 
seeding the cells in 96 well assay plates. However, the colorectal cancer cell lines HT-29 were 
seeded onto the 96 well assay plates were allowed for attachment for 24 h at 37℃ in 
incubator. The cells upon attachment were replaced with fresh medium, except for the dead 
controls to prevent cell loss and subsequent treatments were performed. The cells were then 
allowed for incubation for 24 h or 48 h for the treatments. Following incubation, the cells in 
culture medium were incorporated with 100 µl/well of propidium iodide dye, the cells were 
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subjected to incubation at 18℃  provided protection from light for 20 min. The relative 
fluorescence thus produced were measured using microplate reader (Varioskan LUX). 
2.3.6 Determination of annexin V and PI by flow cytometer 
The cancer cell lines U937 and HT-29 were detached from 75 cm² tissue culture flasks using 
trypsin/EDTA as illustrated in (section 2.3.1). The cell count was determined using 
haemocytometer (section 2.3.3). Cells at cell density of 1 × 10⁶ cells/ml were seeded onto 
each well of the sterile 6 - well assay plates. HT-29 cell lines were allowed for attachment for 
24 h incubation at 37℃. U937 cell lines were subjected to subsequent treatments 
simultaneously upon cell seeding onto 6 well assay plates. Following cell treatments and 
incubations, the cells were detached using trypsin/EDTA and transferred onto sterile v - 
bottom 96 well assay plates for cell preparation for flowcytometric assay. The cells were 
subjected to centrifugation in centrifuge pre - set at 500 x g for 5 min. The cells were then 
resuspended with ice cold phosphate buffered saline solution (100 µl) and centrifuged. This 
washing procedure was performed for 3 consecutive times. Following subsequent washing 
steps, all the treated cells, except for the controls were suspended with equal volumes of 
annexin V and PI reagents (2.5 µl each) diluted in 50 µl of binding buffer (1x). The annexin V 
reference were treated with only annexin V reagent (2.5 µl in 1X binding buffer) and PI 
reference control with PI 2.5 µl in 1X binding buffer). The assay plates were placed in plate 
shaker for uniform mixing of the reagents and placed in the dark for 15 min. All the cells were 
then subjected to addition with 200 µl of 1x binding buffer and flow cytometric analysis was 
performed within 60 min. 
2.3.7 Flow cytometric determination of HSPA1A and p21 protein   
2.3.7.1 Evaluation of intracellular and cell surface HSPA1A protein 
The cancer cell lines at cell density of 1× 10⁶ cells/ml /well of the 6-well assay plates, upon 
subsequent treatments were centrifuged at 500 x g for 5 min and resuspended in 100 µl of 
cell culture medium and transferred into 96 well v - bottom assay plates for preparing the 
cells for flowcytometric determination of protein expression. The cells were then centrifuged 
at 500 x g for 5 min and resuspended uniformly in 200 µl of DPBS solution to prevent 
formation of cell clumps. This washing procedure with DPBS was repeated for three 
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consecutive intervals. For determining intracellular proteins, the cells following centrifugation 
were resuspended in 70 µl of cell fixative and permeating reagent, sealed and placed in 
refrigerate for 20 min. Followed by 20 min refrigeration, the cells in fixative were diluted by 
adding 70 µl of DPBS solution without mixing. The cells were then centrifuged at 500 x g for 
5min and resuspended with 100 µl of blocking buffer for 5min and again centrifuged. 
The cells were resuspended with primary HSPA1A antibody in the ratio 1:100 (antibody: FBS 
blocking buffer- 5% v/v in DPBS) and allowed for incubation for 10 min. Following incubation, 
the cells were centrifuged and resuspended in blocking buffer (FBS 5% v/v in DPBS) for 5 min 
duration and the cells were resuspended with 50 µl of extravidin FITC labelled secondary 
antibody in the ratio 1:200 and allowed for incubation for 10 min. The cells were then 
incorporated with 50 µl of blocking buffer (FBS 5% v/v in DPBS) and centrifuged. And finally, 
the cells were resuspended in 100 µl of DPBS solution and analysed using flow cytometer. 
2.3.7.2 Evaluation of extracellular HSPA1A proteins 
For determination of extracellular HSPA1A proteins by flow cytometer, the cancer cells upon 
treatment with antimycotic/ antibiotics, pifithrin - µ or hyperthermia were subjected to all 
the steps described in (section 2.3.7.1), except that of incorporation of cell fixative and 
permeating reagent as this may permeabilize the cell membrane, which could result in 
antibodies to detect HSPA1A in the cell interior. 
2.3.7.3 Flow cytometric determination of p21 proteins 
Colorectal cancer cell lines HT-29 subjected to p21 plasmid DNA transfection studies (section 
2.3.21) were evaluated for p21 protein expression at both the intracellular and cell surface 
levels using FITC conjugated p21 primary antibody using flow cytometer. 
2.3.7.4. Evaluation of intracellular p21 proteins 
Colorectal cancer cell lines HT-29 were seeded at cell density 1 × 10⁶ cells in 6 well assay 
plates, the cells could attach for 24 h in EMEM medium devoid of FBS in incubator at 37℃, 
provided with standard cell culture conditions. Following incubation, the cells were 
transfected with p21 plasmid DNA and pMT5 empty vector using transfection reagent 
lipofectamine 2000 and EMEM medium without FBS. Untreated cells were placed as controls. 
The transfection was allowed for 24 h. The untreated cells, cells resulted from transfections 
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were detached using trypsin EDTA as illustrated in (section 2.3.1.2) and floating cells were 
collected and centrifuged at 500 x g for 5 min. The cells were then resuspended in EMEM 
medium and transferred onto 96 well - v bottom assay plates. The cells were subjected to 
centrifugation, for 5 min, followed by resuspension in 200 µl cold DPBS. The cells following 
centrifugation, were resuspended in 70 µl cell fixative. The cells were then placed under 
sealed condition in refrigerator for 20 min. Following refrigeration, the fixative was diluted 
with the addition of DPBS (70 µl). This was followed by resuspension in DPBS (100 µl), 
centrifuged and resuspended with pre - prepared blocking buffer (100 µl) (section 2.2.2.4). 
Following incubation with blocking buffer (FBS 5% v/v in DPBS) for 5 min at room 
temperature, centrifugation was performed, and cell were resuspended with 1µg (10 µl) of 
FITC labelled p21 antibody/1 × 10⁶ cells in 50 µl of blocking buffer (FBS 5% v/v in DPBS). The 
antibody was uniformly mixed, and the cells were sealed, covered to protect from light and 
placed in refrigerator for 45 min. The cells were then incorporated with blocking buffer 50 µl 
and subjected to centrifugation for 5min at 500 x g. The cells were then finally resuspended 
with 100 µl of DPBS solution and measured by flow cytometer. 
2.3.7.5 Evaluation of cell surface p21 proteins 
For determination of cell surface p21 proteins by flow cytometer, the cancer cells upon 
subsequent treatments were subjected to all the steps described in (section 2.3.7.4), except 
the addition of fixative and 20 min of refrigeration, followed by dilution of fixative with DPBS 
solution, which was excluded as the fixative may permeabilize the cell membrane, which 
could result in antibodies to detect p21 in the cell interior. 
2.3.8 Preparation of chitosan microgels 
Chitosan microgels and microparticle delivery systems were prepared to analyse the effect of 
these agents independently and in combination with chemotherapeutic 5 - fluorouracil in 
colorectal cancer cell lines HT-29, with the objective of using it for the safe delivery of p21 
plasmid DNA in HT-29 cell lines. 
Chitosan microgels were prepared by simultaneous drop wise addition of 15℃ β - glycerol 
phosphate solution (concentrations ranging – 10%, 5%, 1% and 0.5%) (section 2.2.4.2) into 
15℃ low molecular weight chitosan (1% w/v) section 2.2.4.1) in 0.1M hydrochloric acid 
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solution (section 2.2.4.3) under continuous vortexing. 5 - fluorouracil was delivered using 
chitosan microgels for enhanced cytotoxic activity. The 5 - fluorouracil at varying 
concentrations of 5 and 10 µM were mixed in 500 µl of cold chitosan solution separately. 125 
µl of cold β - glycerol phosphate solution was added dropwise to the cold 5 fluorouracil - 
chitosan mixtures with continuous vortexing. The pH of the solution was adjusted to 7.0 using 
1M sodium hydroxide solution. All the solutions were passed through sterile membrane 
filters. The chitosan - β glycerol phosphate emulsion thus formed by vortexing was placed in 
water bath pre - set at 37℃ for 3 - 4 h until the microgels were formed (Fig 2.1).  
                                                                                                  
                                                                                                                
Fig 2.1   Preparation of chitosan - β - glycerol phosphate modified microgel systems.   
                                                                                                                                                                                                                          
2.3.9 Preparation of chitosan microparticles  
Chitosan microparticles were prepared by modifying the ionic gelation method (Fig 2.2) by 
adjusting the pH (7.0). The low molecular weight chitosan powder 0.5% w/v was prepared 
using aqueous acetic acid (1% w/v) solution by magnetic stirring. The microparticles were 
formed simultaneously by dropwise addition of chitosan (2.5 ml) into 1ml of (0.1%) cross 
linking agent sodium tri - polyphosphate (TPP) pre - incorporated with glutaraldehyde (20%) 
under strong magnetic stirring for 3 - 4 h. 5 - fluorouracil particle combinations were produced 
by mixing 5 - fluorouracil in chitosan solution prior to addition of the cross - linking agent. The 
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particles thus formed were centrifuged at 15,000 x g for 30 min. The particles were washed 
using distilled water and centrifuged 15,000 x g for 30 min. Followed by centrifugation, the 
particles were resuspended in distilled water, sterile filtered and added to HT-29 cell lines 
pre-seeded in 96 well assay plates in EMEM medium containing 10% FBS. 5 - fluorouracil free 
microparticles, 5 - fluorouracil treated, untreated cells and dead cells were placed as controls. 
 
       
                                      
 Fig 2.2 Preparation of Chitosan - TPP -5 - fluorouracil microparticles. 
 
2.3.10 Preparation of bovine serum albumin microparticles 
Bovine serum albumin protein microparticles were prepared to analyse its effect 
independently and in combination with chemotherapeutic 5 - fluorouracil in colorectal cancer 
cell lines HT-29, with the objective of using it for the safe delivery of p21 plasmid DNA in HT-
29 cell lines. 
BSA microparticles were prepared by ethanol dissolvation - temperature induced 
denaturation method (Yu et al. 2014). The BSA in powder form was dissolved in NaCl solution 
(section 2.2.4.7) to obtain a final concentration of 10% w/v solution and filter sterilized. 1 ml 
of bovine serum albumin particles pre - incorporated with 5 fluorouracil were subjected to 
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dropwise incorporation of approximately 10 ml of ethanol at the rate of (1ml/min) to BSA 
suspension under magnetic stirring. Ethanol was added until the BSA solution turned turbid. 
The turbid BSA solution was then subjected to heat denaturation by transferring the emulsion 
containing tubes in water bath pre - set at 80 ℃  for 1 h. The microparticles thus formed were 
centrifuged at 15,000 x g for 30 min and subjected to washing using distilled water. Following 
centrifugation, the particles were resuspended in distilled water, sterile filtered and added to 
HT-29 cell lines pre-seeded in 96 well assay plates in EMEM medium containing 10% FBS. 5 - 
fluorouracil free microparticles, 5 - fluorouracil treated, untreated cells and dead cells were 
placed as controls. 
2.3.11 Sample preparation for scanning electron microscopy 
A drop of the sample to be scanned was mounted onto SEM sample stub fixed with a piece of 
double-sided carbon tape to create adhesive surface both to the stub surface and to the 
sample placed on the carbon tape. Compressed air was used to remove excess loose sample 
elements to ensure complete fixation. The samples were then observed by the scanning 
electron microscope. 
2.3.12 Bacterial culturing and storage 
2.3.12.1 Culturing 
The full length p21 gene was a gift from Mien – Chie Hung, Addgene, United states. The 
Escherichia coli strains incorporated with p21 plasmid DNA was inoculated onto sterile Luria 
Bertani agar medium containing ampicillin antibiotic using streak plate technique. The plates 
were incubated with the lid facing down in incubator pre - set at 37℃ for 24 h. Bacterial starter 
cultures (500 ml) were then prepared by inoculating the bacterial inoculum in Luria Bertani 
broth pre - incorporated with ampicillin antibiotic. Following incubation at 37℃ for 24 h the 
broth culture was then ready for experimental proceedings. 
2.3.12.2 Bacterial storage 
The bacterial broth cultures for prolonged use were aliquoted into sterile eppendrof tubes 
0.5 ml each. 0.5 ml of 50% v/v filter sterilized glycerol was added to each of the tubes 
containing bacterial broth cultures. The tubes were labelled and stored at -80℃. 
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2.3.13 Extraction of p21 plasmid DNA from bacterial cells 
The plasmid DNA was extracted from the bacterial cells using Qiagen endofree maxi prep kit 
as illustrated as follows: 
• Escherichia coli pure cultures carrying human p21 plasmid DNA were subcultured in 
250 ml of lactose broth pre - incorporated with ampicillin antibiotic (1% w/v) in incu-
bator at 37℃  for 24h. 
• The bacterial cells were collected by centrifugation at 6000 x g using cooling centrifuge 
pre - set at 4℃ for 15 min. 
• The pelleted cells were re - suspended in buffer P1 (10 ml) and then in 10 ml of buffer 
P2 with uniform mixing for 5 min at 25℃. 
• Following incubation, the cells were mixed with buffer P3 (10 ml) and mixed until the 
suspension was clear. 
• The bacterial lysate was subjected to filtration using QIA filter cartridge thus provided 
with the kit to remove chromosomal DNA, proteins or detergents from the bacterial 
lysate. 
• Following filtration, the lysate was treated with 2.5 ml of buffer ER with continuous 
mixing and incubated for 30 min on ice.  
• Following incubation, the lysate was then passed through a Qiagen tip column pre - 
equilibrated using buffer QBT thus provided within the kit, which allows successful 
binding of the plasmid DNA, along with removal of cellular proteins including de-
graded RNA and cellular metabolites in the lysate.   
• The plasmid DNA retained within the Qiagen tip was purified by washing procedure 
using 6 ml of buffer QC. 
• The plasmid DNA was finally eluted from the Qiagen tip using buffer QN 15ml into 
sterile tube free of endotoxin. 
• The plasmid DNA was precipitated upon treatment with 10.5 ml of 70% v/v isopropa-
nol and subjected to centrifugation in cooling centrifuge pre - set at 15,000 x g and 4 
℃ for 30 min duration. 
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• Following centrifugation, the supernatant was discarded, and the pellet thus retained 
was subjected to washing using 5 ml of 70% v/v ethanol thus provided. The pellet was 
then carefully retained following centrifugation at 15,000 x g for 10 min.   
• The pellet following air drying was resuspended with required levels of buffer TE thus 
provided with the Qiagen kit. 
• The DNA in TE buffer was then quantified using nano drop. 
2.3.14 Sub cloning of the pMT5 vector DNA 
The p21 plasmid DNA was subjected to restriction digestion to isolate the pMT5 vector 
DNA. The restricted Pmt5 vector DNA was separated using agarose gel electrophoresis 
and purified from the agarose gel, repaired for blunt ends, ligated, purified and sub cloned 
on to DH5 alpha competent Escherichia coli cells for its use as vector DNA control in p21- 
plasmid DNA transfection study in HT-29 cell lines as illustrated as follows:  
 2.3.15 Restriction of p21 gene and purification of PMT5 vector DNA 
This was performed by optimization of Thermo scientific double restriction protocol thus 
illustrated as follows: 
                                                  Tango buffer (1X)                                     4 µl 
                                                  Restriction Enzyme BamHI (10U/ µl)    4 µl 
                                                  Restriction Enzyme Ndel (10U/ µl)       4 µl 
                                                  DNA (118.3 µg/ml)                                   5 µl (591.5 ng DNA)         
                                                  Nuclease free water                                3 µl  
                                                  Total volume                                            20ul 
The double digestion was proceeded by uniform mixing and allowed for incubation for 15 min 
at 37℃. Following incubation, the restriction enzyme activity was arrested using pre - 
prepared 0.5M EDTA to 20mM concentration of the total restriction mixture. 
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 2.3.16 p21 plasmid DNA map 
 
Fig 2.3 Illustrates the p21 plasmid DNA #16240 map adapted from the Addgene plasmid depository.  
 
2.3.17 Electrophoretic separation of pMT5 vector 
The restriction digestion mixture from (section 2.3.15) was subjected to agarose gel 
electrophoresis, for electrophoretic separation of restricted p21 plasmid DNA and pMT5 
vector. The electrophoresis was performed as follows: 
• 1% agarose gels in TAE buffer were loaded with hyper ladder (2.5 µl) and 10 µl of DNA 
sample (0.281 µg) diluted in 2 µl 6x loading dye, along undigested plasmid DNA. The 
gel concentration was optimized for obtaining separation of large kb DNA fragments.  
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• The gels were then subjected to electrophoresis at 100 volts for 50 - 60 min. Following 
sample running, the gels were carefully removed and analyzed by gene G - Box gel 
imaging (Chemi X RQ) software.  
2.3.18 Extraction and purification of pMT5 vector from agarose gel 
The pMT5 vector DNA thus separated by electrophoresis (section 2.3.17) was analysed by gel 
imaging software gene sys. Sterile forceps were used to excise the gel fragment containing 
separated pMT5 vector DNA. The vector DNA in the excised gel fragment was isolated from 
the gel matrix using Isolate II PCR and gel commercial kit, according to the instructions thus 
enclosed, illustrated as follows: 
• The excised gel fragment (300mg) was solubilised in 600 µl binding buffer by heating 
the mixture in water bath pre - set at 50◦C for 10 min, whilst hand vortexing, thus 
allowing the complete dissolution of the gel fragment. The gel mixture was then trans-
ferred onto silica - based gel column pre - inserted on top of a collection tube and 
centrifuged for 0.5 min at 11000 × g to bind the DNA to the column. The column con-
taining DNA was subjected to washing using (700 µl) of wash buffer each interval. Fol-
lowing the washing steps, the column was centrifuged for 1 min at 11000 × g to dry 
the column. 
• The column upon discarding the flow - through was transferred to a new collection 
tube and incorporated with DNA elution buffer (30 µl), thus provided with the kit. This 
was subjected to incubation in room temperature for a minute. 
• Following incubation, the column was centrifuged at 11000 × g. The restricted DNA 
thus eluted was measured using nano drop and proceeded for DNA repair and ligation 
procedures.  
2.3.19 DNA repair, purification and ligation of the pMT5 vector DNA   
2.3.19.1 DNA repair  
The vector DNA restriction illustrated in (section 2.3.15) resulted in generation of sticky ends 
in linear DNA fragment. Hence the DNA was subjected to DNA repair enzymes for forming 
blunt ends in the DNA, which was required for the ligation of the DNA, the ligated DNA was 
then subjected to sub cloning using DH5 α chemical competent cells. 
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Hence, the DNA purified from the agarose gel was repaired using DNA repair kit (section 
2.1.19.1) as per the manufacturers protocol as illustrated as follows: 
• The DNA to be repaired was mixed with 2 µl of Anza DNA repair buffer and the DNA 
end repair buffer (1 µl) thus provided with the Kit. This DNA - buffers mixture was then 
made up to 20 µl using deionised water. Following incubation at 20℃  for 15 min. The 
repaired DNA was then made free from impurities for further experimental studies.  
2.3.19.2 DNA purification 
The repaired DNA from (section 2.3.19.1) was purified from repair enzymes and other 
impurities with the aid of Pure link PCR purification kit according to the product protocol as 
illustrated as follows: 
• The repaired DNA (20 µl) was mixed with 80 µl of binding buffer B2 pre - incorporated 
with 10 ml isopropanol. 
• The reaction mixture was transferred onto pure link spin column pre - inserted onto 
sterile collection tube thus provided and subjected to 1min centrifugation at >10,000 
× g. Upon discarding the flow through, the column was then rinsed with washing 
buffer (650 µl) and the centrifugation step was repeated for 2 min. 
• Following final centrifugation, the column from previous step was inserted onto a ster-
ile eppendrof tube. 50 µl of the elution buffer provided with the kit, was added to the 
centre of the column and allowed to stand for 1min and centrifuged to elute the puri-
fied DNA for ligation of the blunt ends. The purified DNA was then measured by nano 
drop. 
2.3.19.3 Ligation of DNA blunt ends  
Following purification, the DNA was subjected to ligation reactions using BIOLINE quick stick 
ligation kit - protocol as illustrated as follows: 
• The vector DNA 66ng (12 µl) of 5.5 µg/ml concentration) from (section 2.3.19.2) was 
adjusted to 14 µl (4.71 µg/ml DNA concentration), as the kit protocol recommended 
the use of no more than 100ng DNA which was needed to be further diluted with dis-
tilled water, making up the total reaction volume to 14 µl using distilled water in a 
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microcentrifuge tube. 1µl of quick stick ligase and 5 µl of quick stick buffer was added 
to the DNA mixture upon vortexing. 
• The ligation reaction was fulfilled by allowing the reaction to proceed for 15 min at 
room temperature.  
2.3.20 Transformation of pMT5 vector DNA using DH5 α chemical competent  
                 Cells 
The 5 µl of the ligated mixture was transformed into α - select competent cells using DH5 α 
chemical competent cells, Bioline, according to the manufacturers protocol as illustrated as 
follows: 
• α - select competent E-coli cells from -80◦C storage were thawed on ice and subjected 
to mixing with the DNA in the ratio 1:10 µl (5 µl DNA: 50 µl competent E-coli cells). The 
same was conducted with reference DNA pUC 19 thus provided with the kit. 
• Following 30 min incubation in ice, the DNA - competent cell mixtures were subse-
quently incubated in water bath pre - set at 42℃ for 30 s. The DNA - competent cell 
mixture of the pMT5 vector and the pUC 19 control DNA was then allowed to cool in 
ice for 2 min. 
• The DNA - competent cell mixtures were subsequently made up to 1 ml using 900 µl 
of sub cloning medium SOC. Following dilution, the cultures were incubated in a shak-
ing incubator pre - set at 37℃ at 200 rpm for 1 h. 
• Following incubation, 100 µl of the transformation mixtures were spread plated on 
Petri dishes containing Luria-Bertani agar prepared with ampicillin antibiotic (1% w/v). 
• The inoculated plates were incubated for 24 h at 37℃. 
The pUC 19 control plasmid provided with the α - select chemically competent strains were 
used as positive refence. The pUC 19 transformation reaction mixture (5 µl) was inoculated 
onto sterile petri plates containg SOC sub-cloning medium pre - supplemented with ampicillin 
antibiotic by spreading 5 µl of the inoculum.     
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2.3.21 Transfection of the p21 plasmid DNA and vector DNA onto HT-29 cancer 
cell lines  
The cancer cell lines HT-29 grown in 75 cm² tissue culture flasks were trypsinated using trypsin 
EDTA as illustrated in (section 2.3.1.2).  The cell count was determined using haemocytometer 
(section 2.3.3). Cells at cell density of 1 × 10⁶ cells were seeded onto each well of the sterile 6 
well assay plates, HT-29 cell lines were allowed for attachment for 24 h in incubator at 37◦C. 
Following incubation, the cells were resuspended with EMEM culture medium devoid of FBS.  
Batch cultures of Luria-Bertani broth containing p21 plasmid DNA or vector DNA (thus 
obtained by transformation reaction) were prepared for plasmid DNA isolation. The Plasmid 
DNA were quantified using nanodrop. The vector DNA was measured to be 80.2 µg/ml and 
p21 plasmid DNA was (118.3 µg/ml) in concentration. EMEM culture medium devoid of FBS 
was used for the transfection as the FBS may interfere with the transfection using 
lipofectamine 2000. The transfection using lipofectamine 2000 was performed as per the 
manufactures protocol, illustrated as follows:  
4.0µg of plasmid DNA and the vector DNA was subjected to dilution in 250 µl EMEM medium 
separately. Lipofectamine 10 µl was also simultaneously diluted in EMEM medium. Following 
a 5 min incubation, both the DNA in EMEM medium and lipofectamine in EMEM medium 
were mixed together. The DNA - lipofectamine mixture could form complexes by incubating 
at room temperature for 20 min. The DNA - lipofectamine complexes (500 µl) were then 
added to HT-29 cells, which had been pre-seeded in 6 well assay plates containing 1.5 ml of 
EMEM medium. 
2.3.22 Statistical analysis 
Statistical analysis was performed using graph - pad (version7) software. Data were analyzed 
statistically using one - way ANOVA with post hoc Sidaks multiple comparisons test, Turkey’s 
multiple comparisons test and paired T- test accordingly. 
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Chapter 3 
Effect of antimycotic/antibiotic on colorectal cancer cell line HT-29 
3.1 Introduction 
The antimycotic/antibiotic solution at recommended dosage are incorporated in cell culture 
medium to avoid mammalian cell lines from microbial or fungal contaminations in in vitro 
experimental studies, however these agents at high dosage are reported to disrupt the cells 
semi - permeable membrane layers, hindering the normal metabolic activities of cancer cells 
including mRNA translation processes finally inducing cytotoxicity (Kuhlmann. 1995; Llobet et 
al. 2015). 
In case of in vitro gene transfection studies, using commercial transfection reagents such as 
lipofectamine 2000, the antibiotics incorporated in cell culture medium may tend to form 
complexes with the transfection reagent. These agents if transported in vitro may induce 
toxicity, hampering successful gene expressions. Hence considering, the undesirable effects 
of these agents, their use are highly unsuitable for in vitro experimental transfection studies 
(www.thermofisher.com). 
Report evidence the anti-cancer activity of broad category of commercial antibiotics in 
obstructing the mitochondrial pathway in cancer tissues and arresting further proliferation of 
several cancer types. Antibiotic such as Doxycycline in combination with natural vitamins such 
as ascorbic acid evidence to target the mitochondria of cancer cells, which adversely affect 
the translational processes, resulting in cellular instability. These anti-cancer agents not only 
arrest cancer growth but also attenuate cancer stem cells, preventing future reoccurrences 
according to recent investigation (De Francesco et al. 2017). Moreover, cancer cells are also 
reported to experience cellular stress upon exposure to antibiotic such as thiostrepton, which 
elevated the expression of HSPA1A (Sandu et al. 2014). 
Although the antibiotics serve as effective anti-cancer agents, the after effects generated by 
these compounds upon prolonged administration are of high consideration. Studies confirm 
not only the deleterious effects of these compounds in damaging human intestinal walls, but 
also the elimination of the intestinal microbial flora that plays a key role in the digestion 
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processes in the human intestinal system (Modi et al. 2014). More over population - based 
research outlines the probability of developing bowel malignancies in patients subjected to 
antibiotic exposure for prolonged periods (Kilkkinen et al. 2008) thus suggesting the negative 
impact of using antibiotics in conditions like cancer which requires prolonged administration 
of these agents.  
3.1.2 Aims and hypotheses 
This chapter includes the following aims and hypotheses: 
1. To elucidate the effect of antimycotic/antibiotic on colorectal cancer cell line 
HT-29. 
 Hypotheses- 
 H0 antimycotic/ antibiotic do not inhibit the growth of HT-29 cells. 
 H1 H0 antimycotic/ antibiotic may inhibit the growth of HT-29 cells. 
                      2.To analyse the interaction of Heat shock protein HSPA1A in response to  
                         antimycotic/ antibiotic exposure on HT-29 cell lines.  
Hypotheses- 
H0 antimycotic/antibiotic will not produce any intracellular or extracellular stress on the 
growth of HT-29 cells. 
H1 antimycotic/antibiotic may induce intracellular or extracellular stress on the growth of 
HT-29 cells. 
3.2 Methods 
3.2.1 Cell seeding and experimental design 
Adherent colorectal cancer cell lines HT-29 at seeding density 5 × 10⁵ cells/ml were used in all 
experiments (section 2.3.1.2). 
3.2.2 Treatment with antimycotic/antibiotic  
Cells were treated with varying concentrations of antimycotic/antibiotics. Untreated cells 
were placed as controls. 
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3.2.3 Measurements of cell viability 
The cells were analyzed for cytotoxicity by MTS (Section 2.3.4) and PI assays (Section 2.3.5) 
following 24 h incubation. Flow cytometric analysis were also used to confirm the percentage 
of apoptosis and necrosis by annexin V and PI staining method (section 2.3.6). 
3.2.4 Determination of HSPA1A protein expression 
 
The colorectal cancer cell line HT-29 upon treatment with varying concentration of anti-
mycotic/antibiotics for 24 h were evaluated for HSPA1A protein expression at both 
intracellular and cell surface levels by flow cytometry (section 2.3.7.1, 2.3.7.2). 
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3.3 Results  
3.3.1 Determination of apoptosis and necrosis 
The following experiments were performed to evaluate the effect of antimycotic/antibiotic 
on the growth of colorectal cancer cell lines HT-29. The MTS cell viability assay presented a 
gradual decrease in cell viability upon treatment with antimitotic/antibiotics in a 
concentration dependent manner (P<0.0001, Fig 3.3.1A, Table 3.1). The results from the PI 
assay showed no significant increase in PI uptake, suggesting the effect may be due to 
apoptosis (Fig 3.3.1B, Table 3.1) rather than necrosis.  
The cells treated with the antibiotics were confirmed for apoptotic cell death using annexin V 
and PI staining assay by flow cytometry which confirmed the increased rate of apoptosis with 
statistical significance as high as 89.7% (Fig 3.3.2,3.3.3) of late apoptosis and 2.8% early 
apoptosis of HT-29 cells.  
3.3.2 Evaluation of HSPA1A expression profiles post antimycotic/ antibiotic on HT-29 cancer 
cell lines 
The HSPA1A stress proteins were studied to be released upon antimycotic/antibiotic 
treatment. The study analyzed the expression of HSPA1A at both intracellular as well as cell 
surface levels. The intracellular HSPA1A results (Fig 3.3.4, 3.3.5) presented no significant 
variation on the HSPA1A status compared to the untreated controls. 
On the other hand, the expression of cell surface HSPA1A protein were measured (Fig 3.3.6, 
3.3.7) to be significantly higher with that of the control cell line and the expression increased 
with increase in concentration of the antimycotic/ antibiotic in HT-29 colorectal cell lines.  
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Fig: 3.3.1 Effect on cell viability by antimycotic/antibiotic on HT-29 cell lines. Cell lines were seeded onto 96 well 
assay plates at cell density (5 × 10⁵ cells/ml) and treated with varying concentration of antimycotic/antibiotic. The cells were 
incubated for 24 h in incubator at 37℃, cell viability was measured by (A) MTS or (B) PI. Data were analyzed statistically using 
one- way ANOVA, with post hoc Sidaks multiple comparisons test. Significant differences of untreated and different anti - 
mycotic /antibiotic concentrations are indicated by **** (p<0.05, mean±SD; n=4).  
Table 3.1 Statistic presentation of Sidaks multiple comparisons test (ns* insignificant)                               
MTS Assay                                   
 
PI Assay 
Untreated vs Anti - 
mycotic /antibiotic 
0 vs 12.5 
0 vs 25 
0 vs 50 
 
Significance  
 
**** 
**** 
**** 
P value 
 
P<0.0001 
P<0.0001 
P<0.0001 
Untreated vs Anti -   
mycotic /antibiotic/Dead  
0 vs dead control                               
0 vs 12.5 
0 vs 25 
0 vs 50 
    Significance  
         
      **** 
       ns 
       ns 
       ns 
            P value 
           
             P<0.0001 
             P 0.9803 
             P 0.9251 
             P 0.9990 
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                 A                                                                                    B 
 
                        
                   C                                                                                  D 
                                                                            
                                                            E                                                                                        
                                                                                                                                                                                                                              
Fig: 3.3.2 Flowcytometric data presentation of annexin V and PI staining in HT-29 cell lines exposed to 
antimycotic/ antibiotic. HT-29 cell lines at cell density (1 × 10⁶ cells), the cells were subjected to antimycotic/ antibiotic 
treatment and were allowed for incubation at 37◦C for 24h. The cells were then analyzed for apoptosis by annexin V and PI 
staining using flow cytometer- (A) unstained control, (B) untreated (C) 6.25%, (D) 12.5%, (E) 25%.                                      
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Fig: 3.3.3 Effect on cell viability by antimycotic /antibiotic on HT-29 cell lines by annexin V and PI staining. Cell 
lines were seeded at cell density of (1 × 10⁶ cells) onto 6 well assay plates and treated with varying concentration of anti - 
mycotic/antibiotic. The cells were incubated for 24 h in incubator at 37℃. Cell viability was measured by annexin v and PI 
staining by flow cytometer. Data were analyzed statistically using one - way ANOVA, with post hoc Sidaks multiple 
comparisons test. Significant differences of untreated and different concentrations are indicated by **** (p<0.05, mean±SD; 
n=3).  
Table 3.1 Statistic presentation of Sidaks multiple comparisons test (ns* insignificant)                               
  Annexin v and PI staining assay (Control vs antimycotic antibiotic concentration) (ns* insignificant)  
                              
% of viable cells       Significance       P value                 % of early apoptosis    Significance          P value                      
0 vs 6.25                                ns                     P 0.0840                             0 vs 6.25                                ns                   P 0.1303 
0 vs 12.5                                ns                     P 0.2129                             0 vs 12.5                                ns                   P 0.4112 
0 vs 25                                   ***                   P 0.0007                             0 vs 25                                   ns                   P 0.223 
 
% of necrosis             Significance      P value                  % of late apoptosis     Significance          P value                      
0 vs 6.25                                 ns                    P 0.9978                              0 vs 6.25                               ns                    P 0.9077 
0 vs 12.5                                 ns                    P 0.297                                0 vs 12.5                               ns                    P 0.8553 
0 vs 25                                    ns                     P 0.380                                0 vs 25                                  ns                    P< 0.0001 
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                A                                                                                         B
                  
           C                                                                                           D 
                                                                                                                    
                                                                                                                                                       
                                      
Fig: 3.3.4 Intracellular HSPA1A expression resulted from antimycotic/ antibiotic treatment in HT-29 cell lines. 
HT 29 cell lines were seeded at cell density of (1 × 10⁶ cells) onto 6 well assay plates and treated with varying concentration 
of anti – mycotic/antibiotic. The intracellular HSPA1A expression was analyzed using flow cytometer. Flow cytometry data 
presentation of histograms gated with primary antibody stained control(A)(B); untreated controls(C); 12.5% concentration 
(D); 25% concentration.  
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Fig: 3.3.5 Graphical representation of Intracellular HSPA1A expression resulted from antimycotic/antibiotic 
treatment in HT-29 cell line. Statistical analysis performed using one - way Anova represented mean±SD(P<0.05) n=3, 
depicted insignificant variation in HSPA1A expression between the control and treated groups expressing p values; control 
vs 12.5(p0.2890); 12.5 vs 25% (p0.0749). 
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Fig: 3.3.6 Cell surface HSPA1A expression resulted from antimycotic/ antibiotic treatment in HT-29 cell lines 
HT 29 cell lines were seeded at cell density of (1 × 10⁶ cells) onto 6 well assay plates and treated with varying concentration 
of antimycotic/antibiotic. The cell surface HSPA1A expression was analyzed using flow cytometer. Flow cytometry data 
presentation of histograms gated with primary antibody stained control (A); untreated controls (B); 12.5% concentration (C); 
25% concentration (D).  
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Fig: 3.3.7 Graphical representation of surface HSPA1A expression resulted from antimycotic/antibiotic 
treatment in HT-29 cell line. Statistical analysis performed using one - way Anova represented mean±SD(P<0.05) n=3, 
depicted no significant difference in HSPA1A expression between the control and treated groups expressing p values; control 
vs 12.5 (p<0.0001****); control vs 25 (p<0.0001****). 
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3.4 Discussion 
The aim of this chapter was to evaluate the effect of antimycotic/ antibiotic on colorectal 
cancer cell lines HT-29. Previous studies have evidenced the negative impacts of using anti-
mycotic/antibiotics in mammalian tissues (Kuhlmann 1995; Llobet et al. 2015), which has 
shown to interfere with in vitro experimental outcomes. In case of in vitro experiments using 
nanoparticles or microparticles, the antimycotic/ antibiotic used in mammalian tissue culture 
medium, may get encapsulated within these delivery systems and reach the cellular 
compartments at undesirable amounts, affecting experimental results.  
The penicillin and streptomycin combination are also reported to induce  genes, mainly ATF3- 
Activating transcription factor 3, which are studied not only to deregulate gene transcription 
but also involved in dephosphorylation of proteins, affecting protein synthesis in HepG2 liver 
cell lines in vitro (Ryu et al. 2017). The proliferation of cultured mammalian cell lines is also 
studied to be adversely affected by antibiotics, showcasing enhanced proliferation of cultured 
cell lines in antibiotic free culture medium compared to that grown in antibiotic enriched 
medium (Ricarda et al 2013).  
Besides, the adverse effect of antibiotics in mammalian cell culture, research report have 
previously stated the extensive application of several anti - microbial agents in arresting 
several cancer types (De Francesco et al. 2017). The results from this study also reports the 
apoptotic activity of these compounds in a dose dependent manner in HT-29 cell lines (Fig 
3.3.1,3.3.2).  
Penicillin - streptomycin antibiotics play an active role  in altering the expression profiles of 
several genes which are exclusively linked with the transcription process and stress responses 
in HepG2 liver cell lines (Ryu et al. 2017). The results in this chapter were shown to trigger an 
increase in external HSPA1A protein expression in a dose dependent manner (Fig 3.3.6, 3.3.7), 
which may act as alarm signals for attracting host immune cell response, finally triggering 
cancer cell death. The HSPA1A expression profiles in this study matches other studies which 
presented a similar response of HSPA1A as in case of hyperthermia treatments and HSPA1A 
stress response induced by antibiotic thiostrepton  (Jolesch et al. 2012; Sandu et al. 2014). 
However, antimycotic/ antibiotics did not induce the expression of HSPA1A proteins at the 
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intracellular regions, suggesting the treatment reflected no stress induction internally (Fig 
3.3.4, 3.3.5).  
Although antibiotics evidence to arrest several cancer malignancies, several reports at same 
time express concerns regarding the side effects of these agents, which contribute to the risk  
of acquiring bowel cancers due to prolonged intake of high dose antibiotics (Cao et al. 2017). 
Moreover, population based studies show that  more than 5 course administration of several 
class of antibiotics such as penicillin’s and tetracyclines, showed approximately 0.9% of the 
tested population  at risk of acquiring prostate and breast malignancies  (Boursi et al. 2015; 
Friedman et al. 2006). 
The antibiotics intake adversely affect the survival of intestinal microflora by hampering the 
synthesis of peptidoglycan - an inevitable polymer required for the formation of bacterial cell 
wall (Mucsi et al. 2013). Reduced microbial flora in turn resulted in increasing the  pH of the 
intestinal region, which is one of the factors favoring colorectal cancer initiation (Ohigashi et 
al. 2013). Antibiotic treatments are shown to hamper the metabolic processes and protein 
synthesis in gut microbes, in turn disrupting their growth. Previous studies also highlight the 
adverse effect of antibiotic persistence, which prevented the survival of intestinal microflora 
for prolonged duration of several years for a normal recovery (Mai et al. 2013). This late 
recovery of the gut microflora in antibiotic treated patients were shown to enhance the 
survival of microbial pathogens such as vancomycin resistant enterococcus species, which 
resulted in infection and sepsis (Ubeda et al. 2010).  
The experimental outcomes from previous studies having demonstrated the adverse effects 
of antibiotics and the results presented in this chapter, collectively not only addressed the 
growth inhibitory effect of antimycotic/ antibiotic in HT-29 cell lines (Fig 3.3.1,3.3.2), but also 
showed the interference of these agents in inducing external stress response in culture cell 
lines (Fig 3.3.6, 3.3.7),  which may in turn affect in vitro experimental results. Therefore, all 
the experiments in this thesis were performed with cancer cell lines maintained in culture 
medium devoid of antimycotic/ antibiotics as this may interfere with the microgel or 
transfection studies performed throughout the thesis. Hence, considering the negative 
impacts generated by the presence of antibiotics in tissue culture medium, it`s use is not 
recommended for mammalian cell culture (Ricarda et al. 2013;  Ryu et al. 2017). 
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Chapter 4 
Inhibition of HSPA1A in combined therapies 
4.1 Introduction 
Radiation exposure is widely accepted as first line conventional treatment strategy for 
detaining cancer progression. According to studies at the molecular level, these ionizing 
radiations disrupt the genetic material (Maier et al. 2016), leading to the activation of tumour 
suppressor genes directing cells towards apoptosis. Excessive oxidative stress creates a 
cellular imbalance in cells exposed to gamma radiation, finally resulting in cell death (Lee et 
al. 2017). Although radiation therapy effectively destroys cancer cells, the resistance to some 
cancer cells (De Bacco et al. 2011) and the undesirable side effects produced due to prolonged 
exposure of radiation is of high consideration, hence to overcome the side effects, researches 
are aiming at improving the therapeutic index of this therapy by limiting duration of radiation 
exposure and applying it in combination with chemotherapeutics. One factor which may 
result in resistance to apoptosis is the elevated expression of HSPA1A proteins in cancer cells 
(Sherman et al. 2015). The transcriptional activation of HSPA1A is studied to be dependent 
on the acetylated status of this protein, HSPA1A is studied to be acetylated by ARD1 acetyl 
transferase which in turn determines its function in maintaining the conformational status of 
proteins, on the other hand HSPA1A deacetylation works in ubiquitination  of proteins within 
mammalian cells (Seo et al. 2016). Moreover, HSPA1A generated from stress response act as 
alarm system, eliciting the natural defense mechanism, or in some instances, their expression 
works to demote natural immunity, allowing the progression of malignant cells. Cellular 
contents released as result of necrosis, allows the intracellular heat shock proteins reach the 
surface of cell membrane, which signals the immune system, identify the threat and act 
accordingly (Klink et al. 2012). 
Studies have explored the effect of HSPA1A protein inhibitor compounds 
Phenylethylsulphomide (Pifithrin - µ) and 2-(3-chlorophenyl) ethynesulfonamide (Pifithrin 
chloride), hindering autophagy - which is a lysosome enzyme catalysed  mechanism and plays 
a major role in discarding of unwanted metabolic residues within cancer cells thus allowing 
successful proliferation (Mizushima et al. 2008; Jones et al. 2016). Previous report with  
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pifithrin - α and pifithrin - β reported to express a protective role, against hampering UV 
induced apoptosis in embryonic testicular carcinoma (Keller et al. 1999), while other 
researcher presented accelerated apoptotic effects with pifithrin - α in combination with 
radiation treatment in ovarian and colorectal cancers (Walton et al. 2005). However, reports 
of pifithrin - µ in combination with UV has not been reported yet. Hence the first phase of this 
chapter concentrated on addressing the combined effect of UV radiation with pifithrin - µ in 
the leukaemia cell line U937 and the colorectal cancer cell line HT-29.  
Interestingly, given the importance of HSPA1A proteins in cancer cells, hyperthermia is 
another treatment modality, which evidence cytotoxicity at elevated temperature as high as 
42℃ in in several cancer types (Jolesch et al. 2012). Temperature fluctuation in the cancer 
environment due to hyperthermia results in increased release of HSPA1A proteins, which 
assist in the activation of immune cells towards the destruction of cancer cells releasing 
HSPA1A (Horowitz. 2007). 
Introducing heat with the aid of electronic devices has been employed for the treatment of 
solid malignancies. Electro hyperthermia has been extensively tested as a cancer therapeutic 
strategy, studies demonstrate increased survival rates in relapsed tumour conditions upon 
administration of electro hyperthermia in combination with radiotherapy and 
chemotherapeutics such as sorafenib in hepatic malignancies (Gadaleta  et al. 2014). 
Report demonstrate hyperthermia induced cytotoxicity at elevated temperatures ranging 
from 40 - 44℃ in solid malignancies (Van der Zee. 2002), hyperthermia administration  for an 
hour duration at 41.5℃  alongside combination therapies also shown to enhance the cancer 
cells capability of increased expression rate of HSPA1A proteins, making chemotherapy and 
radiation therapies more effective in invitro colorectal cancers in human and mouse models 
(Schildkopf et al. 2011).  
The experiments in this chapter will investigate the treatment effects of UV radiation, pifithrin 
- µ and pifithrin chloride or hyperthermia at 42℃  , which may induce cytotoxicity in both 
leukaemia cell line U937 and the colorectal cancer cell line HT-29. This study also evaluated 
whether pifithrin - µ at low dosage may accelerate the effect of UV radiation in both the 
cancer cell lines, which may reduce the risk of prolonged radiation exposure, enhancing the 
therapeutic potential of radiation therapy for cancer treatments. 
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4.1.1 Aims and hypotheses 
This chapter evaluated the potential for using inhibitors of HSPA1A protein activity in 
combination with UV or temperature. 
The objectives of the study are: 
1. To evaluate the cytotoxicity induced by UV radiation, pifithrin - µ and pifithrin   chlo-
ride in the leukaemia cell line U937 and the colorectal cancer cell line HT-29. 
Hypotheses- 
H0 UV radiation, pifithrin - µ and pifithrin chloride treatment will not induce cell death in 
leukaemia cell lines U937 and colorectal cancer cell lines HT-29. 
H1 HSPA1A inhibitors - pifithrin chloride and pifithrin - µ and UV treatments will arrest the 
growth of U937 and HT-29 cells. 
 
2. Investigate whether cytotoxicity could be enhanced by applying UV radiation with 
pifithrin - µ at low dosage in both the cancer cell lines used in the study. 
Hypotheses- 
H0 the HSPA1A protein inhibitor pifithrin - µ in combination with UV will not enhance the 
effect of UV radiation in arresting cell growth at limited time of UV exposure in both the 
cancer cell lines. 
H1 the HSPA1A protein inhibitor pifithrin - µ in combination with UV may enhance the effect 
of UV radiation in arresting cell growth at limited time of UV exposure in both the cancer cell 
lines. 
 
3. Study the effects of hyperthermia cytotoxicity in the leukaemia cell line U937  
and the colorectal cancer cell line HT-29. 
Hypotheses 
H0 hyperthermia treatment at 42℃ will not arrest the growth or induce stress response in 
U937 and HT-29 cell lines. 
H1 hyperthermia at 42℃ will induce stress response and arrest the growth of both U937 and 
HT-29 cells.  
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4.2 Methods 
4.2.1 Cell seeding and experimental design 
Cells were cultured as described in (section 2.3.1.2). Cells at seeding density 5 × 10⁵ cells/ml 
were used in all experiments. 
4.2.2    UV irradiation exposure 
The cells pre - seeded onto 96 well plated were carefully exposed to UV radiation at low 
voltage by moving the plates across the UV light, in a time dependent manner. The cells 
following treatment were incubated for 24 h duration at 37℃.  Unexposed cells were placed 
as controls. 
4.2.3    Hyperthermia  
Aliquots of 3 ml of cells in suspension were introduced into 10 ml sterile tubes and subjected 
to 42℃ for 1 h. The cells were then allowed to recover at 37℃ for 2 h. The cells were 
immediately plated onto 96 well assay plates and incubated for 24 h duration at 37℃. Cells 
subjected to treatment at 37℃  were placed as controls.  
4.2.4   Treatment with pifithrin - µ and pifithrin chloride  
Cells were treated with pifithrin - µ and pifithrin chloride at varying concentrations prior to 
UV or temperature treatment. The cells following treatment were incubated for 24 h or 48 h 
duration at 37℃ accordingly. Unexposed cells were placed as controls. Dead cells were 
placed as dead controls 
4.2.5 Measurements of cell viability 
The cells were analyzed for cytotoxicity by MTS and PI assays (Section 2.3.4, 2.3.5) following 
24 h and 48 h incubation duration. The effect of UV along with pifithrin - µ treatments were 
also observed in both the cancer cell lines. 
Flow cytometric analysis were also used to confirm the percentage of apoptosis and necrosis   
by annexin V and PI staining method (Section 2.3.6). 
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4.2.6 Determination of hyperthermia induced HSPA1A proteins 
The cancer cell lines U937 and HT-29 post hyper thermic treatments were evaluated for 
HSPA1A protein expression at cell surface levels by flowcytometry (section 2.3.7.2). 
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4.3: Results 
4.3.1: Effect of UV on U937 cell lines  
The following experiments were conducted to determine the effect of UV radiation exposure 
(0, 2, 4, 6 and 8 s) on U937 leukaemia cell line. Following UV treatment cells were incubated 
for 24 h at 37℃. The MTS assay results displayed that increased UV exposure resulted in a 
decline in cell viability in cells exposed for 4 s or longer (Fig 4.3.2A, Table 4.1). Microscopic 
observation also displayed cytotoxicity with increase in exposure time (Fig 4.3.1). However, 
at no time was necrosis observed by PI (Fig 4.3.2B).                 
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Fig: 4.3.1 Microscopic observation of U937 cell lines treated with UV radiation at magnification of 20X objective 
(2048 × 1536 px). The cells following treatment followed by incubation for 24 h at 37℃ were microscopically observed for 
cytotoxicity; (A) untreated, (B) 2s, (C) 4s, (D) 6 s and (E) 8 s of UV exposed. 
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Fig: 4.3.2: The effect on cell viability by UV exposure on U937 cell lines. U937 cell lines seeded onto 96 well assay 
plates at cell density (5 × 10⁵ cells/ml) were exposed to UV light at varying time intervals of 2,4,6,8 s. The cells were allowed 
for 24 h incubation at 37℃, cell viability was measured by (A) MTS or (B) PI. Data were analyzed statistically using one - way 
ANOVA, with post hoc Sidaks multiple comparisons test. Significant differences from the 0 UV exposure are indicated by 
**** (p<0.05, mean±SD; n=4).   
Table 4.1 Statistic presentation of Sidaks multiple comparisons test (ns* insignificant) 
MTS Assay                                   
 
PI Assay 
UVexposure time (s) 
0 vs 2 
0 vs 4 
0 vs 6 
0 vs 8 
Significance  
ns 
**** 
**** 
**** 
P value 
P 0.1515 
P<0.0001 
P<0.0001 
P<0.0001 
UVexposure time (s) 
0 vs 2 
0 vs 4 
0 vs 6 
0 vs 8 
Significance  
ns 
ns 
ns 
ns 
P value 
P>0.9999 
P 0.9971 
P 0.5109 
P 0.4793 
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4.3.2 Effect of pifithrin - µ and pifithrin chloride on U937 cell lines 
U937 cell lines were subjected to treatment with pifithrin - µ at varying concentrations 25,50 
and 100µM and allowed for incubation for 24 h and 48 h. The cells were then analyzed by 
MTS and PI assays. The cells displayed a progressive decline in cell viability at all the treated 
concentrations within 24 h (Fig 4.3.4 A) and by microscopic examination (Fig 4.3.3) in contrast 
to the untreated controls. The data showed no significant difference between treated 
concentrations 25 and 50 µM (P 0.6374, Table 4.2), while the 50 µM expressed significant 
variation with the next higher concentration 100 µM (P 0.0040**, Table 4.2). PI assay (Fig 
4.3.4 B) showed necrotic effect with increase in pifithrin - µ concentrations exhibiting 
significance of (P<0.0001) Table 4.2) at 100µM with respect to next lower concentration 50 
µM of pifithrin - µ used in the study. Upon prolonged exposure of the pifithrin treatment for 
48 h, the MTS assay expressed no alteration from the effect presented by 24 h treatment (Fig 
4.3.5 A, Table 4.3) while the PI assay displayed reduced necrosis after 48 h pifithrin - µ 
treatment compared to 24 h treatments (Fig 4.3.5 B), Table 4.3). 
Treatment with pifithrin chloride also expressed cytotoxicity in U937 cell lines in a 
concentration dependent manner. 24 h treatment with pifithrin chloride displayed 
progressive cytotoxicity at concentrations starting 25µM with significance of P<0.0001 (Fig 
4.3.7 A, Table 4.4) compared to untreated cell lines with MTS cell viability assay. PI staining 
assay confirmed necrotic effect with increase in drug dose showing significance of P<0.0001 
between doses 25 µM and 50 µM (Fig 4.3.7 B) displaying significance of (P<0.0001***) Table 
4.4), with a further rise in cell necrosis with concentration compared to pifithrin - µ 
treatments. pifithrin chloride inferred no change from 24 h MTS assay results and the results 
also stated reduced necrotic effect after 48h exposure in U937 cell lines (Fig 4.3.8 B, Table 
4.5).  
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Fig: 4.3.3 Microscopic observation of U937 cell lines treated with pifithrin - µ at magnification of 20X objective (2048 × 1536 px). 
The cells, following treatment and incubation for 24 h at 37℃, were microscopically observed for cytotoxicity; (A) untreated, pifithrin-µ- (B) 25µM, 
(C) 50µM, (D) 100µM; Pifithrin chloride treated – (E) 25µM, (F) 50µM and (G) 100µM. 
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Fig: 4.3.4: Effect on cell viability by pifithrin - µ on U937 cell lines. U937 cell lines seeded onto 96 well assay plates 
at cell density (5 × 10⁵ cells/ml) were treated with varying concentrations of pifithrin - µ (0,25,50,100µM). The cells were 
allowed for 24 h incubation at 37℃. Cell viability was measured by (A) MTS or (B) PI. Data were analyzed statistically using 
one - way ANOVA, with post hoc Sidaks multiple comparisons test. Significant differences between untreated (0) and pifithrin 
- µ concentrations are indicated by **** (p<0.05 mean±SD; n=4,).   
Table4. 2 Statistic presentation of Sidaks multiple comparisons test (ns* insignificant) 
MTS Assay PI Assay 
Pifithrin -µ(µM)  
0   vs 25 
25 vs 50 
50 vs 100 
Significance  
**** 
ns 
** 
P value 
P<0.0001 
P 0.6374 
P 0.0040 
Pifithrin -µ(µM)  
0   vs 25 
25 vs 50 
50 vs 100 
Significance 
ns 
* 
**** 
P value 
P 0.9875 
P 0.0463 
P<0.0001 
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Fig: 4.3.5: Effect on cell viability by pifithrin - µ on U937 cell lines. U937 cell lines seeded onto 96 well assay plates 
at cell density (5 × 10⁵ cells/ml) were treated with varying concentrations of pifithrin - µ (0,25,50,100µM). The cells were 
allowed for 48 h in incubation at 37℃: cell viability was measured by (A) MTS or (B) PI. Data were analyzed statistically using 
one - way ANOVA, with post hoc Sidaks multiple comparisons test. Significant differences between untreated (0) and Pifithrin 
- µ concentrations are indicated by **** (p<0.05, mean±SD; n=4).   
Table 4.3 Statistic presentation of Sidaks multiple comparisons test (ns* insignificant) 
MTS Assay PI Assay 
pifithrin -µ(µM)  
0   vs 25 
25 vs 50 
50 vs 100 
Significance  
**** 
ns 
ns 
P value 
P<0.0001 
P>0.9999 
P 0.9970 
pifithrin -µ(µM)  
0   vs 25 
25 vs 50 
50 vs 100 
Significance 
ns 
ns 
ns 
P value 
P 0.3032 
P>0.999 
P 0.3700 
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Fig: 4.3.6 Microscopic observation of U937 cell lines treated with pifithrin - µ, pifithrin chloride at magnification of 20X objective 
(2048 × 1536 px). Cells following treatment and incubation for 24 h at 37℃, were microscopically observed for cytotoxicity; (A) untreated, 
pifithrin-µ- (B) 25µM, (C) 50µM, (D) 100µM; Pifithrin chloride treated – (E) 25µM, (F) 50µM and (G) 100µM. 
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Fig: 4.3.7: Effect on cell viability by pifithrin chloride on U937 cell lines. U937 cell lines seeded onto 96 well assay 
plates at cell density (5 × 10⁵ cells/ml) were treated with varying concentrations of pifithrin chloride (0,25,50,100µM). The 
cells were allowed for 24h in incubation at 37℃. Cell viability was measured by (A) MTS or (B) PI. Data were analyzed 
statistically using one- way ANOVA, with post hoc Sidaks multiple comparisons test. Significant differences between 
untreated (0) and pifithrin chloride concentrations are indicated by **** (p<0.05) mean±SD; n=4).  
Table 4.4 Statistic presentation of Sidaks multiple comparisons test (ns* insignificant) 
MTS Assay PI Assay 
pifithrin chloride(µM) 
0 vs 25 
25 vs 50 
50 vs 100 
Significance 
**** 
ns 
ns 
P value 
P<0.0001 
P 0.9012 
P 0.9830 
pifithrin chloride(µM) 
0 vs 25 
25 vs 50 
50 vs 100 
Significance 
**** 
**** 
ns 
P value 
P<0.0001 
P<0.0001 
P 0.0780 
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Fig: 4.3.8 Effect on cell viability by pifithrin chloride on U937 cell lines. U937 cell lines seeded onto 96 well assay 
plates at cell density (5 × 10⁵ cells/ml) were treated with varying concentrations of pifithrin chloride (0,25,50,100µM). The 
cells were allowed for 48 h incubation at 37℃. Cell viability was measured by (A) MTS or (B) PI. Data were analyzed 
statistically using one- way ANOVA, with post hoc Sidaks multiple comparisons test. Significant differences between 
untreated (0) and pifithrin chloride concentrations are indicated by **** (p<0.05 mean±SD; n=4).   
Table 4.5 Statistic presentation of Sidaks multiple comparisons test (ns* insignificant) 
MTS Assay PI Assay 
pifithrin chloride (µM) 
0   vs 25 
25 vs 50 
50 vs 100 
Significance 
**** 
ns 
ns 
P value 
P<0.0001 
P 0.9957 
P 0.9837 
pifithrin chloride (µM) 
0 vs 25 
25 vs 50 
50 vs 100 
Significance 
ns 
ns 
ns 
 
P value 
P 0.1081 
P >0.999 
P 0.835 
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4.3.3 Effect of pifithrin - µ (20µM) and (10µM) combined with low UV radiation on U937 
cell line  
The experiments followed were designed to determine the effect of UV radiation exposure 2 
s and 4 s in combination with pifithrin - µ at concentrations of 20 µM and 10 µM. pifithrin - µ 
only expressed significant drop in viability at 20 µM (P<0.0001****) by MTS assay in 
combination with UV (Fig 4.3.10A, Table 4.6). Even so no necrosis was observed with any of 
the UV - pifithrin - µ combination treatments (Fig 4.3.10 B, Table 4.6). No significant difference 
in the cell viability was observed in this combination treatment as pifithrin - µ at 20 µM itself 
produced considerable cytotoxicity at this tested concentration. Hence, the treatment was 
repeated with reduced doses of pifithrin -µ (10µM) together with low intensity UV irradiation 
to reveal whether it could present a progressive cytotoxic activity with response to UV 
exposure.  
Though pifithrin - µ (10 µM) expressed insignificant difference in cell viability (P 0.8991) in 
contrast to untreated controls by microscopic observation (Fig 4.3.9) or MTS assay that 
presented significant difference in combination with UV exposure at 2 s (P<0.0001****) and 
4 s (P <0.0001***, Fig 4.3.11A, Table 4.7).  The PI assay expressed insignificant variation 
between pifithrin - µ - UV treated groups at 2 s (P 0.8708) and 4 s (P 0.9115) respectively (Fig 
4.3.10B).  
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Fig: 4.3.9 Microscopic observation of U937 cell lines treated with pifithrin-µ and UV radiation at 
magnification of 20X objective (2048 × 1536 px). U937 cell lines seeded onto 96 well assay plates at cell density 
(5 × 10⁵ cells/ml) were treated with Pifithrin-µ (10 µM) I h prior to UV exposure for 2 and 4 s , were microscopically 
observed for cytotoxicity; (A) untreated, (B) pifithrin-µ (10 µM) (C) UV 2(s), (D) UV 4(s), (E) pifithrin-µ- UV 2(s), (F) 
pifithrin-µ- UV 4(s). 
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Fig: 4.3.10 Effect on cell viability by pifithrin- µ(20µM) with low UV on U937 cell line. U937 cell lines seeded onto 
96 well assay plates at cell density (5 × 10⁵ cells/ml) were treated with pifithrin-µ (20 µM) for 1h prior to UV exposure for 2 
and 4 s, Cell viability was measured by (A) MTS or (B) PI. Data were analyzed statistically using one- way ANOVA, with post 
hoc Sidaks multiple comparisons test. Significant differences between UV and Pifithrin- µ - UV concentrations are indicated 
by **** (p<0.05, mean±SD; n=4).   
Table 4.6 Statistic presentation of Sidaks multiple comparisons test (ns* insignificant)                         
MTS Assay PI Assay 
UV exposure (s) / pifithrin - µ (µM) 
Pifithrin (-) UV 2(+) vs UV 2 (+) pifithrin (+) 
pifithrin (-) UV 4(+) vs UV 4 (+) pifithrin (+) 
pifithrin (-) UV 2(-) vs UV 2 (+) pifithrin (-) 
pifithrin (-) UV 4(-) vs UV 4 (+) pifithrin (-) 
 
 
Significance 
**** 
**** 
ns 
ns 
P value 
P <0.0001 
P <0.0001 
P   0.9983 
P   0.0790 
UV exposure (s) / pifithrin -µ (µM) 
pifithrin (+) UV 2(-) vs UV 2 (+) pifithrin (+) 
pifithrin (+) UV 4(-) vs UV 4 (+) pifithrin (+) 
pifithrin (-) UV 2(-) vs UV 2 (+) pifithrin (-) 
pifithrin (-) UV 4(-) vs UV 4 (+) pifithrin (-) 
 
 
Significance 
ns 
ns 
ns 
ns 
 
P value 
P   0.9952 
P >0.9999 
P >0.9999 
P >0.9999 
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Fig: 4.3.11 Effect on cell viability by pifithrin µ(10µM) combined with UV on U937 cell line U937 cell lines seeded 
onto 96 well assay plates at cell density (5 × 10⁵ cells/ml) were treated with pifithrin - µ (10 µM) 1 h prior to UV exposure for 
2 and 4 s. Cell viability was measured by (A) MTS or (B) PI. Data were analyzed statistically using one - way ANOVA, with post 
hoc Sidaks multiple comparisons test. Significant differences between UV and Pifithrin- µ - UV treatments are indicated by 
**** (p<0.05) mean±SD; n=4.   
 Table 4.7 Statistic presentation of Sidaks multiple comparisons test (ns* insignificant)                         
MTS Assay PI Assay 
UV exposure(s) Piffithrin - µ (µM) 
pifithrin (-) UV 2(+) vs UV 2 (+) pifithrin (+) 
pifithrin (-) UV 4(+) vs UV 4 (+) pifithrin (+) 
pifithrin (-) UV 2(-) vs UV 2 (+) pifithrin (-) 
pifithrin (-) UV 4(-) vs UV 4 (+) pifithrin (-) 
 
 
 
Significance 
**** 
**** 
ns 
ns 
P value 
P<0.0001 
P<0.0001 
P 0.9987 
P 0.1050 
UVexposure(s)/Piffithrin - µ (µM) 
pifithrin (+) UV 2(-) vs UV 2 (+ pifithrin (+) 
pifithrin (+) UV 4(-) vs UV 4 (+) pifithrin (+) 
pifithrin (-) UV 2(-) vs UV 2 (+) pifithrin (-) 
pifithrin (-) UV 4(-) vs UV 4 (+) pifithrin (-) 
 
Significance 
ns 
ns 
ns 
ns 
P value 
P 0.8708 
P 0.9115 
P 0.6747 
P 0.9115 
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4.3.4 Effect of hyperthermia 42◦C on U937 cell lines                         
Hyperthermia induced a significant drop in cell viability on U937 cell lines exposed to 
42℃  treatment (P 0.0025**, Fig:4.3.12 A, Table 4.8) with respect to the untreated controls. 
However, no necrosis was detected by PI (P 0.0883) at 42℃  or 37℃ treatment (Fig:4.3.12 B, 
Table 4.8).  
4.3.5 Determination of hyperthermia induced apoptosis by flow cytometry 
The cytotoxic activity induced by heat shock treatment in U937 cell line were confirmed by 
performing annexin V and PI double staining. The flow cytometry data (Fig:4.3.13 C) 
expressed a viable population of 92.4% in the untreated controls. Heat shock treatment 
displayed decline in viable population around 38% due to 42℃ heat shock exposure 
(Fig:4.3.13 A). The data also exhibited significant early apoptotic rate of 17.9% (P 0.0219**, 
Fig:4.3.13 B), 23.5% of the population directed towards late apoptosis (P 0.0257**, Fig:4.3.13 
D) and confined cells 4.4% undergoing necrosis that were displayed insignificant (P 0.0914, 
Fig:4.3.13 C) in contrast to untreated cells at 37℃. Hence the results stated that hyperthermia 
induced cytotoxicity is resulted due to apoptotic cell death. 
4.3.6 Hyperthermia and HSPA1A protein in U937 cell lines 
The U937 cell line exposed to hyperthermia treatment at 42℃ resulted in increased surface 
release of HSPA1A. HSPA1A expression was measured by flow cytometry using FITC - labelled 
secondary antibody as presented in (Fig 4.3.15). Heat treatment resulted in significant surface 
release of HSPA1A proteins at a rate of around 38.6% (P 0.0002***), which was comparatively 
higher with that of the untreated cells, which also expressed HSPA1A (18.6%) (Fig:4.3.15 D).  
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Fig: 4.3.12 Effect on cell viability by hyperthermia - 42℃ on U937 cell lines. U937 cell lines at cell density (5 × 
10⁵(cells/ml), 3ml of cells were subjected to heat shock treatment at 42◦C for 1 h, followed by 2 h recovery at 37◦C. The cells 
were allowed for incubation at 37◦C for 24 h. The cells were then analyzed by(A) MTS or (B) PI. Data were analyzed statistically 
using (A) paired t test and (B) one- way ANOVA, with post hoc Sidaks multiple comparisons test. Significant differences 
between temperature treatments are indicated by **** (p<0.05 mean±SD; n=4).   
Table 4.8 Statistic presentation of Sidaks multiple comparisons test (ns* insignificant) 
MTS Assay PI Assay 
Temperature℃ 
 
37 vs 42 
Significance 
 
** 
P value 
 
P 0.0025 
Temperature℃ 
 
37 vs 42 
Significance 
 
ns 
 
P value 
 
P 0.0883 
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            A Unstained control                                        B 37℃                        
          
                                                    C   42℃ Heat shock 
                                           
 
Fig: 4.3.13 Flowcytometric data presentation of annexin V and PI staining in U937 cell lines exposed to 42 ℃ 
heat shock treatment. U937 cell lines at cell density (1 × 10⁶ cells), aliquots of 3 ml cells were subjected to heat shock 
treatment at 42℃ for 1 h, followed by 2 h recovery at 37℃. The cells were allowed for incubation at 37℃ for 24 h. The cells 
were then analyzed by annexin V and PI staining using flow cytometer (A) unstained control, (B) 37℃ and (C) 42℃ heat shock 
treated. 
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Fig: 4.3.14 Data interpretation of annexin V and PI staining in U937 cell lines exposed to 42 ℃ heat shock 
treatment. U937 cell lines at cell density (1 × 10⁶ cells), aliquots of 3 ml cells were subjected to heat shock treatment at 
42℃ for 1 h, followed by 2 h recovery at 37℃. The cells were allowed for incubation at 37℃ for 24 h. The cells were then 
analyzed by annexin V and PI staining using flow cytometer. Data were analyzed statistically using paired t test and significant 
differences between temperature treatments are indicated by * (p<0.05) n=3; (A) 37 vs 42 (P 0.0085**) (B) (P-0.0219**) 
significant; (C) P 0.0914) insignificant;(D) (P 0.0257**). 
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Fig: 4.3.15 Expression of cell surface HSPA1A in U937 leukaemia cell lines exposed to 42 ℃  heat shock 
treatment. U937 cell lines at cell density (1 × 10⁶ cells), aliquots of 3 ml cells were subjected to heat shock treatment at 
42℃ for 1 h, followed by 2 h recovery at 37℃. The cells were allowed for incubation at 37℃ for 24 h. The cells were then 
analyzed for HSPA1A expression using FITC labelled secondary antibodies using flow cytometer. Flow cytometry data 
presentation of histograms gated with (A) primary antibody stained control); (B 37℃); (C) 42 ℃ heat treatment (D) Data 
were analyzed statistically using paired-t test represented mean±SD(P<0.05) n=3; control vs 42℃ treatment (p-0.0105***) 
mean±SD; n=3. 
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4.3.7 Effect of pifithrin - µ and pifithrin chloride in HT-29 colorectal cancer cell lines 
The HT-29 cancer cell lines were treated with pifithrin - µ at concentrations ranging 25,50 and 
100µM allowed for incubation for 24 h. MTS cell viability assay which exhibited cytotoxicity 
at all the treated concentrations (Fig:4.3.16 A) with insignificant variations between 
concentrations -25 µM vs 50 µM (P 0.9774);100 (P >0.9999, Table 4.9).  PI assay presented 
necrosis with increase in concentration with significant difference between different treated 
concentrations (Fig:4.3.16 B) as presented in (Table 4.9). Upon continuing pifithrin - µ 
treatment for 48 h, MTS results showed same effect as depicted at 24 h (Fig:4.3.17 A), while 
the necrotic effect declined considerably, displaying insignificant difference between the 
tested concentrations as presented in (Fig:4.3.17 B, Table 4.10). 
The HT-29 cancer cell lines were found more effective upon treatment with Pifithrin chloride 
compared to pifithrin - µ.  pifithrin chloride were tested at concentrations ranging 25,50 and 
100µM/ml and allowed for incubation for 24 hours.  MTS cell viability assay and PI assay 
displayed a progressive cytotoxic activity at all the treated concentrations (Fig 4.3.18A) in 
contrast to the untreated control, while there exhibited no significance difference between 
treated dose,25 vs 50 (P 0.9988); 50 vs 100(P 0.9994) (Table 4.11). PI staining assay revealed 
necrotic effect with significant variation between 25 vs 50 concentrations (P 0.0155*) 
(Fig:4.3.18 B) and was found insignificant with higher concentration of 100µM (P 0.2611). 
Upon continuing pifithrin chloride treatment for 48 h, MTS results remained same as 
exhibited at 24 h (Fig:4.3.19 A), while the necrotic effect declined considerably with 
insignificant variation between tested doses as displayed in (Fig:4.3.19 B, Table 4.12). 
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Fig: 4.3.16 Effect on cell viability by pifithrin µ on HT-29 cell lines for 24h. HT-29 cell lines seeded onto 96 well assay 
plates at cell density (5 × 10⁵ cells/ml) could adhere to the surface of the plates for 24 h. Cells were then treated with varying 
concentrations of pifithrin - µ (0,25,50,100µM). The cells were allowed for 24 h incubation at 37℃. Cell viability was 
measured by (A) MTS or (B) PI. Data were analyzed statistically using one - way ANOVA, with post hoc Sidaks multiple 
comparisons test. Significant differences between untreated (0) and pifithrin - µ concentrations are indicated by **** 
(p<0.05) mean±SD; n=4.   
Table 4.9 Statistic presentation of Sidaks multiple comparisons test (ns* insignificant) 
MTS Assay PI Assay 
pifithrin -µ (µM) 
0   vs 25 
25 vs 50 
50 vs 100 
Significance 
**** 
ns 
ns 
P value 
P<0.0001 
P 0.9774 
P>0.9999 
pifithrin-µ (µM) 
0 vs 25 
25 vs 50 
50 vs 100 
Significance 
**** 
** 
** 
 
P value 
P<0.0001 
P 0.0032 
P 0.8926 
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Fig: 4.3.17 Effect on cell viability by pifithrin - µ on HT-29 cell lines for 48 h. HT-29 cell lines seeded onto 96 well 
assay plates at cell density (5 × 10⁵ cells/ml) could adhere to the surface of the plates for 24 h. Cells were then treated with 
varying concentrations of Pifithrin-µ (0,25,50,100µM). The cells were allowed for 48 h in incubation at 37℃. Cell viability was 
measured by (A) MTS or (B) PI. Data were analyzed statistically using one - way ANOVA, with post hoc Sidaks multiple 
comparisons test. Significant differences between untreated (0) and pifithrin - µ concentrations are indicated by **** 
(p<0.05) mean±SD; n=4.    
Table 4.10 Statistic presentation of Sidaks multiple comparisons test (ns* insignificant) 
MTS Assay PI Assay 
pifithrin -µ (µM) 
0   vs 25 
25 vs 50 
50 vs 100 
Significance 
**** 
ns 
ns 
P value 
P< 0.0001 
P 0.9903 
P>0.9856 
pifithrin -µ (µM) 
0   vs 25 
25 vs 50 
50 vs 100 
Significance 
* 
ns 
ns 
 
P value 
P 0.0393 
P 0.9882 
P 0.3894 
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Fig: 4.3.18 Effect on cell viability by pifithrin chloride on HT-29 cell lines for 24h. HT-29 cell lines seeded onto 96 
well assay plates at cell density (5 × 10⁵ cells/ml) could adhere to the surface of the plates for 24 h. Cells were then treated 
with varying concentrations of pifithrin chloride (0,25,50,100µM). The cells were allowed for 24 h incubation at 37℃. Cell 
viability was measured by (A) MTS or (B) PI. Data were analyzed statistically using one - way ANOVA, with post hoc Sidaks 
multiple comparisons test. Significant differences between untreated (0) and pifithrin chloride concentrations are indicated 
by **** (p<0.05) mean±SD; n=4.   
Table 4.11 Statistic presentation of Sidaks multiple comparisons test (ns* insignificant) 
MTS Assay PI Assay 
pifithrin chloride(µM) 
0   vs 25 
25 vs 50 
50 vs 100 
Significance 
**** 
ns 
ns 
P value 
P<0.0001 
P 0.9988 
P 0.9994 
pifithrin chloride(µM) 
0   vs 25 
25 vs 50 
50 vs 100 
Significance 
**** 
* 
ns 
 
P value 
P<0.0001 
P 0.0155 
P 0.2611 
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Fig: 4.3.19 Effect on cell viability by pifithrin chloride on HT-29 cell lines for (48 h). HT-29 cell lines seeded onto 96 
well assay plates at cell density (5 × 10⁵ cells/ml) could adhere to the surface of the plates for 24 h. Cells were then treated 
with varying concentrations of pifithrin chloride (0,25,50,100µM). The cells were allowed for 48 h incubation at 37℃. Cell 
viability was measured by (A) MTS or (B) PI. Data were analyzed statistically using one - way ANOVA, with post hoc Sidaks 
multiple comparisons test. Significant differences between untreated (0) and pifithrin chloride concentrations are indicated 
by **** (p<0.05) mean±SD; n=4.   
Table 4.12 Statistic presentation of Sidaks multiple comparisons test (ns* insignificant) 
MTS Assay PI Assay 
pifithrin chloride(µM) 
0 vs 25 
25 vs 50 
50 vs 100 
Significance 
**** 
ns 
ns 
P value 
P<0.0001 
P 0.9999 
P 0.9999 
pifithrin chloride(µM) 
0 vs 25 
25 vs 50 
50 vs 100 
Significance 
** 
ns 
ns 
 
 
P value 
P 0.0013 
P 0.9999 
P 0.5107 
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4.3.8 Effect of pifithrin - µ combined with UV (4 s) exposure on HT-29 cell line 
The colorectal cancer cell line HT-29 subjected to treatment with pifithrin - µ at varying 
concentrations 5, 10 and 15µM and the same concentrations were tested in combination with 
UV exposure for 4 s and allowed for incubation for 24 h. Cells expressed a pronounced drop 
in cell viability upon combination treatment of pifithrin - µ with UV at 4 s exposure by MTS 
assay displaying significant difference between varying concentration of pifithrin - µ with UV 
4 s - pifithrin - µ, displaying 5 µM (P <0.0001****), 10 µM (P <0.0001****), 15µM (P 
<0.0001****) (Fig 4.3.20 A, Table 4.13). 
The PI assay expressed no significant variation in combination treatment with UV 4 s exposure 
in all the pifithrin - µ concentrations tested, displaying 5 µM (P 0.9999), 10 µM (P >0.9999), 
15µM (P 0.9999) (Fig 4.3.20 B, Table 4.13). The results from the study states the positive 
response of UV irradiation together with pifithrin - µ even at concentrations as low as 5 µM 
(P <0.0001****), accelerated the rate of cytotoxicity HT-29 cancer cell lines compared to 
pifithrin - µ treatment independently.  
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 Fig: 4.3.20 Effect on cell viability by pifithrin - µ combined with UV (4s) exposure on HT-29 cell line. HT-29 cell 
lines seeded onto 96 well assay plates at cell density (5 × 10⁵ cells/ml) were treated with pifithrin - µ (5,10, 15 µM) for 1 h 
prior to UV exposure for 4 s. The pifithrin -µ treatments independently were placed as reference. The cells were allowed for 
24 h incubation at 37℃ . Cell viability was measured by (A) MTS or (B) PI. Data were analyzed statistically using one - way 
ANOVA, with post hoc Sidaks multiple comparisons test. Significant differences between UV and pifithrin - µ -UV 
concentrations are indicated by **** (p<0.05) mean±SD; n=4.   
Table 4.13 Statistic presentation of Sidaks multiple comparisons test (ns* insignificant) 
MTS Assay PI Assay 
pifithrin-µ (µM)/UV(4s) 
pifithrin 5 (+) UV (-) vs UV (+) pifithrin 5 (+) 
pifithrin 10 (+) UV (-) vs UV (+) pifithrin10 (+) 
pifithrin 15 (+) vs UV (-) vs UV (+) pifithrin15(+) 
pifithrin (-) UV (-) vs UV (+) pifithrin (-) 
 
Significance 
**** 
**** 
*** 
**** 
  P value 
P<0.0001 
P<0.0001 
P 0.0009 
P<0.0001 
pifithrin-µ (µM)/UV(4s) 
pifithrin 5 (+) UV (-) vs UV (+) pifithrin 5 (+) 
pifithrin 10 (+) UV (-) vs UV (+) pifithrin10 (+) 
pifithrin 15 (+) vs UV (-) vs UV (+) pifithrin15(+) 
pifithrin (-) UV (-) vs UV (+) pifithrin (-) 
 
Significance 
ns 
ns 
ns 
ns 
 
P value 
P 0.9999 
P 0.9999 
P 0.9999 
P 0.9992 
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4.3.9 Effect of hyperthermia in HT-29 cancer cell lines 
The HT-29 colorectal cancer cell lines subjected to hyperthermia treatment at  42℃ displayed 
significant drop in cell viability according to MTS assay (Fig 4.3.21 A, P-0.0349*). No necrosis 
was observed due to hyperthermia by PI assay (Fig 4.3.21 B).                                          
4.3.10 Determination of hyperthermia induced apoptosis by flowcytometry  
The cytotoxicity induced hyperthermia by cell viability assays was further confirmed for 
apoptosis by annexin V and PI staining using flow cytometer.  Hyperthermia at 42℃ resulted 
in a decline in viability to 30% (Fig 4.3.23 C), of which the early apoptotic % was 4.1 with late 
apoptosis of 25.8% (P 0.0085**, Fig: 4.3.23D). 
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Fig: 4.3.21 Effect of heat shock exposure on HT-29 cell lines. U937 cell lines at cell density (5 × 10⁵ cells/ml), aliquots 
of 3ml cells were subjected to heat shock treatment at 42◦C for 1 h, followed by 2 h recovery at 37◦C. The cells were allowed 
for incubation at 37◦C for 24 h. Cell viability was measured by (A) MTS or (B) PI. Data were analyzed (A) using paired t test, 
control vs 42 ℃ (P 0.0349*) (B) Using one - way ANOVA, with post hoc Sidaks multiple comparisons test. Significant 
differences between temperature treatments are indicated by (p<0.05) mean±SD; n=4 (37℃ vs 42℃  (P 0.0992).   
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4.3.10 Determination of hyperthermia induced apoptosis by flowcytometry 
The apoptotic induced by hyperthermia at 42℃, examined by cell viability and PI assays were 
confirmed with annexin V and PI double staining in colorectal cancer cell line HT-29.  
                                          
                                         A Unstained control 
                             
        B   37 ℃                                                                             C 42℃ Heat shock     
 
Fig: 4.3.22 Flowcytometric data presentation of annexin v and pi staining in HT-29 cell lines exposed to 42 ℃ 
heat shock treatment. HT-29 cell lines at cell density (1 × 10⁶ cells), aliquots of 3 ml of cells were subjected to heat shock 
treatment at 42℃ for 1 h, followed by 2 h recovery at 37℃. The cells were allowed for incubation at 37℃ for 24 h. The cells 
were then analyzed for apoptosis by annexin V and PI staining using flow cytometer- (A) unstained control, (B) 37◦C and (C) 
42◦C heat shock treated. 
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Fig: 4.3.23 Graphical determination of apoptosis by annexin V and PI staining in HT-29 cell lines exposed to 42 
℃. HT-29 cell lines at cell density (1 × 10⁶ cells), aliquots of 3 ml of cells were subjected to heat shock treatment at 42◦C for 
1 h, followed by 2 h recovery at 37℃. The cells were allowed for incubation at 37℃ for 24 h. The cells were then analyzed 
for apoptosis by annexin V and PI staining using flow cytometer. Statistical analysis performed using paired-t test represented 
mean±SD(P<0.05) n=3; 37 vs 42 (A) (P-0.0173**; (B) P-0.0914 insignificant; (C) P-0.0219*;(D) p-0.0085**). 
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4.4. Discussion 
The aim of the work in this Chapter was to evaluate whether inhibiting HSPA1A protein 
activity using the inhibitors pifithrin - µ & pifithrin chloride resulted in increased effectiveness 
of UV exposure or hyperthermia in inducing cell death. 
Firstly, the study evaluated the cytotoxicity induced by UV radiation. UV induced cell death 
(Fig (Fig 4.3.1,4.3.2 A, Table 4.1) as hypothesized, however no necrosis was observed by PI 
(Fig 4.3.2 B, Table 4.1). Results from the experiments suggests cell cytotoxicity by UV maybe 
due to apoptosis (Fig 4.3.2). Studies relates apoptotic signaling pathways including members 
of the caspase family - 3, 8 and 9, evidence to play a major role in stimulating UV assisted 
apoptosis in Leukaemia cancers (Salucci et al. 2013). Secondly, considering the defensive role 
of HSPA1A proteins (Mansilla et al. 2014), which encounter for the resistance of cancer cells 
to conventional treatments, studies have evidenced the potential role of  pifithrin - µ in 
inhibiting HSPA1A proteins, which relates to  enhanced sensitivity to treatments in several 
malignancies (Kaiser et al. 2011). The HSPA1A protein inhibitor compounds - 
Phenylethylsulphomide (Pifithrin - µ) and 2-(3-chlorophenyl) ethynesulfonamide (Pifithrin 
chloride) function in hampering the lysosome enzyme catalysed mechanism, which plays a 
major role in discarding of unwanted metabolic residues within cancer cells thus allowing 
successful proliferation (Mizushima et al. 2008; Jones et al. 2016). 
Administration of HSPA1A protein inhibitors pifithrin - µ and pifithrin chloride on U937 cell 
lines displayed decline in cell viability with increased necrosis (Fig 4.3.3&4 A, Table 4.2) at 24 
h and the necrosis declined upon prolonged exposure for 48 h (Fig 4.3.6 B Table 4.3), this may 
be due to disintegration of DNA due to prolonged treatment duration, which may have 
resulted in improper binding of the propidium iodide dye. Cytotoxic assessment with pifithrin 
chloride, which also expressed significant drop cell viability on U937 cell lines (Fig 4.3.7 A, 
Table 4.4) with enhanced necrotic effect at 24 h treatments (Fig 4.3.7 B, Table 4). Pifithrin 
chloride also showed a decline in necrosis similar to that of pifithrin - µ upon prolonged 
exposure for 48 h (Fig 4.3.8 B, Table 5). 
Pifithrin - µ was selected for the combination experiments with UV as pifithrin - µ was found 
to be less cytotoxic than pifithrin chloride, and the study designed at experimenting whether 
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lower dose of pifithrin - µ could accelerate the rate of cytotoxicity with limited UV exposure. 
The two - pronged approach, ablation of HSPA1A protein activity using pifithrin - µ (20µM) 
and UV for 2 and 4 s (Fig 4.3.10, Table 4.6) failed to identify any significant variation as pifithrin 
-µ at this tested concentration itself produced considerable cytotoxicity. The results from the 
study interpreted enhanced cytotoxic response of UV irradiation with pifithrin - µ at low 
concentration (10µM) (Fig 4.3.11, Table 4.7) accelerated the rate of cytotoxicity in U937 
cancer cell lines. 
And these experimental results match the results of previous studies which presented 
enhanced cytotoxicity upon introducing radiation with other pifithrin forms α and β (Walton 
et al. 2005). Hence this combination treatment displayed the potential role of pifithrin - µ in 
accelerating apoptosis in leukaemia cancer cell line U937 and reduces the risk of prolonged 
radiation exposure, enhancing the therapeutic index of radiation treatment. 
Having postulated the eminent role of HSPA1A proteins in shielding intracellular proteins 
from elevated heat, exposure to chemical toxins, ultra violet radiation cancer survival and 
resistance towards cancer treatments. The study also attributed to the positive response of 
HSPA1A proteins on hyperthermia treatment.  
Intracellular heat shock proteins reaching the exterior, elicit signals to trigger the immune 
system identify the threat and respond accordingly. Previous report evidence differentiation 
of U937 cell lines upon mid hyperthermia exposure (Goliaei. 1998).  
Recent findings reveal that, the transcription of these genes can be achieved indirectly by 
attenuating the intracellular link mediated through several other operons such as NEF-
Nucleotide exchange factors and TPR - Tetratricopeptide chains, which works in close 
connection with HSPA1A protein resulting insensitiveness to natural host defense, promoting 
cancer survival (Assimon et al. 2013; Daming. 2016).  The over expression of HSPA1A genes 
are studied to be key factors associated to cellular proliferation in most of the malignancies. 
Hence an explicit overview of function of these proteins at intracellular and extracellular 
levels may help improve conventional therapeutic index of different malignancies. (Multhoff. 
2006; Daming. 2016).  
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Hyperthermia at 42℃  in U937 cell lines presented significant drop in cell viability (P 0.0025**) 
(Fig 4.3.12 A, Table 4.8), which was confirmed to be resulted from apoptotic cell death by 
annexin v and PI staining (Fig 4.3.13), which showed similar drop in viability of around 38% 
(Fig 4.3.14). Hyperthermia treatment encountered for 20% increase (Fig 4.3.15) in release of 
HSPA1A proteins compared to untreated cells maintained at 37℃ . Previous in vitro report 
exhibited significant release of HSPA1A in response to hyperthermia treatment, directing 
apoptosis in hepato - carcinoma cancers (Yang et al. 2016). Therefore, therapeutic modalities 
targeting HSPA1A may help in improving cancer treatments according to (Schildkopf et al. 
2011). 
This study also examined significant cytotoxic effects displayed by pifithrin - µ in colorectal 
cancer cell line HT-29 at varying concentrations for 24 h (Fig 4.3.16, Table 4.9) and 48 h (Fig 
4.3.17, Table 4.10). Similar cytotoxic studies were studied using pifithrin chloride, which was 
found to be significantly more necrotic (Fig 4.3.18, Table 4.11) compared to pifithrin - µ at 24 
h treatment exposure. Pifithrin chloride also presented similar reduction in necrosis as that 
of leukaemia cancer cell line U937 with 48 h prolonged exposure treatment (Fig 4.3.19, Table 
4.12). This study further reveals the active participation of pifithrin - µ at low doses 5 and 
10µM in accelerating the effect of UV radiation treatment (Fig 4.3.20, Table 4.13). 
Hyper thermic treatment was studied to be effective as hypothesized against colorectal 
cancer survival at 42℃ (P 0.0349*, Fig 4.3.21), which were confirmed to be due to apoptotic 
cell death (Fig 4.3.21 & 4.3.22). 
This chapter concludes that UV radiation, pifithrin - µ, pifithrin chloride and hyperthermia 
treatments are effective anti - cancer agents in both Leukemia cell line U937 and colorectal 
cancer cell line HT-29 in vitro. And pifithrin - µ at doses as low as 5 and 10µM combined with 
limited UV exposure duration of 2 and 4 s evidenced pronounced cytotoxicity compared to 
UV exposures at 2 and 4s independently in both the tested cancer cell lines.  
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Chapter 5 
Intracellular delivery systems of chitosan and BSA 
5.1 Introduction  
The efficacy and efficiency of therapeutics relies on several factors such as prolonged 
bioavailability, targeted delivery and protection from enzymatic degradation. Direct 
administration of drugs often fails to produce expected results, due to poor absorption and 
interference of intestinal enzymes with the therapeutics resulting in inadequate drug 
bioavailability. Intriguingly, the exoskeleton of crustaceans possesses a component known as 
chitin, which is decalcified and deacetylated to extract chitosan which is an efficient natural 
polymeric carrier system which evidence to be successful for safe and targeted delivery of 
biological entities and chemotherapeutics (Saranya et al. 2011; Ghasemi et al. 2015). 
Moreover, its high degradability and biocompatible nature makes chitosan nano drug 
combinations perfect candidate for drug delivering applications (Kalpana. 2010). The pH 
sensitive and mucus - adhesive characteristic feature of chitosan confines it not only to cancer 
drug deliveries but also for clinical conditions, in which drugs are required to be transported 
across the mucosal barriers (Artursson. 1994). Studies have presented the accelerated drug 
delivering ability of chitosan based microparticles and nanoparticles (Chua et al. 2012; Hou et 
al. 2014). These particles not only exhibited enhanced drug entrapment  but also experienced 
prolonged drug activity in vivo, thus increasing the therapeutic potential of commercial drugs 
including atropine sulphate and folic acid  (Addo et al. 2015; Driton et al. 2013). Reports show 
that proteins such as insulin embedded in chitosan polymer matrix were shown to promote 
greater drug retention and controlled release for prolonged time duration (Zhang. 2010; Nam 
et al. 2010).  
Although the stability and bioavailability of drugs are well maintained within chitosan 
microgel (Marchand et al. 2009; Depani et al. 2013). The side effects produced by these 
systems remain unclear and still under exploration. Furthermore, studies have showcased the 
effective release and drug entrapment of glycerol phosphate cross linked chitosan microgels 
with the aid of dialysis bags, however the efficiency and cytotoxicity of β - glycerol phosphate 
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grafted microgel systems in human colon cancer cell lines has not been yet reported to our 
knowledge (Haddad et al. 2013). 
In addition to chitosan, bovine serum albumin (BSA) formulated micro and nano based 
systems are shown to be excellent natural entities for several drug delivery applications (Yu 
et al. 2014; Casa et al. 2015; Antonio et al. 2016). Evidence suggests that BSA nano 
formulations can improve the therapeutic potential of chemotherapeutics including 
doxorubicin, paclitaxel, anthracycline etc. (Sahaet al. 2016). This chapter will investigate the 
effect of chitosan or BSA particles encapsulated with 5 - fluorouracil for an accelerated 
cytotoxicity on HT-29 colon cancer cell lines, such that, these particles if presented an 
enhanced drug cytotoxicity and found to be non - cytotoxic in drug free states, may be 
postulated safe and could be used for plasmid DNA transfection studies. 
5.1.1 Aims and Hypotheses 
To evaluate the application of intracellular drug delivery particles of chitosan or BSA proteins 
The objectives of the study are- 
1.To evaluate the cytotoxicity of cross linking agent β - glycerol phosphate or 
glutaraldehyde in chitosan microgels or microparticles independently or in 
combination with 5 - fluorouracil on HT-29 colorectal cancer cell lines. 
Hypotheses- 
H0 chitosan microgels cross linked with β - glycerol phosphate or glutaraldehyde will not 
inhibit the growth of HT-29 cells in drug free state. 
H1 chitosan microgels cross linked with β - glycerol phosphate or glutaraldehyde may inhibit 
the growth of HT-29 cells in drug free state. 
 
2.To evaluate the effects of BSA microparticles independently or in 
combination with 5 - fluorouracil on HT-29 cancer cell lines.  
Hypotheses- 
H0 BSA microparticles will not induce growth inhibition of HT-29 cell lines in drug free form 
and hence may be safe intracellular delivery system.  
 
H1 BSA microparticles may induce cell cytotoxicity on HT-29 cells in its intact form. 
126 
 
5.2 Methods 
5.2.1 Cell culture and experimental design 
Cells were cultured and maintained as illustrated in (section 2.3.1.2). Colorectal cancer cell 
lines HT-29 at 5 × 10⁵ cells/ml seeding density were used for all the experiments. 
5.2.2 Chitosan - β - glycerol phosphate microgels treatment 
HT-29 cell lines were subjected to treatment with the chitosan microgels prepared as 
described in (section 2.3.8) with chemotherapeutic 5 - fluorouracil and drug free controls in 
EMEM cell culture medium. Drug free microgels, 5 - fluorouracil treated, and untreated cell 
lines were placed as controls. Microgel treatments were allowed for 24 h at 37℃ in incubator. 
5.2.3 Chitosan - glutaraldehyde microparticle treatment 
HT-29 cell lines were subjected to treatment with glutaraldehyde cross linked chitosan 
microparticles (prepared as illustrated in section 2.3.9) in EMEM cell culture medium.  
5.2.4 Treatment with BSA microparticles 
Microparticles of BSA was prepared using heat denaturation method as described in (section 
2.3.10). HT-29 cell lines were treated with microparticles encapsulated with 5 - fluorouracil. 
Drug free microparticles, 5 - fluorouracil treated, and untreated cell lines were placed as 
controls. Microparticle treatment was allowed for 24 h at 37℃ in incubator. 
5.2.5 Determination of cytotoxicity and microscopic observations 
Cell cytotoxicity were assessed by MTS cell viability assay (section 2.3.4) following 24 h 
microgel/microparticle formulation treatments on HT-29 cell lines. The formulations thus 
prepared using chitosan or BSA were observed using scanning electron microscopy for the 
formation of microgels and microparticles. 
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5.3 Results 
5.3.1 Microscopic observation of Chitosan β - glycerol phosphate microgels and chitosan    
           microparticles 
Chitosan β - glycerol phosphate crosslinked microgels prepared were observed for structural 
morphology determination by scanning electron microscopy (Fig 5.3.1 A, B, C) prior to in vitro 
cytotoxicity assays in colorectal cancer cell line HT-29. The microgels appeared to have 
densely scaffolded parallel structures at 1 KX, a magnified image revealed at 2 KX showcased 
tightly packed microspheres in appearance and the microsperes were visible upto a 
magnification to 10.13 KX.  
The chitosan - glutaraldehyde microparticles under scanning electron microscopic 
observation produced image of microspheres with a ring - shaped appearance at 
magnification of 1.44 K X, 10µM scale (Fig 5.3.2). 
 
 
Fig: 5.3.1A Scanning electron microscopic observation of β - glycerol phosphate crosslinked chitosan 
microgels at magnification of(A) 1.00 K X,10µm scale. 
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Fig: 5.3.1 B Scanning electron microscopic observation of β - glycerol phosphate crosslinked chitosan 
microgels at magnification of (B )2.00 K X, 10µm scale. 
 
 
 
 
Fig: 5.3.1 C Scanning electron microscopic observation of β - glycerol phosphate crosslinked chitosan 
microgels at magnification of (C) 10.13 K X, 2µm scale. 
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Fig: 5.3.2 Scanning electron microscopic observation of glutaraldehyde crosslinked chitosan microparticles at 
magnification of 1.44 K X,10µm scale. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
130 
 
5.3.2 Cytotoxicity of β - glycerol phosphate on HT-29 cell  
The following experiment were performed to determine the cytotoxicity of cross-linking 
agent β - glycerol phosphate in chitosan microgels on colorectal cancer cell lines HT-29. The 
microgels prepared (section 2.3.8) were then diluted using EMEM medium containing 10% 
FBS and added to HT-29 cell lines pre-seeded in 96 well assay plates. 5 - fluorouracil free 
microgels, 5 - fluorouracil treated, untreated cells and dead cells were placed as controls. The 
cells were then allowed for incubation for 24 h at 37℃ in incubator.   
The MTS assay presented decreased cell viability on HT-29 cancer cell lines with microgels 
prepared with all the tested concentrations of β - glycerol phosphate content, with significant 
difference of (P<0.0001) with reference to untreated controls (Fig 5.3.3). The results 
demonstrated no significant difference between cytotoxicity induced by tested 
concentrations 1 and 5% β - glycerol phosphate microgels, however the cytotoxicity exerted 
by higher concentrations 5 and 10% were significant as presented in Table 5.1.  
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Fig: 5.3.3. Effect on cell viability by β - glycerol phosphate concentration in chitosan microgels on HT-29 cell 
lines. Adherent cells of HT-29 seeded at cell density (5 × 10⁵ cells/ml) were used in all experiments. Cells were then treated 
with chitosan microgels of varying concentrations of glycerol phosphate. The cells were allowed for 24 h incubation at 37℃. 
Cell viability was measured by MTS assay. Data were analyzed statistically using one- way ANOVA, with post hoc Turkey’s 
multiple comparisons test. Significant differences between glycerol phosphate concentrations with reference to the 
untreated control are indicated by * (p<0.05) mean±SD; n=4.     
 
Table 5.1 Statistic presentation of Turkey’s multiple comparisons test (ns* insignificant) 
MTS Assay 
Beta -glycerol phosphate (%) 
0 vs 1 
0 vs 5 
0 vs 10 
1 vs 5 
5 vs 10 
Significance 
**** 
**** 
**** 
ns 
*** 
P value 
P<0.0001 
P<0.0001 
P<0.0001 
P 0.9168 
P 0.0006 
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5.3.3 Effect of 5 - fluorouracil encapsulated chitosan microgels on HT-29 cell lines 
Colorectal cancer cell lines HT-29 were subjected to treatment with chitosan microgels of 
varying β - glycerol concentration and encapsulated with 5 - fluorouracil at concentrations 5 
and 10 µM for 24 h incubation at 37℃. 
Cells treated with 5 - fluorouracil, drug free microgels and untreated cell lines were plated as 
controls. The reduced cell viability exerted by drug free microgels of varying concentrations 
of β - glycerol phosphate concentrations tested were consistent with previous experiments 
(Fig 5.3.3).    
The chitosan microgels cross linked with 10% of β - glycerol phosphate grafted with 5 - 
fluorouracil expressed significant drop in cell viability (P<0.0001) in contrast to 5 - fluorouracil 
in its intact form at both tested concentrations (Fig 5.3.4, Table 5.2). Upon reducing the ratio 
of β - glycerol phosphate in the microgels to 0.5% w/v (Fig 5.3.7 Table 5.5) the drug free 
microgel showed significant decline in cell viability with enhanced effect with the 5 - 
fluorouracil combination on HT-29 cell lines. Even though chitosan microgels with β -   glycerol 
phosphate of 0.5% w/v (Fig 5.3.7, Table 5.5) expressed considerably less cytotoxicity in its 
intact form compared to toxicity exerted by higher β - glycerol phosphate concentrations from 
previous experiments, the 5 - fluorouracil combinations of 0.5% w/v β -   glycerol phosphate 
did not produce expected reduction in cell viability of HT-29 cell lines as compared to 
combinations tested with higher β -   glycerol phosphate content.  
5.3.4 Effect of 5 - fluorouracil encapsulated glutaraldehyde linked chitosan microparticles 
on HT-29 cell lines 
Colorectal cancer cell lines HT-29 were subjected to treatment with chitosan microparticles 
encapsulated with 5 - fluorouracil at concentrations 5 and 10 µM for 24 h incubation at 37℃. 
Cells treated with 5 - fluorouracil independently, drug free microparticles and untreated cell 
lines were placed as controls. The chitosan microparticles cross linked with glutaraldehyde 
and combined with 5 - fluorouracil (section 2.3.9) and drug free microparticles expressed 
significant drop in cell viability (P<0.0001) in contrast to 5 - fluorouracil in its intact in both 
the tested concentrations and the untreated controls (Fig 5.3.8 Table 5.6).  
 
133 
 
 
 
                     
0 0 5 5
1
0
1
0
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
1 .2
1 .4
1 .6
1 .8
2 .0
A
b
s
o
rb
a
n
c
e
 (
4
9
0
n
m
)
   * * * * * * * *
C h ito s a n                 -        +        -           +        -          +
5  -  f lu o ro u ra c il (M )  -       -        +          +        +          +
 
 
                                                                                                                                                          
Fig: 5.3.4 Effect on cell viability by chitosan - β - glycerol phosphate (10 %) – 5 - fluorouracil microgels on HT-
29 cell lines.  Adherent cells of HT-29 seeded at cell density (5 × 10⁵ cells/ml) were used in all experiments. Cells were then 
treated with chitosan microgel (glycerol phosphate- 10 %) with 5 - fluorouracil 5 & 10µM and allowed for 24 h incubation at 
37℃. Cell viability was measured by MTS assay. Data were analyzed statistically using one- way ANOVA, with post hoc 
Turkey’s multiple comparisons test. Significant differences between 5 - fluorouracil and chitosan-5 - fluorouracil at 
concentrations 5 and 10 µM are indicated by **** (p<0.05) mean±SD; n=4.       
Table 5.2 Statistic presentation of Turkey’s multiple comparisons test (ns* insignificant) 
MTS Assay 
5 - Fluorouracil (µM) 
Chitosan (-) 5 - fluorouracil (-) vs 5 - flurouracil-5 
Chitosan (-) 5 - fluorouracil (-) vs 5 - flurouracil-10 
Chitosan (-) 5 - fluorouracil (-) vs Chitosan (+) 
5 - flurouracil-5 vs Chitosan (+) 5 - fluorouracil -5 (+) 
5 - flurouracil-10 vs Chitosan (+) 5 - fluorouracil -10 (+) 
 
 
 
Significance 
ns 
* 
**** 
**** 
**** 
P value 
P 0.1101 
P 0.0102 
P<0.0001 
P<0.0001 
P<0.0001 
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Fig: 5.3.5 Effect on cell viability by chitosan - β - glycerol phosphate (5 %) - 5 - fluorouracil microgels on HT-29 
cell lines.  Adherent cells of HT-29 seeded at cell density (5 × 10⁵ cells/ml) were used in all experiments. Cells were then 
treated with chitosan - 5 - fluorouracil microgels of 5 & 10µM. The cells were allowed for 24 h incubation at 37℃. Cell viability 
was measured by MTS assay. Data were analyzed statistically using one - way ANOVA, with post hoc Turkey’s multiple 
comparisons test. Significant differences between 5 fluorouracil and chitosan -5 - fluorouracil combinations are indicated by 
**** (p<0.05) mean±SD; n=4.    
Table 5.3 Statistic presentation of Turkey’s multiple comparisons test (ns* insignificant)      
MTS Assay 
5 - fluorouracil (µM) 
Chitosan (-) 5 - fluorouracil (-) vs 5 - flurouracil-5 
Chitosan (-) 5 - fluorouracil (-) vs 5 - flurouracil-10 
Chitosan (-) 5 - fluorouracil (-) vs Chitosan (+) 
5 flurouracil-5 - vs Chitosan (+) 5 - fluorouracil -5 (+) 
5 - flurouracil-10 vs Chitosan (+) 5 - fluorouracil -10 (+) 
 
 
 
 
Significance 
ns 
ns 
**** 
**** 
*** 
 
P value 
P 0.1764 
P 0.0581 
P<0.0001 
P<0.0001 
P 0.0006 
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Fig: 5.3.6 Effect on cell viability by chitosan - β - glycerol phosphate (1 %) - 5 - fluorouracil microgels on HT-29 
cell lines. Adherent cells of HT-29 seeded at cell density (5 × 10⁵ cells/ml) were used in all experiments. Cells were treated 
with chitosan- 5 - fluorouracil 5 & 10µM microgels. The cells were allowed for 24 h incubation at 37℃. Cell viability was 
measured by MTS assay. Data were analyzed statistically using one - way ANOVA, with post hoc Sidaks multiple comparisons 
test. Significant differences between 5 - fluorouracil vs chitosan - 5 - fluorouracil combination   is indicated by **** (p<0.05) 
mean±SD; n=4.      
Table 5.4 Statistic presentation of Turkey’s multiple comparisons test (ns* insignificant)          
MTS Assay 
5 - Fluorouracil (µM) 
Chitosan (-) 5 - fluorouracil (-) vs 5 - flurouracil-5 
Chitosan (-) 5 - fluorouracil (-) vs 5 - flurouracil-10 
Chitosan (-) 5 - fluorouracil (-) vs Chitosan (+) 
5 - flurouracil-5 vs Chitosan (+) 5 - fluorouracil -5 (+) 
5 - flurouracil-10 vs Chitosan (+) 5 - fluorouracil -10 (+) 
 
Significance 
ns 
*** 
**** 
**** 
**** 
 
P value 
P 0.3039 
P 0.0003 
P<0.0001 
P<0.0001 
P<0.0001 
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Fig: 5.3.7 Effect on cell viability by chitosan - β - glycerol phosphate (0.5 %) - 5 - fluorouracil microgels on HT-
29 cell lines. Adherent cells of HT-29 seeded at cell density (5 × 10⁵ cells/ml) were used in all experiments.  Cells were then 
treated with 5 - fluorouracil and chitosan - microgels of 5 - fluorouracil at 5 & 10 µM. The cells were allowed for 24 h 
incubation at 37℃. Cell viability was measured by MTS assay. Data were analyzed statistically using one - way ANOVA, with 
post hoc Turkey’s multiple comparisons test. Significant differences between 5 - fluorouracil vs chitosan - 5 - fluorouracil 
combinations are indicated by **** (p<0.05) mean±SD; n=4.      
Table 5.5 Statistic presentation of Turkey’s multiple comparisons test (ns* insignificant)      
MTS Assay 
5 - fluorouracil (µM) 
Chitosan (-) 5 - fluorouracil (-) vs 5 - flurouracil-5 
Chitosan (-) 5 - fluorouracil (-) vs 5 - flurouracil-10 
Chitosan (-) 5 - fluorouracil (-) vs Chitosan (+) 
5 - flurouracil-5 vs Chitosan (+) 5 - fluorouracil -5 (+) 
5 - flurouracil-10 vs Chitosan (+) 5 - fluorouracil -10 (+) 
 
Significance 
ns 
* 
**** 
**** 
**** 
P value 
P 0.9998 
P 0.0102 
P<0.0001 
P<0.0001 
P<0.0001 
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Fig: 5.3.8 Effect of cell viability by 5 - fluorouracil (glutaraldehyde cross linked) on HT-29 cell lines. Adherent 
cells of HT-29 seeded at cell density (5 × 10⁵ cells/ml) were used in all experiments. Cells were then treated with 
microparticles of Chitosan - 5 - fluorouracil 50 µM, along with respective controls. The cells were allowed for 24 h incubation 
at 37℃. Cell viability was measured by MTS assay. Data were analyzed statistically using one - way ANOVA, with post hoc 
Turkey’s multiple comparisons test. The analysis depicted insignificant differences between chitosan -5 - fluorouracil and 5 
fluorouracil (50 µM) are indicated by (p<0.05) mean±SD; n=4.    
     
Table 5.6 Statistic presentation of Turkey’s multiple comparisons test (ns* insignificant)      
MTS Assay 
5 - fluorouracil (µM) 
Chitosan (-) 5 - fluorouracil (-) vs Chitosan (+) 
Chitosan (-) 5 - fluorouracil (-) vs 5 - flurouracil-50 
Chitosan (+) vs chitosan (+)-5 - flurouracil-50 
Chitosan (+) vs chitosan (+)-5 - flurouracil-50 
5 - fluorouracil (+) vs chitosan (+)-5 - flurouracil-50 
 
 
 
Significance 
* 
**** 
**** 
**** 
ns 
P value 
P 0.0130 
P<0.0001 
P<0.0001 
P<0.0001 
P 0.9924 
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5.3.5 Effect of BSA microparticles encapsulated with 5 - fluorouracil on HT- 29 cell lines 
The following experiments were performed to determine the effect of BSA microparticles 
encapsulated with 5 - fluorouracil on HT- 29 cell lines. The cell lines were treated with BSA 
microparticles combined with 5 - fluorouracil. The cells were then incubated for 24 h at 37℃ 
in incubator. Cells were treated with 5 - fluorouracil independently, drug free microparticles 
and untreated cell lines were placed as controls. The microparticles size ranged between 1.9 
- 3.8µM in size according to scanning electron microscopy (Fig 5.3.9). MTS cell viability assay 
expressed cytotoxicity with drug free microparticles which were insignificantly variant with 5 
- fluorouracil encapsulated particle treatments on HT-29 cell lines (Fig 5.3.10, Table 5.7).   
 
 
 
Fig: 5.3.9 Scanning electron microscopic observation of BSA protein microparticles at magnification of (A) 1.44 
K X,10µM scale. 
 
 
 
 
 
                                                       
139 
 
                                 
0 0
5
0
5
0
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
1 .2
1 .4
1 .6
1 .8
2 .0
A
b
s
o
rb
a
n
c
e
 (
4
9
0
n
m
)
B S A                          -               +            -              +
5  -  f lu o ro u ra c il (M )    -               -            +              +
 
                                                  
                                    
Fig: 5.3.10 Effect of cell viability by BSA microparticles loaded 5 - fluorouracil on HT-29 cell lines. HT-29 cell lines 
seeded onto 96 well assay plates at cell density (5 × 10⁵ cells/ml) could adhere to the surface of the plates for 24 h. Cells 
were then treated with microparticles of BSA - 5 - fluorouracil at 50µM. The cells were allowed for 24 h incubation at 37℃. 
Cell viability was measured by MTS assay. Data were analyzed statistically using one - way ANOVA, with post hoc Turkeys 
multiple comparisons test. Significant differences between BSA vs BSA – 5 - fluorouracil concentrations are indicated by 
(p<0.05) mean±SD; n=4.    
 
 Table 5.7Statistic presentation of Turkey’s multiple comparisons test (ns* insignificant)       
MTS Assay 
5 - fluorouracil (µM) 
BSA (-) 5 - fluorouracil (-) vs 5 - flurouracil-50 
BSA (-) 5 - fluorouracil (-) vs BSA (+) 
BSA (-) 5 - fluorouracil (-) vs BSA (+)-5 - flurouracil-50 
5 - flurouracil-50 vs BSA-5 - flurouracil-50 
BSA (+) – 5 - fluorouracil (-) vs BSA (+) – 5 - fluorouracil (+) 
 
 
Significance 
**** 
*** 
** 
**** 
 ns 
P value 
P<0.0001 
P 0.0007 
P 0.0012 
P<0.0001 
P 0.990 
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5.4 Discussion 
The objective of the second phase of the study was to evaluate the cytotoxicity of chitosan or 
BSA microparticle/microgel drug delivery systems on colorectal cancer cell line HT-29. The   
chitosan microgels tested not only enhanced cytotoxic activity on HT-29 cell lines in drug frees 
states itself, but also failed to produce expected drug cytotoxicity with low concentrations of 
the cross - linking agent used to graft the microgels. The microparticles of BSA and chitosan 
were also found to be toxic to HT-29 cell lines in its drug free form. 
Studies suggests the potential application of chitosan modified microgel systems for drug 
encapsulation and release (Mahattanadul et al. 2016; Puga et al. 2013). Although previous 
report showed, chitosan β - glycerol phosphate microgels as efficient in drug encapsulation 
and release, these microgels in its free state are prone to be cytotoxic in a concentration - 
based manner in fibroblast cells in mouse (Depani et al. 2013). The reports from this present 
study also reveal the toxicity exerted by chitosan - β - glycerol phosphate microgels in 
colorectal cancer cell line HT-29.  
The cytotoxicity of the microgels were studied to be resulted from the toxicity of the cross-
linking agent β - glycerol phosphate in a dose dependent manner (Fig 5.3.3, Table 5.1). The 
chitosan microgels cross linked with all the different concentration of β - glycerol phosphate 
produced accelerated cytotoxicity with 5 - fluorouracil encapsulations in all concentration 
compared to 5 - fluorouracil in its native form (Fig 5.3.4 – 5.3.7).  
Although microgels modified with the lowest β - glycerol phosphate concentration tested 
0.5%  expressed considerably less toxicity in drug free state compared to its higher doses in 
HT-29 cell lines, 5 - fluorouracil encapsulation displayed slight decline in cytotoxicity 
compared to 5 - fluorouracil - chitosan microgels with higher β - glycerol phosphate 
concentrations tested, this may be due to the lower quantity of β - glycerol phosphate (0.5%), 
which maybe insufficient enough to trap the all the 5 - fluorouracil incorporated. Apart from 
chitosan microgels, the glutaraldehyde cross linked chitosan microgels also presented 
cytotoxicity in drug free state (Fig 5.3.8).  
Besides the application of chitosan, BSA protein - based nanoparticles are proved to be 
efficient and safe intracellular drug transport systems, expressing enhanced therapeutic 
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effect (Yu et al. 2014). However, in this present study, although the BSA microparticles were 
successfully formed (Fig 5.3.9), the results showed no fluctuation in 5 - fluorouracil 
encapsulations in contrast to drug in its native state (Fig:5.3.10), this may be due to the large 
size of the particles thus formed which failed to entrap the 5 - fluorouracil used in the study.  
Due to the cytotoxicity exerted by chitosan or BSA based delivery systems on the growth of 
HT-29 cells in their drug free forms, these particles were found unsuitable for use in 
transfection studies in the later part of the study. Hence, the thesis did not further investigate 
the encapsulation efficiency or drug release profiles of these delivery systems, as the use of 
these particles were found not suitable for intracellular delivery application in this study. 
The scanning electron microscopic images of chitosan or BSA based delivery systems were 
observed to be morphologically similar to previous literatures (Depani et al. 2013; Yu et al. 
2014). However, there are chances for artefact appearances in the images produced, which 
may be due to the physical or chemical alteration, resulted from dehydration process during 
sample fixation for scanning electron microscopic analysis.                            
Hence the findings in this chapter collectively  stated that all the delivery systems tested were 
found inadequate due to the cytotoxicity exerted by subsequent cross-linking agents β - 
glycerol phosphate or glutaraldehyde in chitosan microgels or microparticles and BSA 
microparticles in drug free states on colorectal cancer cell line HT- 29.  
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Chapter 6 
Effect of p21 plasmid cDNA transfection and HSPA1A inhibition in 
colorectal cancer cell line HT-29 
6.1 Introduction 
Cancer cells are developing resistance to conventional therapeutics (Axelrod et al. 2017), even 
with high dosage administration, hence the necessity of developing highly personalised 
treatment strategies is at the top priority. The p21 gene product functions as negative 
attenuator of DNA replication, in response to translation of several operons including PCNA, 
P53 genome, most importantly, these proteins are unique in their mechanism of interactive 
binding of cyclin dependent kinase inhibitors, attenuating cancer proliferation (Pavelic et al. 
2008). Although, in some malignant cells, the function of p21 is resumed with respect to the 
malfunctional status of wild type p53 gene, in cancers possessing functional p53, p21 protein 
functions as potent negative regulator of cell cycle (Galanos et al. 2016).  
Research, over the years has illustrated the eminent role of several genes, pre - programmed 
in cell cycle regulation in different cancer types, making explicit the vital role of tumour 
suppressor gene p21 in arresting cancer proliferation, suggesting its therapeutic potential in 
cancer gene therapy (Abbas et al. 2009; Pasz et al. 2001; Van Etten et al. 2002). 
Eukaryotic cells under physiological stress response exhibits elevated levels of stress protein 
HSPA1A, which are studied to participate closely with signalling pathways assisting a 
protective role under cellular stress, enhancing tumorigenicity. According to recent reports, 
Inhibition of HSPA1A improved the sensitivity to chemotherapeutics in colorectal cancer 
(Goloudina et al.  2015; Jagadish et al. 2016). Recent studies reveal the resistance acquired by 
5 - fluorouracil in colorectal cancer cells, due to the elevated levels of HSPA1A, expressing its 
defensive role against apoptosis (Grivicich et al. 2007).  
However, the role of HSPA1A proteins in p21 tumor suppressor protein induced cancer arrest 
is not reported elsewhere according to our knowledge, and hence this present study 
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investigated a two - pronged approach inhibition of HSPA1A protein activity and simultaneous 
overexpression of suppressor protein p21.  
In the previous experiments (chapter 5), it was determined that chitosan and BSA based 
intracellular delivery systems were not suitable for p21 - plasmid DNA delivery applications, 
so a different transfection approach using lipofectamine 2000 was performed. 
Previous studies, evidence the insensitiveness of several chemotherapeutics is due to 
elevated levels of HSPA1A, expressing its defensive role against apoptosis in colorectal cancer 
cells (Grivicich et al. 2007). Hence, repression of HSPA1A proteins evidenced to improve the 
chemotherapeutic sensitivity in colorectal cancers (Goloudina et al; Sherman. 2015; Jagadish. 
et al. 2016). This work postulated the inhibition of HSPA1A in combination with increased p21 
would enhance the apoptosis induced by p21 plasmid cDNA and may be a promising 
therapeutic strategy for the treatment of colorectal cancers. 
 6.1.1 Aims and hypotheses 
The aims of this chapter were to evaluate- 
                   1.The effect of overexpression of p21 protein through genetic approach in 
                       inducing apoptosis in colorectal cancer cell lines HT-29. 
Hypotheses-  
H0 transfection with p21 plasmid cDNA will not arrest the growth of HT-29 cells. 
H1 p21 plasmid cDNA transfection may arrest the growth of HT-29 cells. 
 
                     2.  Whether inhibition of HSPA1A proteins and p21 overexpression would  
                          accelerate the apoptosis induced by p21 plasmid cDNA transfection in  
                          HT-29 cell lines.  
Hypotheses-    
H0 the inhibition of HSPA1A in combination with increased p21 will not accelerate apoptosis 
in HT-29 cells.  
H1 the inhibition of HSPA1A in combination with increased p21 will enhance apoptosis in 
HT-29 cells.  
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6.2 Methods 
6.2.1 Cell culture 
Colorectal cancer cell lines HT-29, were cultured as described in (Secion 2.3.1). Cells at seeding 
density 5 × 10⁵ cells/ml were used in all experiments. 
6.2.2 p21 plasmid DNA isolation, extraction, purification, transformation and transfection  
p21 plasmid cDNA was provided in Escherichia coli as stabbed agar cultures. Isolated bacterial 
colonies were produced by streaking the culture onto Lactose agar plates supplemented with 
ampicillin antibiotic, provided 37℃ in incubator for 24 h. Batch cultures were prepared in 
lactose broth medium Bacterial stock cultures were maintained in glycerol at -80℃ for future 
analysis. The plasmid cDNA was extracted from the bacterial cells using endo free maxi prep 
kit as illustrated in (section 2.3.13).  
The extracted plasmid cDNA was quantified by DNA nano drop. The DNA was sequenced with 
aid from Euro fins laboratory services and confirmed for full length human P21 coding 
sequence. The sequence was further confirmed for p21 by blasting the sequence using NCBI 
nucleotide blast tool. The p21 plasmid cDNA was also analysed by agarose gel electrophoresis. 
The PmT5 vector was restricted using digestion enzymes Ndel and BamHI as illustrated in 
(section2.3.15), to remove the PMT5 backbone and religate it to generate a vector only 
control.  
The restricted PmT5 vector DNA was separated by agarose gel electrophoresis, extracted 
from the gel fragment, repaired for blunt ends, ligated, purified and transformed into DH5α 
competent cells. The p21 plasmid cDNA which was transfected using lipofectamine 2000 in 
colorectal cancer cell line HT-29 according to manufacturer’s protocol. The experimental 
steps from plasmid cDNA extraction to transfection were performed according to the 
respected commercial kit instructions provided. 
6.2.3 Pifithrin - µ assisted inhibition of HSPA1A protein and p21 plasmid cDNA transfection 
HT- 29 cells were seeded onto 96 well assay plates at a concentration of 5 ×10⁵ cells/ml and 
allowed for incubation for 24 h. Following attachment, the cells were treated with pifithrin - 
µ (15µM) and p21 plasmid cDNA in lipofectamine 2000 in serum free EMEM cell culture 
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medium devoid of antibiotics. Untreated, PmT5 vector in lipofectamine, pifithrin - µ treated 
cell lines were placed as controls. 
6.2.4 Measurement of cell viability, apoptosis, necrosis and protein expression profiles. 
The subsequent treatments were allowed for 24 h and cells were analyzed for cytotoxicity by 
MTS assay as illustrated in (Section 2.3.4). 
Flow cytometric analysis were also used to confirm the percentage of apoptosis and necrosis   
by annexin V and PI staining method as illustrated in (section 2.3.6) 
6.2.5 Observation of apoptosis and protein expression profiles 
HT-29 cells upon subsequent transfection treatments were observed for cytotoxicity under 
light microscopy (Fig 6.3.1). p21 plasmid cDNA and vector plasmid DNA transfected HT-29 cell 
lines were pooled and probed with FITC labelled p21 primary antibodies for protein 
expression profiles as illustrated in (section 2.3.7.4, 2.3.7.5) by flowcytometry. The 
transfected cells were confirmed for apoptosis using annexin V and PI staining as illustrated 
in (section 2.3.6) using flow cytometer. 
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6.2.6 Experimental design of p21 - plasmid cDNA - extraction, purification and transfection 
 Fig 6.2.6.1Isolated colonies of Escherichia coli containing p21 plasmid cDNA 
                               
Batch culturing of p21 plasmid cDNA inserted Escherichia coli in Luria-Bertani broth as illustrated in (section 
2.3.12.1) 
            
Plasmid cDNA extracted and purified by Qiagen Endofree maxi - plasmid prep protocol as illustrated in (section 
2.3.13) 
                                                         
   Fig 6.2.6.2 Identification of p21 plasmid DNA by agarose gel - electrophoresis  
             
  Fig 6.2.6.3 Restriction digest of p21 plasmid cDNA from vector DNA  
           
 
DNA blunt end repair, purification of repaired DNA, ligation and sub cloning of vector DNA onto DH5 alpha E. 
coli cells (sections 2.3.19.1 – 2.3.19.3)   
                                
        Fig 6.2.6.4 Transformation of PmT5 vector in DH5 alpha E. coli cell 
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6.2.7 Sequencing of p21 plasmid cDNA by Eurofins laboratories, UK 
pBABE3 reverse sequencing 
TCACAGGCATCTACTGAGTGGACCCAACGCATGAGAGGACAGTGCCAAGCAAGCAACTCA 
AATGTCCCACCGGTTGGGCATGGCCAGGTAGCCTATGCTGTGTCTGGACGTCCTCCTGCT 
GGTATAGTTATTTTAAAATCAGAAGGACAGGGAAGGGAGCAGTGGTTCACGCCTGTAATC 
CCAGCAATTTGGGAGGCCAAGGTGGGTAGATCACCTGAGATTAGGAGTTGGAGACCAGCC 
TGGCCAATATGGTGAAACCCCGTCTCTACCAAAAAAACAAAAATTAGCTGAGCCTGGTCA 
TGCATGCCTGGAATCCCAACAACTCGGGAGGCTGAGGCAGGAGAATCGCTTGAACCCAGG 
AGGCGGAGATTGCAGTGAGCCAAGATTGTGCCACTGCACTCCAGCTTGGTTCCCAATAGA 
CCCCGCAGGCCCTACAGGTTGTCTTCCCAACTTGCCCCTTGCTCCATACCACCCCCCTCC 
ACCCCATAATATTATAGAAGGACACCTAGTCAGACAAAATGATGCAACTTAATTTTATTA 
GGACAAGGCTGGTGGGCACTGGAGTGGCAACTTCCAGGGCCAGGAGAGGCACTGGGGAGG 
GGTCACAGGGATGCCACCCGGGATCCCCCGGGCTGCAGGAATTCGATATCTGCAGAATTC 
GGCTTTAGAATTCTTAGGGCTTCCTCTTGGAGAAGATCAGCCGGCGTTTGGAGTGGTAGA 
AATCTGTCATGCTGTCCTGCCGCCGTTTTCGACCCTGAGAGTCTCCAGGTCCACCTGGGG 
ACCCTTCAGCCTGCTCCCCTGAGCGAGGCACAAGGGTACAAGACAGTGACAGGTCCACAT 
GGTCTTCCTCTGCTGTCCCCTGCAGCAGAGCAGGTGAGGTGCCAGGCCGCCTGCCTCC 
 
 
 
 
CMV forward sequencing 
GCAGAGCTCGTTTAGTGAACCGTCAGAATTCAGATCTGGTACCACGCGTATCGATAAGCT 
TGCATGCCTGCAGGTCGACTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACC 
ATGGACTACAAAGACGATGACGATAAAGCAAGAAGAGCATCTGTGCATATGTCAGAACCG 
GCTGGGGATGTCCGTCAGAACCCATGCGGCAGCAAGGCCTGCCGCCGCCTCTTCGGCCCA 
GTGGACAGCGAGCAGCTGAGCCGCGACTGTGATGCGCTAATGGCGGGCTGCATCCAGGAG 
GCCCGTGAGCGATGGAACTTCGACTTTGTCACCGAGACACCACTGGAGGGTGACTTCGCC 
TGGGAGCGTGTGCGGGGCCTTGGCCTGCCCAAGCTCTACCTTCCCACGGGGCCCCGGCGA 
GGCCGGGATGAGTTGGGAGGAGGCAGGCGGCCTGGCACCTCACCTGCTCTGCTGCAGGGG 
ACAGCAGAGGAAGACCATGTGGACCTGTCACTGTCTTGTACCCTTGTGCCTCGCTCAGGG 
GAGCAGGCTGAAGGGTCCCCAGGTGGACCTGGAGACTCTCAGGGTCGAAAACGGCGGCAG 
GACAGCATGACAGATTTCTACCACTCCAAACGCCGGCTGATCTTCTCCAAGAGGAAGCCC 
TAAGAATTCTAAAGCCGAATTCTGCAGATATCGAATTCCTGCAGCCCGGGGGATCCCGGG 
TGGCATCCCTGTGACCCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGTTGCCACTCCAGTG 
CCCACCAGCCTTGTCCTAATAAAATTAAGTTGCATCATTTTGTCTGACTAGGTGTCCTTC 
TATAATATTATGGGGTGGAGGGGGGTGGTATGGAGCAAGGGGCAAGTTGGGAAGACAACC 
TGTAGGG       
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6.3 Results 
6.3.1 Effect of p21 plasmid cDNA transfection and pifithrin - µ mediated HSPA1A inhibition 
and p21 plasmid cDNA transfection in HT-29 colorectal cancer cell line 
HT-29 cells transfected with the plasmid cDNA containing full length p21 were observed for 
morphology changes suggesting cell death using light microscope (Fig 6.3.1). The cells 
exhibited significant decrease in cell viability P<0.0001 by MTS cell viability assay with 
reference to the respected controls. (Fig 6.3.2). This decline in cell viability was confirmed by 
annexin V and PI staining assay by flow cytometer. Flow cytometer interpreted total apoptotic 
rate of 58.1 % (Fig 6.3.3 C) for the p21 transfected cell lines. pifithrin - µ assisted inhibition of 
HSPA1A protein activity with p21 plasmid DNA transfection presented a pronounced arrest 
of 90% of the treated population of HT-29 cells within 24 h (Fig 6.3.3E), which was 
approximately 62% higher than treatment with pifithrin - µ independently (Fig 6.3.3D).  
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  A                                                                         B                                                       
           
  C                                                                                 D 
      
   E 
   
  
 
Fig: 6.3.1 Microscopic observation of HT-29 cell lines treated with p21 plasmid cDNA transfection at magnification of 
20X objective (2048 × 1536 px). (A) Mock transfected control(B) vector-Lipofectamine control (C) p21-lipofectamine 
transfected(D)piffithrinµ and (E) pifithrin - µ combined p21 gene transfection. 
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Fig: 6.3.2 Effect of p21-plasmid DNA transfection on HT-29 cell lines. HT-29 cell lines seeded onto 96 well assay 
plates at cell density (500,000 cells/ml) could adhere to the surface of the plates for 24 h. Cells were then treated with human 
p21 plasmid DNA incorporated in lipofectamine complex. The cells were incubated for 24 h in incubator at 37℃. Cell viability 
was measured by MTS assay. Data were analyzed statistically using one - way ANOVA, with post hoc Tukey’s multiple 
comparisons test. Significant differences between control and transfected cell lines are indicated by * (p<0.05) mean±SD; 
n=4.   
Table 6.1 Statistic presentation of Tukey’s multiple comparisons test (ns* insignificant) 
MTS Assay 
p21 plasmid DNA(2.0µg) 
Control vs lipofectamine control 
Control vs vector control 
Control vs p21 plasmid DNA 
Lipofectamine control vs p21 plasmid DNA 
Vector control vs p21 plasmid DNA 
Significance 
* 
ns 
**** 
**** 
**** 
P value 
P 0.0311 
P 0.1338 
P<0.0001 
P<0.0001 
P<0.0001 
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                  C                                                                             D 
                 
                                                                                    
                                                        E                                                                                
                                                                                          
Fig: 6.3.3 Flowcytometric data presentation of annexin V and PI staining in HT-29 cell lines. HT-29 cell lines at cell density 
(1 × 10⁶ cells), seeded onto 6 well assay plates were exposed to pifithrin - µ (15µM) followed by transfection with p21 plasmid 
DNA. The cells were allowed for incubation at 37◦C for 24h. The cells were then analyzed by annexin V and PI staining using 
flow cytometer- (A) unstained control, (B) Vector transfected, (C) p21 plasmid DNA transfected, (D) pifithrin - µ treated and 
(E) pifithrin -µ- p21 plasmid DNA. 
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Fig: 6.3.4 Effect of p21 plasmid cDNA transfection determination by annexin V and PI staining. HT-29 cell lines seeded 
onto 6 well assay plates at cell density (1 × 10⁶cells) could adhere to the surface of the plates for 24 h. Cells were then treated 
with human p21 plasmid cDNA - lipofectamine complex, vector DNA in lipofectamine independently and in combination with 
pifithrin-µ (15µM). The cells were incubated for 24 h in incubator at 37℃. Cell viability was measured by Annexin V and PI 
by flow cytometer. Data were analyzed statistically using one - way ANOVA, with post hoc Tukey’s multiple comparisons test. 
Significant differences between control and transfected cell lines are indicated by * (p<0.05) mean±SD; n=4.   
Table 6.2 Statistic presentation of Tukey’s multiple comparisons test (ns* insignificant) 
%of cell viability                                      Significance      P value                 % of apoptosis                                         Significance    P value                  
Control vs pifithrin - µ                                        ****                    P<0.0001                    Control vs pifithrin - µ                                          *                    P 0.0126 
Control vs vector control                                     ns                       P 0.9804                     Control vs vector control                                     ns                  P 0.9693 
Control vs p21 plasmid cDNA                              ****                 P<0.0001                     Control vs p21 plasmid cDNA                             ns                  P >0.9999                        
Vector control vs p21 plasmid cDNA                  ****                 P<0.0001                    Vector control vs p21 plasmid cDNA                 ns                  P 0.9486 
Pifithrin - µ vs p21 plasmid cDNA-pifithrin-µ                                                                   Pifithrin - µ vs p21 plasmid cDNA-pifithrin-µ   ****             P <0.0001 
 
 % of necrosis                                                  Significance     P value                 % of late apoptosis                                Significance    P value 
Control vs pifithrin - µ                                            **                        P 0.0069                  Control vs pifithrin - µ                                           **                  P 0.0069 
Control vs vector control                                        ns                       P 0.9994                  Control vs vector control                                       ns                  P 0.8388 
Control vs p21 plasmid cDNA                                ns                       P 0.0572                   Control vs p21 plasmid cDNA                              ****              P<0.0001 
Vector control vs p21 plasmid cDNA                    ns                       P 0.0787                  Vector control vs p21 plasmid cDNA                   ****             P<0.0001 
Pifithrin - µ vs p21 plasmid cDNA-pifithrin-µ      ns                       P 0.3590                  Pifithrin - µ vs p21 plasmid cDNA-pifithrin-µ     ****             P<0.0001 
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6.3.2 Evaluation of pifithrin - µ assisted inhibition of HSPA1A in colorectal cancer cell line 
HT-29 
The HT-29 cell lines subjected to treatment with pifithrin -µ were analysed for HSPA1A protein 
inhibition using HSPA1A primary antibody and FITC labelled secondary antibody showed 
significant inhibition of HSPA1A with pifithrin - µ at 15µM concentration (Fig 6.3.5). 
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Fig: 6.3.5 Intracellular inhibition of pifithrin - µ facilitated HSPA1A protein expression in HT-29 colon cancer 
cell line HT-29 cell lines seeded onto 6 well assay plates at cell density (1 × 10⁶cells) could adhere to the surface of the plates 
for 24 h. Cells were then treated with Pifithrin-µ(15µM). The cells were incubated for 24 h in incubator at 37℃. Cells were 
subjected to determination of HSPA1A protein expression by flow cytometer using FITC labelled secondary antibody. Data 
were analyzed statistically using paired t-test. Significant differences between control and treated cell lines are indicated by 
* (p<0.05) mean±SD; n=3, HSPA1A proteins(p0.099**).   
  
155 
 
 
 
6.3.3 Determination of intracellular and cell surface levels of p21 protein resulted from p21  
          plasmid DNA transfection by flow cytometer 
The overexpression of p21 was analysed using FITC labelled p21 primary antibody showed no 
difference in expression in endogenous p21 levels with reference to untreated cell lines (Fig 
6.3.6). However, p21 induction expressed a significant rise in expression of cell surface p21 
protein 20.8% compared to the untransfected controls (Fig 6.3.7). 
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Fig: 6.3.6 Intracellular p21 protein expression in HT-29 colon cancer cell line HT-29 cell lines seeded onto 6 well 
assay plates at cell density (1 × 10⁶ cells) could adhere to the surface of the plates for 24 h. Cells were then treated with p21 
plasmid cDNA in lipofectamine. The cells were incubated for 24 h in incubator at 37℃. Cells were subjected to determination 
of endogenous p21 protein expression by flow cytometer using FITC labelled p21 primary antibody. Data were analyzed 
statistically using paired t-test showed insignificant differences between p21 levels in control and treated cell lines are 
indicated by * (p<0.05) mean±SD; n=3, p21 proteins(p0.1193).   
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Fig: 6.3.7 p21 protein expression at cell surface in HT-29 colon cancer cell line. HT-29 cell lines seeded onto 6 well 
assay plates at cell density (1 × 10⁶ cells) could adhere to the surface of the plates for 24 h. Cells were then treated with p21 
plasmid cDNA in lipofectamine). The cells were incubated for 24h in incubator at 37℃. Cells were subjected to determination 
of cell surface p21 protein expression by flow cytometer using FITC labelled p21 primary antibody. Data were analyzed 
statistically using paired t-test. Significant differences between control and treated cell lines are indicated by * (p<0.05) 
mean±SD; n=3, p21 proteins(p0.0163*).   
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6.4 Discussion 
Over the years studies have shown the efficient role of p21 gene in accelerating programmed 
cell death due to elevated expression levels of this gene which in turn resulted in improved 
sensitivity towards conventional chemotherapeutics in a wide range of malignancies. 
Adenoviral mediated gene transfection studies support the efficiency of p21 gene in arresting 
the roots of colorectal progression and metastasis (Wang et al. 2015). p21 gene expression is 
studied to be accelerated in colorectal cancers by various pathways, one such route is 
MEK/ERK, which is counter regulated by transforming growth factor. TGF β works through 
SMAD signalling cascade boosting the level of p21 protein initiating cell cycle arrest (Bauer. 
et al. 2015; Padua. 2009). 
Cancer cells are protected from undesirable survival conditions by genes of the heat shock 
family. These stress responsive chaperons possessing different molecular weights, are found 
elevated in cancer cells are evidenced to play an eminent role in angiogenesis and metastasis, 
demoting cellular death pathways involving caspase stimulation (Beere et al. 2000).The 
underlying molecular functions of heat shock proteins and their interactions with tumors 
suppressor proteins are still unclear and needed to be explored in depth.  
This present study demonstrated that p21 overexpression induced apoptosis in the HT-29 
colorectal cancer cell line and the levels of apoptosis were more pronounced when cells 
overexpressing p21 were treated with pifithrin - µ which inhibits HSPA1A (Fig 6.3.5). This 
study appears to be a novel finding. Hence HSPA1A proteins are showcased to be potential 
targets for successful p21 induced gene therapies for colorectal malignancies. Biopsy studies 
evidence increased expression of HSPA1A, which are observed to be intimately linked with 
tumors nodule assisted angiogenesis in relapsed colorectal cancers (Murphy 2013; Hwang et 
al. 2003). Hence inhibiting HSPA1A may enhance the sensitivity of cancer cells towards 
conventional therapies, improving survival rates. 
Pifithrin - µ assisted apoptosis (Fig 6.3.3D) in HT-29 cell lines, studies show that Pifithrin - µ 
hampers the function of HSPA1A by directly binding to the C terminal domain of HSPA1A, in 
turn preventing its interaction with pro-apoptotic proteins of the mitochondrial apoptotic 
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signaling pathway and p53 gene resulting in promoting apoptosis in cancer cells (McKeon et 
al. 2016) . Studies reveals that, Pifithrin - µ administration hinders autophagy - which is a 
lysosome catalysed cellular mechanism, which plays a major role in discarding of unwanted 
metabolic residues within cancer cells thus, allowing successful proliferation.  (Mizushima et 
al. 2008; Jones et al. 2016).  
The colon cancer cell lines HT - 29 exhibited elevated levels of HSPA1A proteins with reference 
to pifithrin - µ treated cell lines which drastically inhibited HSPA1A intracellularly (Fig 6.3.5). 
Due to HSPA1A protein suppression, the cells expressed reduced cell viability, which predicts 
the eminent role of HSPA1A in colon cancer survival. As expected, the overexpression of p21 
(Fig 6.3.3), reflected significant apoptosis in HT-29 cell lines, and the cell lines subjected to 
p21 over expression combined with pifithrin - µ assisted HSPA1A inhibition interpreted more 
pronounced effect with reference to respected controls. As the data controls for pifithrin - µ 
in lipofectamine has not been evaluated in this study. There are also chances of lipofectamine 
in the transfection medium to form complexes with pifithrin - µ, which may also account for 
enhanced apoptosis in P21 plasmid cDNA transfected HT-29 cell line. Moreover, as the 
lipofectamine transfection may have created pores in the cell membrane, there are chances 
for leakage of protein overexpressed to reach the cell surface, detecting enhanced p21 levels 
in the cell surface as compared to mock transfected controls as shown in (Fig 6.3.7), and this 
may account for the lack of overexpressed p21 at the intracellular levels. 
Our results collectively interpret the active participation of tumor suppressor gene p21 in 
arresting the proliferation of colon cancer cell line HT-29 and also reflects the inhibitory status  
of HSPA1A proteins in enhancing p21 induced apoptosis in HT-29 cell lines (Archer et al. 1998; 
Yamamoto et al. 1999). 
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Chapter 7 
7.1 Discussion and future research 
In the current scenario, the increasing resistance together with the side effects produced are 
the major concerns encountered with conventional cancer treatments including 
chemotherapy and radiation. Hence the need to develop potentially targeted therapies, with 
fewer side effects is a priority. Hence, considering the interactive role of the stress protein 
HSPA1A in arresting cancers together with the supporting evidence from previous in vitro and 
in vivo studies stating the therapeutic potential of tumour suppressor gene p21 in arresting 
the growth of colorectal cancer cell lines. This thesis aimed at studying a two - pronged 
approach, to evaluate the effects of p21 protein overexpression in combination with HSPA1A 
inhibition in colorectal cancer cell lines HT-29. 
It is also important to note that all experiments were performed with cancer cell lines 
maintained in culture medium devoid of antimycotic /antibiotics. The results from chapter 3 
shows the involvement of these agents in inducing the expression of HSPA1A at extracellular 
levels in colorectal cancer cell lines. And these proteins may interfere with the protein 
translational processes in cancer cells, thus affecting their normal proliferation. Hence, 
reports highly denounce antimycotic /antibiotic application for in vitro investigations 
(Kuhlmann 1995; Llobet et al. 2015). The thesis looked at two different cancer cell lines in 
chapter 4 - leukaemia cancer cell lines U937 and colorectal cancer cell lines HT-29 to evaluate 
how the role of HSPA1A inhibitor pifithrin - µ or role of HSPA1A in hyperthermia differ with 
their inhibitory status in sustaining cancer growth in the two different cancer types. And the 
results from this chapter provided an understanding of the inhibitory effect of HSPA1A 
proteins, which accelerated UV radiation induced apoptosis.  
The insensitiveness to widely accepted treatment approaches is a major issue in cancer 
treatments. In case of radiotherapy, prolonged exposures may lead to undesirable effects to 
the healthy tissues. Hence studies at the molecular level are trying to modulate radiotherapy 
to display its highest efficiency with limited range of exposures. Previous report had revealed 
the inhibitory activity of HSPA1A proteins using pifithrin isoforms α and β in gama radiation 
induced cancer arrest (Walton et al. 2005). However, the apoptotic role of pifithrin - µ 
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mediated inhibition of HSPA1A proteins in UV induced apoptosis addressed in chapter 4 has 
not been explored previously. Hence the first phase of this thesis initially addressed the 
interaction of pifithrin - µ mediated HSPA1A protein inhibition in combination with UV 
radiation, which showcased accelerated rate in apoptosis induced by UV radiation at limited 
exposure durations in leukaemia cell lines U937 and colorectal cancer cell lines HT-29. Thus, 
suggesting that, resistance to therapies could be tackled by implementing drugs targeting 
HSPA1A proteins as a combination treatment.  
Though, as previously stated the guarding role of HSPA1A proteins, which function in binding 
to and re-establishing the functional status of impaired proteins, thus prevented cell cycle 
arrest, resulting in cancer cell survival. Moreover, studies have also reflected the crucial role 
of HSPA1A in inducing resistance to conventional therapies (Sherman. 2015; Daugaard et al. 
2005), however, their escalated expression is studied to communicate with the host natural 
defence mechanism in treatments such as hyperthermia in cancers in solid malignancies 
(Urano et al. 1983). Previous studies have displayed hyperthermia effects in colorectal cancers 
in vivo, but the role of HSPA1A proteins due to hyperthermia treatment in colorectal cancer 
cell line HT-29 has not been revealed. Hence this study evaluated the role of HSPA1A in 
hyperthermia study in both the cancer cell lines, thus showcasing apoptosis with 
hyperthermia at 42℃. This fluctuation in temperature also triggered the expression of 
HSPA1A proteins to escalate. Studies relate the increased expression of HSPA1A proteins in 
acting as signals for activating natural host defence mechanism against cancer survival 
(Jolesch et al. 2012). 
The second phase of the thesis chapter 5 focussed in selecting a non - cytotoxic transport 
system for the safe delivery of p21 plasmid cDNA in colorectal cancer cell lines HT-29 for p21 
overexpression and apoptosis. In vitro transfection studies rely on electroporation method, 
nanoparticles or microparticles for intracellular delivery of biological entities such as plasmid 
DNA or siRNA, as the cellular mucosal membranes act as barriers, thus hampering the 
exchange of macro molecules. As the particles of micro size and smaller are studied to be 
engulfed by the process of endocytosis, they are widely used for in vitro and in vivo 
experiments. Although studies highlight the therapeutic potential of chitosan-based delivery 
systems (Hejazi. 2003; Bernkop et al .2012; Katas et al. 2013) in terms of its antioxidant 
properties, biodegradable  biocompatible nature, thus making it extraordinary for drug 
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delivery applications, several other in vitro and in vivo reports evidence the side effects and 
toxic effects of chitosan (Qi. 2006; S. Wimardhani et al. 2014; Zhao et al. 2017).  
Since, previous research evidence differing opinions in terms of cytotoxicity of chitosan 
delivery systems, with studies highlighting the cytotoxic effect of the system in its drug free 
state in a dose dependent manner on one side (Depani et al. 2013), and others suggesting it’s 
non - cytotoxic nature (Qi. 2006; S. Wimardhani et al. 2014). This present study investigated 
chitosan microparticles and microgels crosslinked with glutaraldehyde or β - glycerol 
phosphate on colorectal cancer cell lines HT-29, using 5 - fluorouracil for cytotoxicity studies 
in HT-29 cancer cell lines.  
Although these microgels or microparticles expressed enhanced cytotoxicity with 5 - 
fluorouracil compared to its independent cytotoxicity, these formulations were shown to 
exert cytotoxicity resulted from cross linking agents glycerol phosphate or glutaraldehyde 
used to graft the systems. Hence, the study concluded chitosan - based systems unsuitable 
for use as delivery system due to the cytotoxicity exerted by these systems. Besides chitosan, 
BSA formulated microparticles thus examined for cytotoxicity evaluation were also found to 
be unfit due to the cytotoxicity exerted by these particles independently. However, the thesis 
did not investigate the cytotoxic effect of these delivery systems in non - cancerous tissues, 
hence it is difficult at this stage to reveal a complete evaluation of the particles safety in 
medical applications. Hence in this study, the p21 gene inserted plasmid cDNA was delivered 
for transfection studies in colorectal cancer cell lines HT-29 using lipofectamine 2000 which is 
an efficient transfection system highly recommended for the delivery of biological entities for 
in vitro experimental studies (Li et al. 2015).  
As described earlier, the prominent role of p21 in interacting with several apoptosis 
accelerating genes in arresting the cells from further replication, the functional status of p21 
gene as a tumour suppressor is studied to vary with different cancer treatment strategies and 
some cancer types. Although reports evidence it’s negative role in promoting cancer survival 
in treatments such as cryoinjury in colorectal cancer cell lines HT-29 and identified as the main 
cause of insensitiveness towards adjuvant therapeutic approaches involving 
chemotherapeutics and radiation therapies in patients battling with rectal cancers (Rau et al. 
2003). However, the tumour suppressive status of p21 genes is a core factor in reflecting 
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sensitiveness to chemotherapeutics (Ravizza et al. 2004), and in playing an influential role in 
directing cancer cells to induce apoptosis.  
Although previous studies have explored the therapeutic application of ectopic expression of 
the tumour suppressor gene p21, which reflects the active participation of p21 gene in 
initiating cell cycle arrest, thus demoting cancer survival in several malignancies (Yamamoto 
et al. 1999). Studies have not yet revealed the interactive role of HSPA1A ablation and tumour 
suppressor gene p21 overexpression in colorectal cancer cell lines or other cancers. Previous 
studies have demonstrated the active participation of p21 gene in inducing apoptosis (Archer 
et al. 1998; Yamamoto et al. 1999) which is in an agreement with the findings presented in 
this thesis in colorectal cancer cell lines HT-29. 
Besides the role of tumour suppressive gene p21, the thesis also discussed pifithrin -µ assisted 
inhibitory roles of HSPA1A proteins in response to, radiation therapy and hyperthermia. The 
HSP 70 gene family are classified into the following genes, HSPA1A-, HSPA2, HSPA5, HSPA6, 
HSPA7, HSPA8, HSPA9, HSPA13, HSPA12A, HSP12B, HSPA14, which have a variety of individual 
functional roles in human cells.  Intriguingly, studies proved escalated levels of HSPA1A genes 
related to cancer progression in most of the cancer malignancies. The HSP 70 genes plays a 
crucial role in re - establishing the functional status of proteins damaged due to oxidative 
stress response in cancer cells. They are also studied to hamper the mitochondrial apoptotic 
signalling by introducing a conformational alteration of the procaspase - 9, thus preventing 
the interaction of procaspase - 9 with apoptotic activating factor 1, eventually protecting cells 
from apoptosis (Daugaard et al. 2005). Studies also display the defensive mechanism of stress 
protein HSPA1A in protecting cancer cells from any extrinsic or intrinsic physiological stress 
(Klink et al. 2012; Goliaei. 1998). This defensive role exerted by HSP 70 family genes are 
reported to be regulated by blocking its intracellular interaction with NEF - nucleotide 
exchange factors and TPR - tetratricopeptide chains, which works in close connection with 
HSPA1A protein resulting in  insensitiveness to natural host defense, promoting cancer 
survival (Assimon et al. 2013). Hence a deep understanding of the molecular mechanisms by 
which these proteins function in cancer cells, may help to improve the therapeutic index of 
conventional therapies (Kabakov et al. 2006). 
 Although HSPA1A proteins function in defending cancer cells from undergoing apoptosis, 
their functional status is studied to be important in treatments like hyperthermia, as the 
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increased presence of these proteins aid in triggering the natural defense mechanism which 
in turn arrest cancer cells according to previous reports (Milani V. 2002). Therefore, attempts 
of ectopic overexpression of HSPA1A genes have previously evidenced pronounced cancer 
arrest with cancer treatments like hyperthermia, thus outlining the positive response of these 
molecules in cancer attenuation as well. Several studies also reveal the inhibition of HSPA1A 
proteins as useful strategy which enhanced sensitivity of cancer cells towards several 
chemotherapeutics (Demidenko et al. 2005; Chakraborty et al. 2008; Fang et al. 2013).  
Although HT-29 cell lines express p21 proteins as shown in chapter 6, these proteins found 
may be malfunctional to induce apoptosis. Moreover, there are chances for cancer cell 
expressive stress protein HSPA1A to bind with the available p21 and arrest its function, which 
may attribute to the insensitivity produced towards several chemotherapeutics and this may 
account for apoptotic activity observed upon treatment with pifithrin - µ mediated inhibition 
of HSPA1A proteins in P21 plasmid cDNA transfected HT-29 cell lines in this thesis.  
Interactive role of HSPA1A protein in p21 plasmid cDNA transfection 
The inhibitory status of HSPA1A in p21 plasmid cDNA transection study suggests the 
interaction of HSPA1A protein and tumour suppressor protein p21. The p21 protein expressed 
was refrained from undergoing apoptosis due to the high levels of HSPA1A proteins produced 
in cancer cell lines as displayed in (Fig 7.1.). The HSPA1A proteins bind with apoptotic proteins, 
hampering their transcription. Although, previous studies have revealed the direct interaction 
of tumour suppressor gene p53 with HSPA1A  in accelerating p53 directed apoptosis in cancer 
cells (Elengoe et al. 2015). No studies have yet elucidated the interaction between tumour 
suppressor protein p21 and HSPA1A proteins.   
Moreover, reports have highlighted the active role of HSPA1A proteins with several cellular 
components to fulfil its function as cancer promoter. They are studied to attach with lipid 
molecules, which upon binding, assist in delivering HSPA1A within intracellular destinations 
(Mccallister et al. 2015). Studies have also, evidenced the prominent role of HSPA1A protein 
upon attachment with the anti - apoptotic gene BAG 3 in promoting cancer growth by 
demoting the expression of several apoptotic inducing machinery including tumour 
suppressor gene p21 in in vitro studies in malignancies of breast and brain (Colvin et al. 2014; 
Li et al. 2015). Furthermore, induced transcription of p21 gene was illustrated in a two -
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pronged in vitro treatment approach in which HSPA1A proteins were ablated prior to 
hyperthermia treatment (Sekihara et al. 2013). In addition to suggesting the interactive role 
of HSPA1A proteins with the tumour suppressor gene p21, this previous study also reported 
the inhibitory activity of HSPA1A proteins mediated by pifithrin - µ which accelerated the 
efficacy of hyperthermia treatment (Sekihara et al. 2013). The high expression of HSPA1A 
proteins were also associated with downregulation of p21, which enhanced the survival of 
breast and brain tumors (Rohde et al. 2005). 
As a means of extrinsic stress response due to plasmid cDNA transfection, the expression of 
HSPA1 proteins tend to increase dramatically. The p21 plasmid cDNA reaching the destination 
may be affected by HSPA1A proteins, hampering a complete apoptotic activity as illustrated 
in (Fig 7.2). p21 plasmid cDNA induced apoptosis to around only 60% of HT-29 cell lines. Upon 
incorporating HSPA1A inhibitor pifithrin -µ, the inhibitor binds to HSPA1A and thereby 
prevents its interaction with the tumour surressor proteins p21 and p53, thus allowing their 
normal cell cycle regulatory functions, resulting in growth arrest of colorectal cancer cell lines 
HT-29. Apart from tumour suppressor proteins, transcription factors including BAX and death 
receptors will be free from HSPA1A activity, thus promoting the apoptotic pathway.  
Hence, considering these supporting evidences from previous studies, finally suggesting the 
anti - apoptotic interaction of HSPA1A proteins that may account for the enhanced apoptosis 
resulted from HSPA1A inhibition in p21 plasmid cDNA transfection in HT-29 cancer cell lines, 
as presented in this thesis. To recapitulate, the inhibition of HSPA1A prior to p21 gene 
therapies may useful for successful gene therapy. As hypothesized, the p21 overexpression 
induced apoptosis on HT-29 cell lines and pifithrin - µ assisted HSPA1A   protein inhibition set 
the p21 protein free from HSPA1A protein binding, thus allowing a healthy apoptotic pathway 
in colorectal cancer cell lines HT-29 (Fig 7.2), thus revealing a more promising therapeutic 
approach in p21 induced gene therapies for colorectal cancers.  
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Fig 7.1 Interference of HSP A1A in cancer cells. The diagram shows the escalated expression of HSPA1A normally in 
cancer cell lines which interacts with apoptotic signaling factors p53 and p21, hampering their functional roles thus 
promoting cancer survival. Picture adapted from the data presented in this thesis and (Rohde et al. 2005; Demidenko et al. 
2005; Chakraborty et al. 2008; Fang et al. 2013).  
  
  
Fig 7.2 Interference of HSPA1A in p21 transfection. The diagram shows that cancer cells may experience cellular stress 
due to p21 plasmid DNA transfection, which in turn result in overexpression of HSPA1A. The overexpressed HSPA1A could 
bind to p21 plasmid DNA and may hamper the transfection and p21 expression and prevent apoptosis. Picture adapted from 
the data presented in this thesis and (Rohde et al. 2005; Demidenko et al. 2005; Chakraborty et al. 2008; Fang et al. 2013).  
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Future studies of this present study highlight the following routes yet to be investigated 
• Although this thesis suggests the interactive binding of the HSPA1A proteins to p21 
proteins as one of the reasons which maybe hampering the complete apoptotic effect 
through p21 plasmid DNA transfection. However, this can be confirmed only through 
protein - protein interaction studies. Hence, this needs to be further confirmed using 
far western blotting technique or fluorescent microscopic observations. As an initial 
phase of this future study, untreated colorectal cancer cell line HT-29 should be ex-
plored for the HSPA1A - p21 molecular binding, to understand the binding profiles of 
HSPA1A to tumour suppressors p21 or p53. Secondly, the protein - protein interac-
tions studies needs to be explored with the incorporation of HSPA1A inhibitor 
pifithrin - µ, to ascertain its activity in arresting cancer progression. Finally, the inter-
action of HSPA1A with the ectopically expressed p21 proteins needs be addressed. As 
this may provide an explicit insight of how p21 induced gene therapies could be 
boosted to achieve its maximum treatment efficiency through inhibition of HSPA1A 
proteins. Moreover, the interactive role tumour suppressor protein p53 also needed 
to be evaluated in p21 induced gene therapies as p21 mediated apoptosis also relies 
on the functional mode of p53 gene.  
• Adjuvant gene therapies using p53 and p21, through inhibition of HSPA1A proteins 
needs to be further investigated as it could be useful therapeutic strategy in cancers 
with mutant p53 or p21 genes.  
• Hyperthermia is an effective therapy (Jolesch et al. 2012; Urano et al. 1983). The role 
of hyperthermia along with tumour suppressor gene therapies is yet to revealed. Alt-
hough HSPA1A proteins are considerably triggered by hyperthermia, as this protein 
play a major part in signalling   the immune system, this defensive role of these unique 
proteins may in turn boost the therapeutic efficiency of p21 gene induced gene ther-
apy in cancers with mutated p21 genes. 
• The antibiotics works as efficient anti - cancer agents (De Francesco et al. 2017). The 
side effects of these agents as discussed previously can be minimised by engineering 
these compounds into nanoparticle size as this may provide targeted delivery, thus 
improving the therapeutic efficacy even with low dosage administration. This thesis 
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shows the escalated expression of HSPA1A protein resulted from anti - mycotic anti-
biotic treatment and with hyperthermia treatment. Hence besides independent ef-
fects, a combined therapeutic effect of both these treatments may be good thera-
peutic model for several cancers, those including mutations in apoptotic operons.   
• Although the thesis displayed enhanced apoptotic effects with UV radiation with the 
aid of HSPA1A inhibitor compound pifithrin - µ. The effects of UV radiation could be 
improved by inducing the expression of HSPA1A proteins by administration of treat-
ments such as hyperthermia, which may result in triggering the host immune activity 
and maybe a useful cancer treatment approach to be investigated in future. 
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